The Role of the JNK/AP-1 Pathway in the Induction of iNOS and CATs in Vascular Cells by Zamani, Marzieh
i 
 
 
 
 
 
The Role of the JNK/AP-1 Pathway in 
the Induction of iNOS and CATs in 
Vascular Cells 
 
 
 
M Zamani 
 
 
PhD 
 
2011 
 
ii 
 
 
 
 
The Role of the JNK/AP-1 Pathway in 
the Induction of iNOS and CATs in 
Vascular Cells 
 
 
 
 
Marzieh Zamani 
 
 
 
 
Submitted to the University of Hertfordshire in 
partial fulfilment of the requirements of the 
degree of PhD 
 
August 2011 
iii 
 
Abstract 
Nitric oxide (NO) is an important biological molecule within the body, which over 
production of this molecule in response to different stimulations can cause various 
inflammatory diseases. Over production of this molecule is caused by the induction 
of the inducible nitric oxide synthase (iNOS) enzyme. This enzyme uses L-arginine 
as a substrate and therefore the presence and transport of this amino acid into the 
cells can be a key factor in regulating NO over production.  
Different signalling mechanisms have been implicated in the regulation of this 
pathway and one of which involves the Mitogen Activated Protein Kinases (MAPK). 
This family of proteins respond to inflammatory conditions and may mediate effects 
induced by inflammatory mediators. Of the MAPKs, the role of the c-Jun-N-terminal 
kinase (JNK) pathway in the induction of iNOS is still controversial. JNK and its 
downstream target, the transcription factor Activator Protein-1 (AP-1), have shown 
contradictory effects on iNOS induction leading to controversies over their role in 
regulating iNOS expression in different cell systems or with various stimuli. 
The studies described in this thesis have determined the role of JNK/AP-1 on iNOS 
expression, NO production, L-arginine uptake and also on the transporters 
responsible for L-arginine transport into the cells. The studies were carried out in two 
different cell types: rat aortic smooth muscle cells (RASMCs) and J774 macrophages 
which are both critically associated with the over production of NO in vascular 
inflammatory disease states.  
The first approach was to block the expression of the inducible L-arginine-NO 
pathway using SP600125 and JNK Inhibitor VIII which are both pharmacological 
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inhibitors of JNK. The results from these studies showed that the pharmacological 
intervention was without effect in RASMCs, but inhibited iNOS, NO and L-arginine 
transport in J774 macrophages. In contrast, the molecular approach employed using 
two dominant negative constructs of AP-1 (TAM-67 and a-Fos) revealed a different 
profile of effects in RASMCs, where a-Fos caused an induction in iNOS and NO 
while TAM-67 had an inhibitory effect on iNOS, NO, L-arginine transport and CAT-2B 
mRNA expression. The latter was unaffected in RASMCs but suppressed in J774 
macrophages by SP600125.  
Examination of JNK isoforms expression showed the presence of JNK1 and 2 in 
both cell systems. Moreover, stimulation with LPS/IFN- or LPS alone resulted in 
JNK phosphorylation which did not reveal any difference between smooth muscle 
cells and macrophages. In contrast, expression and activation of AP-1 subunits 
revealed differences between the two cell systems.  
Activation of cells with LPS and IFN- (RASMCs) or LPS alone (J774 macrophages) 
resulted in changes in the activated status of the different AP-1 subunit which was 
different for the two cell systems. In both cell types c-Jun, JunD and Fra-1 were 
increased and in macrophages, FosB activity was also enhanced. Inhibition of JNK 
with SP600125 caused down-regulation in c-Jun in both cell types. Interestingly this 
down-regulation was in parallel with increases in the subunits JunB, JunD, c-Fos and 
Fra-1 in RASMCs or JunB and Fra-1 in J774 macrophages. Since, SP600125 was 
able to exert inhibitory effects in the latter cell type but not in RASMCs, it is possible 
that the compensatory up-regulation of certain AP-1 subunits in the smooth muscle 
cells may compensate for c-Jun inhibition thereby preventing suppression of iNOS 
expression. This notion clearly needs to be confirmed but it is potentially likely that 
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hetero-dimers formed between JunB, JunD, c-Fos and Fra-1 could sustain gene 
transcription in the absence of c-Jun. The precise dimer required has not been 
addressed but unlikely to exclusively involve JunB and Fra-1 as these are up-
regulated in macrophages but did not sustain iNOS, NO or induced L-arginine 
transport in the presence of SP600125. 
To further support the argument above, the dominant negatives caused varied 
effects on the activation of the different subunits. a-Fos down-regulated c-Jun, c-Fos, 
FosB, Fra-1 whereas TAM-67 reduced c-Jun and c-Fos but marginally induced Fra-1 
activity. Associated with these changes was an up-regulation of iNOS-NO by a-Fos 
and inhibition by TAM-67. 
Taken together, the data proposes a complex mechanism(s) that regulate the 
expression of the inducible L-arginine-NO pathway in different cell systems and the 
complexity may reflect diverse intracellular changes that may be different in each cell 
type and not always be apparent using one experimental approach especially where 
this is pharmacological.  Moreover, these findings strongly suggest exercising 
caution when interpreting pure pharmacological findings in cell-based systems 
particularly where these are inconsistent or contradictory. 
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Introduction 
 
1.1 Characteristics of nitric oxide 
Nitric oxide or nitrogen monoxide (NO) is an important intermediate in the chemical 
industry and a toxic air pollutant, as well as being an important signalling molecule in 
the body of mammals (Hou et al., 1999). 
Nitric oxide is probably one of the most studied molecules of the last 20 years. It is 
an important messenger molecule involved in many physiological and pathological 
conditions with both beneficial and detrimental role. The first biological role described 
for NO was as endothelial-derived relaxation factor in 1987 (Ignarro et al., 1987; 
Palmer et al., 1987). Nitric oxide is an uncharged molecule with an unpaired electron 
(Figure 1.1), which does not need any ‘pharmacological’ receptors for its actions and 
can diffuse freely across membranes. Its unpaired electron makes it a highly reactive 
molecule (Stamler et al., 1992). 
Nitric oxide has a short half life of between 4 and 50 seconds and due to its high 
reactivity forms intermediate molecules such as nitrogen dioxide (NO2), nitrite (NO2
-), 
and nitrate (NO3
-). It also reacts with free radicals such as superoxide (O2
-) to form 
other highly reactive species such as peroxynitrite (ONOO-) (Beckman et al., 1990).   
Nitric oxide is well known for its major roles in many physiological systems, for 
example, as a messenger and as a defence molecule in the immune system 
(Ignarro, 2000). Moreover, any abnormalities in NO synthesis may be associated 
with some disorders such as septic shock, high blood pressure, diabetes and 
neurodegenerative diseases (Hughes et al., 2008). 
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While appropriate level of NO production may be critical in protecting organs such as 
the heart and liver from ischemic damage, its over production may result in direct 
tissue toxicity and contribute to the vascular collapse associated with, for instance, 
septic shock. Overproduction of NO may also be associated with various carcinomas 
and inflammatory conditions including diabetes, multiple sclerosis and arthritis 
(Taylor et al., 1997). 
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Figure 1.1 Chemistry of nitric oxide 
Nitric oxide is rapidly oxidized by the removal of one electron to give nitrosonium 
cation (NO+), or reduced by the addition of one electron to form nitroxyl anion (NO-
), which are important intermediates in the biochemistry of NO (Lamattina et al., 
2003). 
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1.2  Physiological properties of nitric oxide 
After the discovery of NO, there was a huge increase in our knowledge on the role of 
endothelium and nitric oxide in cardiovascular diseases. It is now accepted that NO 
derived from the vascular endothelium maintains a vasodilator tone which is 
essential for the regulation of blood flow and pressure. NO also has a role in the 
control of platelet aggregation and the regulation of cardiac development. Moreover 
NO also acts as a mediator in cell-cell communication in the brain. In the peripheral 
nervous system, release of NO from nerves classified as non-adrenergic and non-
cholinergic maintains various gastrointestinal, respiratory and genitourinary tract 
functions (Moncada, 1997). 
Most of the positive physiological functions of NO include regulation of vascular 
smooth muscle tone and vascular resistance. Low physiological concentration of NO 
has been shown to relax blood vessels, reduce vascular resistance and thus lower 
blood pressure (Rees et al., 1989). Additionally, constitutively derived NO has also 
been shown to have a role in the protection against apoptosis (Kim et al., 1991), 
wound repair (Frank et al., 2002), contraction of skeletal muscle and cardiac 
development (Stamler et al., 2001). 
 
1.3  Pathophysiological properties of Nitric oxide 
While the physiological effects of NO like vasorelaxation and neuronal signalling are 
mostly mediated by the activation of guanylate cyclase, NO can also have damaging, 
even fatal effects. In the often fatal condition of septic shock, excessive production of 
NO in blood vessels can lead to vascular leakage and drop in blood pressure 
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(Maeda et al., 1994; Nava et al., 1991). In chronic diseases such as rheumatoid 
arthritis, NO contributes to tissue damage caused by an inappropriate inflammatory 
response (Bernardeau et al., 2001; Sakurai et al., 1995; St Clair et al., 1996). In 
stroke, NO also contributes to brain damage (Iadecola et al., 1997; Iadecola et al., 
1995; Nanri et al., 1998).   
In cytotoxic condition, it seems that NO directly or indirectly exerts its effect through 
the formation of more reactive oxidative species such as ONOO−. This molecule is a 
powerful oxidant that exhibits a wide range of tissue damaging effects including 
nitration of proteins, inactivation of various enzymes and ion channels via protein 
oxidation (Beckman et al., 1996).  
The different physiological and pathophysiological effects of NO may be dependent 
on its concentration in the tissue. At low concentrations, those normally achieved 
after stimulation of constitutively expressed isoforms (NOS1 and NOS3), NO can 
modulate the activity of heme-containing proteins, such as guanylyl cyclase, and 
also important proteins of the mitochondria including the cytochromes. It is also able 
to regulate certain transcription factors like hypoxia inducible factor (HIF-1). At higher 
concentrations, usually produced by the inducible isoform (NOS2) NO can nitrosylate 
cysteine residues or produce tyrosine nitration in different proteins. In some cases, 
DNA deamination have been observed (Agulló; 2007). These effects are 
summarised in Figure 1.2. 
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Figure 1.2 Physiological and pathophysiological effects of nitric oxide 
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1.4 Physiological and pathophysiological target for NO 
Nitric oxide has been shown to have several targets in biological system. Among 
these targets, soluble guanylate cyclase (sGC) may be the most important     
(Ignarro, 1991; Ishii et al., 1990; Russwurm et al., 2002) and converts GTP to cyclic 
GMP (cGMP), mediating various physiological and tissue protective effects (Arnold 
et al., 1977; Durner et al., 1998; Stamler, 1994). NO–sGC–cGMP signalling can be 
compromised either by reducing the bioavailability of NO or by altering the activity of 
sGC. The latter could be mediated through oxidative stress or the action of ONOO− 
which could make sGC unresponsive to endogenous NO (Evgenov et al., 2006). 
Some of the physiological and adverse effects of NO are summarised in Figure 1.3 
and Figure 1.5 below. 
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Figure 1.3 Physiological and deleterious effects of the NO signalling pathway  
Nitric oxide activates guanylate cyclase by combining with the haem group in the 
enzyme. Activation of sGC would convert GTP to cGMP and increase cGMP in 
vessel walls which will result in the various physiological effects shown in the 
diagram. In contrast, interaction of NO with O2
- results in the formation of 
peroxynitrite which can induce a multitude of deleterious effects in cells and tissues 
(Evgenov et al., 2006). 
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1.5  Biosynthesis of Nitric oxide from L-arginine 
Nitric oxide is formed by the oxidation of the amino acid L-arginine and results in NO 
and citrulline production in a reaction that is catalyzed by the nitric oxide synthase 
(NOS) enzymes (Hughes, 2008; Ishimura et al., 2005). 
The NOS enzyme produces NO by a five-electron oxidation catalysis reaction of 
guanidino nitrogen from the cationic amino acid L-arginine (L-Arg). L-Arginine to L-
citrulline oxidation takes place via mono-oxygenation reactions which utilises 
molecular O2 and cofactors such as NADPH. The product of this reaction is the 
intermediate Nω-hydroxy-L-arginine (NOHLA). NOHLA is subsequently converted to 
L-citrulline and NO with NOS again utilising cofactors including NADPH (Korth et al., 
1994; Schmidt et al., 2001). The reaction is summarised in Figure 1.4. 
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Figure 1.4 Synthesis of nitric oxide from L-arginine 
Endogenous NO is formed from the amino acid L-arginine through a catalyzed 
reaction by the NOS family of enzymes, which convert L-arginine into NO and L-
citrulline, requiring two co-substrates: oxygen and reduced nicotinamide adenine 
dinucleotide (NADPH). This reaction also needs FMN, FAD, tetrahydrobiopterin 
(BH4) as the cofactors. L-arginine is first converted to Nω-hydroxy-L-arginine 
(NOHLA) by NOS which utilises molecular O2 and cofactors such as NADPH. 
NOHLA is then converted to L-citrulline and NO with NOS again employing 
cofactors including NADPH. It is estimated that 2 mol of O2 and 1.5 mol of NADPH 
are consumed per mole of NO produced (Andrew et al., 1999; Knowles et al., 1989; 
Moncada et al., 2006; Palacios et al., 1989).  
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1.6  Nitric oxide synthase 
There are three NOS isoforms referred to as neuronal (nNOS or NOS I), inducible 
NOS (iNOS or NOS II) and endothelial (eNOS or NOS III) (Alderton et al., 2001; 
Stuehr et al., 2004). These enzymes share 50-60% homology and are the product of 
different genes. All NOS isoforms are homodimeric enzymes which as explained 
above, require L-arginine and molecular oxygen as the substrate. All three enzymes 
utilise NADPH, FMN, FAD and tetrahydrobiopterin (BH4) as the cofactors. The 
enzyme functions as a dimer consisting of two identical monomers, which 
functionally and structurally is divided into two major domains: a C-terminal 
reductase domain, and an N-terminal oxygenase domain. The C-terminal reductase 
domain contains binding sites for NADPH, FAD, and FMN while N-terminal 
oxygenase domain which binds heam, BH4 and arginine (Andrew et al., 1999).  
The isoforms are different with regards to their main mode of regulation, tissue 
expression pattern and the average amount of NO produced as summarised in Table 
1.1. The eNOS and nNOS enzymes are constitutively expressed in many tissues, 
regulated mainly by Ca2+/Calmodulin and produce low concentrations of NO (Chin et 
al., 1999; Furchgott et al., 1980). The inducible isoform is associated with the 
immune system, independent of elevated Ca2+ and already has calmodulin tightly 
bound to its structure during synthesis (Alderton et al., 2001). Moreover, iNOS 
catalyzes the production of high concentrations of NO in response to various stimuli 
such as cytokines (Cross et al., 2002; Ghosh et al., 2003; Hughes, 2008; Newman et 
al., 2004). As this thesis is focused on iNOS, the rest of the section below will 
concentrate on this enzyme. 
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1.7  Inducible nitric oxide synthase (iNOS) 
The inducible nitric oxide synthase is normally expressed only in the presence of 
stress stimuli, such as bacterial endotoxin and/or cytokines. In the cardiovascular 
system, it can be induced in smooth muscle cells, endothelial cells, and endocardial 
cells. In immune cells iNOS plays an active role in host defence during enteric 
bacterial pathogen infections thus contributing to the host defence mechanisms in 
man. However, its induction in several diseases is believed to contribute to the 
pathogenesis of the disease state. There is strong evidence, for instance, that 
expression of iNOS within the vasculature may play a major role in conditions such 
as septic shock (Albuszies et al., 2007; Bultinck et al., 2006).  
Moreover it is reported to have an important role along with other pro-inflammatory 
mediators in the pathogenesis of inflammatory bowel disease (Dijkstra et al., 1998) 
and intestinal inflammation (Marion et al., 2003). A role for iNOS in inflammatory 
conditions is supported by the fact that pro-inflammatory mediators that increase 
cAMP (an intercellular mediator of pro-inflammatory mediators) levels also increase 
iNOS expression and therefore NO production (Cavicchi et al., 1999). Some of the 
functional properties of iNOS are summarised in Figure 1.5. 
This enzyme functions as a dimer consisting of two identical monomers with two 
major domains: a C-terminal reductase domain (contains binding sites for one 
molecule each of NADPH, FAD, and FMN) and an N-terminal oxygenase domain 
(which binds haem and BH4, as well as the substrate L-arginine) (Andrew et al., 
1999).      
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Figure 1.5 Beneficial and detrimental effects of iNOS 
iNOS is induced in several disease states and plays a major role in conditions with 
both beneficial and detrimental effects as indicated in the diagram. (Pieper et al., 
2008). 
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1.8    Importance of altered NO production in human diseases and 
therapeutic strategies based on regulation of NO production 
Nitric oxide plays a critical role in the physiological regulation of blood flow, 
regulation of integrated cardiac and vascular function, homeostasis and is required 
for normal cardiac physiology. Nitric oxide may also exert a protective role in the 
ischemic heart via different mechanisms such as stimulation of sGC to reduce 
intracellular Ca2+ concentration (Jones et al., 2006; Shah et al., 2000). Nitric oxide 
may act as a physiological regulator of cell respiration and a modulator of the 
generation of reactive oxygen species by mitochondria via interactions with 
components of the mitochondrial respiratory chain and therefore modulates 
mechanisms of cell survival or death (Moncada et al., 2002). At physiological 
concentrations, NO relaxes smooth muscle cells in the walls of the vasculature. At 
each cardiac cycle, in systole, the endothelial cells that line the blood vessels 
release NO which diffuses into the underlying smooth muscle cells causing 
relaxation and therefore facilitate blood flow (Champion et al., 2003; De Belder et al., 
1997; Dusting., 1996; Haywood et al., 1996; Starling., 2005). 
In addition to the above beneficial effects of constitutively derived NO, NO produced 
from iNOS has been shown to have a protective role in cell-mediated oxidative 
modification of LDL (Buttery et al., 1996).  Studies have shown that in an in vivo 
model, iNOS reduced the development of atherosclerosis after immune injury.  In 
addition, iNOS enhanced endothelial integrity, survival and protection against 
apoptotic or necrotic cell death (Hemmrich et al., 2003; Rikitake et al., 1998). 
Similarly, in hepatocytes, enhanced NO generation through iNOS has been reported 
to be a protective mechanism under inflammatory conditions (Kuo et al., 1997).  
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Nevertheless, NO has an important pathophysiological role in various diseases both 
in animal experimental models as well as in different human pathologies, with 
harmful consequences leading to cardiovascular diseases (Champion et al., 2003), 
chronic liver disease (Kirkali et al., 2000), neurodegenerative disease (Titheradge., 
1999), inflammatory bowel disease (Grisham et al., 2002) and ulcerative colitis 
(Middleton et al., 1993). In addition, ONOO− formation under these conditions may 
contribute to the pathology (Singer et al., 1996) and can affect the viability and 
function of cells (Szabo et al., 2007).  
Within the cardiovascular system iNOS derived NO may cause excessive 
vasodilatation, cytotoxicity, inflammation and cardiovascular dysfunction such as that 
seen in septic shock (Smith et al., 1992; Petros et al., 1994). In heart failure and in 
myocardial infarction over-production of NO and superoxide radical generation also 
leads to injury to the coronary endothelium and myocytes, compromising ventricular 
contractile function (Horton et al., 2000; Pacher et al., 2007). Furthermore, NO 
derived from iNOS has been implicated in neurodegenerative diseases like 
Alzheimer’s and Parkinson’s disease and stroke where NO acts as a neurotoxin, 
inhibiting the main enzymes of energy metabolism. Nitric oxide may also damages 
the DNA and reacts with superoxide to form ONOO− (Schulz et al., 1995).  
The potential mechanisms underlying these harmful effects may involve an 
interaction of NO with a wide variety of proteins and enzymes through their amino, 
thiol (SH), diazo, tyrosyl, heme, Fe2+ and sulfur centres (Angeloni et al., 2012). 
Unregulated NO production is also associated with oxidative stress which can result 
in the generation of peroxynitrite and other reactive species that alter protein function 
via nitration and oxidation reactions (Arstall et al., 1999; Lapu-bula et al., 2007; 
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Searles., 2002). Nitric oxide can also lead to apoptosis via activation of mitochondrial 
pro-apoptotic pathways, and mitogen activated protein kinases (MAPK) which then 
results in cell death (Oyama et al., 2002).  
All the observations above support a role for excessive NO production in various 
pathologies. Disease development may also occur under conditions of impaired NO 
bioavailability whic can result from reduced NO release from the endothelial cells or 
through amplified inactivation of NO by reactive oxygen species (ROS). This is in 
fact the case with atherosclerosis where endothelial impairment together with 
oxidative stress reduce bioavailable NO resulting in various deleterious effects 
including impaired vascular function (Kolluru et al., 2012). Kashyab et al. (1990), also 
demonstrated that impaired NO synthase activity in skeletal muscle can contribute to 
insulin resistance in type 2 diabetes. Thus, it is clear that maintaining NO production 
at the physiological concentration range is critical in preventing disease 
development. However, where there is an imbalance, restoring NO production or in 
the case of iNOS, understanding the mechanisms that regulate expression and 
activity of the enzyme would be essential for developing novel strategies in 
controlling disease states.  
Different therapeutic strategies to control diseases associated with changes in NO 
production have been considered. These include the use of NO donor compounds, 
stimulating the receptors linked to the L-arginine-NO pathway, increasing the action 
of endogenous NO, inhibiting substrate supply for iNOS or even inhibiting its 
expression and activity. The NO donor compounds are distributed into diverse 
classes such as organic nitrates (glyceryl trinitrate) and nitrites (amyl nitrite), 
inorganic nitroso compounds (sodium nitroprusside), sydnonimines (molsidomine), 
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and S-nitrosothiols (S-nitroso-N-acetyl-D, L-penicillamine). Most of these compounds 
exert their effect after being metabolised to release NO (Moncada et al., 1995). 
Donors such as nitroglycerin are used to control high blood pressure (Agvald et al., 
2002) and to restore blood flow in conditions such as arterial or myocardial 
ischaemia (Karlberg et al., 1998; Varughese et al., 2001). However, one of the 
limitations of using this compound is the development of tolerance after a few weeks 
of continued usage (Agvald et al., 2002).  
In contrast to up-regulation NO production, inhibition of NO synthesis can be used as 
a therapeutic strategy under conditions associated with enhanced NO production via 
iNOS. In many different diseases NO is considered as a target for therapeutic 
strategy, for instance in Alzheimer’s disease acetylcholinesterase inhibitors and N-
methyl-D-aspartate (NMDA) receptor antagonists are the only recognised treatment 
for managing the cognitive deficits. However, elevated NOS activity has been shown 
to increase the amount of NO which may contribute to the progression of the 
disease. Therefore, a likely approach to regulate disease progression must include 
inhibitors which targets NOS isoforms associated with damage to brain cells 
(Fernandez et al., 2010). There are, however, contradictory reports as to whether 
there is more or less NO synthesis in these diseases. These discrepancies may be 
due to the fact that the method for the direct detection of NO levels in the brain is still 
not difficult. Most studies use various biomarkers and metabolites (such as 
biomarkers of arginine) produced via the NO pathway as an indirect measurement 
for identifying the role of NO, and for this reason it is not clear whether NO plays a 
neuroprotective or cytotoxic role. However, using NOS inhibitors such as L-NAME 
has helped provide a better understanding of the role of NO in diseases such as 
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acute liver injury (Adawi et al., 1997) and gastrointestinal diseases (Wang et al., 
2002). These inhibitors which also include other analogs of L-arginine such as NG 
monomethyl-L-arginine (L-NMMA) act as competitive inhibitors of NOS enzymes 
(Moncada et al., 1995) and may therefore have some potential therapeutic benefits 
in disease states associated with the over production of NO. As an example L-
NMMA has been shown to be effective in reversing hypotension in human with septic 
shock (Schilling et al., 1993; Watson et al., 2004). Similarly, the use of L-NAME as a 
treatment for conditions such as cardiogenic shock has been proposed (Avontuur et 
al., 1998; Cotter et al., 2003; Kiehl; 1998).Despite these reports; the clinical 
exploitation of NOS inhibitors is still limited. This is mainly because the compounds 
mentioned above lack selectivity and inhibit all known NOS isoforms which is not 
desirable. For this reason, many studies have suggested that general NOS inhibition 
is not beneficial in conditions like septic shock and selective inhibition of iNOS was 
suggested. Liaudet et al., 1998 compared the selective inhibitor of iNOS (L-
canavanine) and non-selective inhibitor of NOS (L-NAME) in endotoxemia. Both 
compounds managed to reduce the amount of nitrite. However L-NAME caused liver 
damage and was detrimental in endotoxic shock, while L-canavanine considerably 
reduced mortality with no fatal effects on the liver. Su et al. (2010) compared the 
selective iNOS inhibitor BYK191023 with norepinephrine in septic shock condition 
and showed that selective iNOS inhibition had a more profound and beneficial effect 
on blood pressure and flow. Thus there is promise from these observations to 
develop NOS inhibitors that could be exploited clinically in the future. 
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1.9  Regulation of iNOS activity  
Induced iNOS can generate high nM to µM amounts of NO over prolonged periods 
but this may be critically dependent on the availability of exogenous substrate. 
Moreover, its activity may be directly related to the rate of transport of exogenous 
arginine (Assreuy et al., 1992; Bogle et al., 1992) and could be inhibited following 
blockade of L-arginine transport into cells expressing the enzyme (Bogle et al., 
1992). Interestingly, this dependency of iNOS on exogenous L-arginine occurs 
despite the fact that cells contain concentrations of L-arginine of between 0.1 to 0.8 
mM (Baydoun et al., 1990; Mitchell et al., 1990) which are well above the reported 
Km of iNOS for L-arginine of around 1-20 µM (Knowles et al., 1994). These 
observations indicate a critical role of L-arginine supply and potentially provide an 
alternative novel target for regulating overproduction of NO in disease states beyond 
targeting the enzyme itself. 
 
1.10 L-arginine  
L-arginine is a semi-essential amino acid that is synthesized from citrulline (Figure 
1.6) by the actions of argininosuccinate synthetase (AS) and argininosuccinate lyase 
(AL), the third and fourth enzymes of the urea cycle (ornithine cycle) (Chin-Dusting et 
al., 2007; Mori et al., 2000). L-arginine participates in a variety of key biochemical 
and physiological activities. Other than for NO synthesis, L-arginine is a precursor for 
urea, polyamines, creatine phosphate and various proteins. It is transported from the 
blood circulation into cells via different carrier systems including the cationic amino 
acid transporters (CAT) which are discussed below. When iNOS is induced in 
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various cells stimulated by bacterial lipopolysaccharide (LPS) and/or cytokines, AS 
and sometimes AL are induced (Figure 1.6). iNOS and AS were first found to be co-
induced in murine macrophage after stimulation with LPS and interferon- (IFN-) 
(Nussler et al., 1994), also in cultured rat aortic smooth muscle cells stimulated by 
LPS and IFN-(Hattori et al., 1994), and cultured rat and human pancreatic -cells 
treated with cytokines (Flodstrom et al., 1995; Hattori et al., 1994; Mori, 2007; Mori et 
al., 2004). 
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Figure 1.6 Arginine metabolism 
The urea cycle is composed of carbamylphosphate synthetase I (CPS I), ornithine 
transcarbamylase (OTC), argininosuccinate synthetase (AS), argininosuccinate 
lyase (AL), and arginase. The citrulline–NO cycle is composed of nitric oxide 
synthase (NOS), AS, and AL. CPS I and OTC are present only in hepatocytes and 
small intestinal epithelial cells. CAT-1–3: cationic amino acid transporter-1–3 (Mori et 
al., 2000). 
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1.11  L-arginine transport system 
Entry of L-arginine and other cationic amino acids (CAAs) into cells is mediated by at 
least one of four transport systems referred to as systems y+, y+L, bº,+ and Bº,+ which 
are characterised according to their affinity for CAAs and by their dependence on 
sodium (Deves et al., 1998). Of these, systems y+ is perhaps the most diverse and 
widespread classical system, transporting CAAs Na+ independently and with high 
affinity (Km in the micro-molar range) (Closs et al., 1999; White et al., 1982). By 
comparison, systems bo,+, Bo,+ and y+L, also carry a range of other amino acids, 
including neutral amino acids and do so in a Na+-dependent manner, thus making 
the CATs the only truly selective transporters of CAAs  expressed in vascular cells 
(Deves et al., 1998).The discussion below will therefore concentrate on the CATs as 
these are the other main focus of the studies conducted in this thesis.  
                         
1.12 Cationic amino acid transporters (CATs) 
The CAT family of proteins include CAT-1, CAT-2A, CAT-2B, and CAT-3. Of these, 
CAT-1 is a high affinity carrier cloned by scientists searching for the ecotropic murine 
leukemia virus receptor (ecoR). The protein they cloned was expressed in Xenopus 
oocytes and shown to mediate cationic amino acid transport (Kim et al., 1991). The 
Cat-2 gene was cloned shortly after Cat-1 and initially named Tea (T-cell early 
activation receptor) related to its early induction in the response of normal T cells to 
mitogens. The full length cDNA was subsequently isolated and shown to have 61 % 
homology with CAT-1 (Closs et al., 1993a; Dall'Asta et al., 2000). Both CAT-2A and 
CAT-2B are products of the same gene produced by alternative splicing with 98% 
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homology with each other (Closs et al., 1993a). CAT-1 is expressed ubiquitously 
while CAT-2B is apparently expressed in most cells, including cultured rat astrocytes 
(Gill et al., 1996), J774 macrophages (Baydoun et al., 1994; Closs et al., 2000) and 
cardiac myocytes (Simmons et al., 1996a; Simmons et al., 1996b) following its 
induction by various stimuli. Interestingly, previous studies from our group has 
revealed the expression of CAT-2A and CAT-2B in control non-activated cultured 
vascular smooth muscle cells (Baydoun et al., 1999) suggesting that these carriers 
may be expressed constitutively in certain cell systems. Some of the characteristsics 
of these carriers are summarised in Table 1. 
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Table 1.2 Characteristics of cationic amino acid transporters  
 
 
   CAT-1    CAT-2A     CAT-2B    CAT-3  
               
Km (mM) 
 
0.1-0.2 
 
2.1-5.2 
 
0.04-0.3 
 
0.1-0.15 
 
Na+-independent  Yes Yes Yes Yes 
       
Amino acids  622 657 658 619 
       
MW (kDa)  67 72 72 67 
       
N-glycosylation  Yes Yes Yes Yes 
       
Expression  
 
Constitutive 
 
Constitutive 
 
inducible 
 
Constitutive 
 
       
Key cell type 
 
 
 
Ubiquitous 
Except liver 
 
 
Liver, 
muscle, skin 
 
T-cells, 
Macrophages 
 
 
Brain 
 
 
 
 
 
 
Adopted from (Closs et al., 1993c; Kakuda et al., 1999) 
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1.13 Regulation of iNOS and CAT gene expression 
Since both iNOS and CATs can be induced, it is evident that their induction requires 
the activation of specific signalling pathways within the cells. Considerable progress 
has been made in unravelling those involved for iNOS which can be regulated 
largely at the transcriptional level (Hecker et al., 1999; Kolyada et al., 1996; 
Matsumura et al., 2001; Walker et al., 1997; Wong et al., 1996; Xie et al., 1993). In 
addition, there is some evidence for the possibility of post-transcriptional regulation 
(Korhonen et al., 2007) in rat mesangial cells (Kunz et al., 1996), in RAW 264.7 
macrophages (Walker et al., 1997) and in human chondrocytes (Schmidt et al., 
2010) in which different stimulations regulate the translational rate of iNOS. 
Studies on the 5’-upstream sequence of the iNOS gene (considered as the promoter 
region) have shown that this region contains a number of transcription factor binding 
sites including those for IFN- regulatory factor (IRF), nuclear factor-B (NF-B), 
IFN-stimulated response element (ISRE), activating protein-1 (AP-1), tumor necrosis 
factor (TNF) response element and CAAT box element (Beck et al., 1998; 
Lowenstein et al., 1993; Yang et al., 1998; Zhang et al., 1996). 
Activation of NF-B is being reported as essential for iNOS expression (Forstermann 
et al., 1995; Goldring et al., 1995; Martin et al., 1994; Xie et al., 1993) but NF-B 
alone may not be sufficient for full induction of the iNOS gene (Adcock et al., 1994; 
Beck et al., 1996; Ding et al., 1995; Zhang et al., 1998). Other transcription factors 
involved include AP-1 which is claimed to regulate iNOS expression either positively 
(Kristof et al., 2006; Won et al., 2004) or negatively (Kleinert et al., 1998; Mendes et 
al., 2003). Alternative studies suggested that CAAT box/ enhancer binding protein 
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(C/EBP) and cAMP responsive element binding protein (CREB) may have 
synergistic effects on iNOS induction via the CAAT box (Hecker et al., 1997; 
Kinugawa et al., 1997).  
It should be noted that activation of these nuclear factors is usually associated with 
exposure of tissue or cells to pro-inflammatory mediators including LPS and/or 
cytokines (Beasley et al., 1991; Nussler et al., 1992; Rees et al., 1990; Stuehr et al., 
1989). These pro-inflammatory mediators often act synergistically, activating a series 
of signalling pathways which may include the mitogen activated protein kinases 
(MAPKs) (Chen et al., 1999; Guan et al., 1999; Singh et al., 1996), protein kinase C 
(PKC) (Paul et al., 1995; Scott-Burden et al., 1994), the phosphoinositide-3 kinases 
(PI3Ks) (Matsuzaki et al., 1999) and the c-Jun-N-terminal kinase (JNKs) (Chan et al., 
2001; Chan et al., 1998; Pawate et al., 2006) of which the last is the main focus of 
this thesis and discussed in more detail below. 
In contrast to the vast literature on the regulation of iNOS expression, relatively little 
is known about the signalling that regulates CAT induction. Limited reports have 
suggested that neither tyrosine kinases nor Protein kinase C (PKC) may mediate the 
induction of L-arginine transport by LPS and IFN- in smooth muscle cells (Baydoun 
et al., 1999). These observations indicate a difference in the mechanisms 
responsible for the induction of iNOS and CATs when cells are exposed to 
inflammatory mediators. It was shown that the p38 MAPK pathway could regulate 
both iNOS and CAT function and expression (Baydoun et al., 1999) suggesting a 
critical role for this kinase family in the production of not only NO but also in the 
enhancement of L-arginine transport into cells. Furthermore, the ERKs and p38 have 
been shown to act at the post transcriptional level in controlling CAT-2B synthesis 
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(Caivano, 1998) but at least one other study has suggested no involvement of 
MAPKs in L-arginine transport (Visigalli et al., 2004), thus again highlighting the 
inconsistencies in the current literature. In addition to the kinase signalling, it has 
been shown that NF-B can act as an essential transcription factor for CAT-2B up-
regulation (Hammermann et al., 2000; Visigalli et al., 2004) but again the data are 
limited and it is not clear what role other elements such as AP-1 play in controlling 
CAT expression and function. The p38 MAPK also seems to be related for up-
regulation of CAT expression and function which leads to enhancing the transporter 
activity and induction of transcript for CAT-1, CAT-2A and CAT-2B (Baydoun et al., 
1999). Indeed, in preliminary studies, our research group has obtained data 
suggesting that JNK (and thus AP-1) may not be involved in the induction of CATs. 
Interestingly, the studies also showed opposing actions on iNOS induction and NO 
production with the potent JNK inhibitor SP600125 when compared to AP-1 
dominant negatives, TAM-67 and a-Fos. Thus, it is unclear what role the JNK 
pathway plays in the induction of iNOS and/or CATs and this has been the major 
focus of the studies carried out for this thesis. 
 
1.14 c-Jun-N-terminal kinase (JNK) signalling pathway 
The JNKs, also called stress activated protein kinase (SAPK) belong to the mitogen-
activated protein (MAP) kinases family of signalling proteins. Three different MAPK 
pathways have been described in mammalian cells: the extracellular signal regulated 
kinase (ERK), JNK and the p38 MAPK pathways. The ERKs are activated by 
mitogenic stimuli, and the JNKs and p38 MAPKs respond to environmental stress, 
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including ultraviolet light, heat, osmotic shock and inflammatory cytokines. The 
molecular cloning of human (Derijard et al., 1994; Kallunki et al., 1994) and rat JNK 
(Kyriakis et al., 1994) has led to the identification of JNK as a member of MAPK 
family. 
These MAP kinases are activated by dual phosphorylation within their protein kinase 
subdomain VIII. This phosphorylation is mediated by a protein kinase cascade that 
consists of a MAP kinase kinase kinase, a MAP kinase kinase, and a MAP kinase. 
Individual MAP kinases are activated by diverse signalling molecules that are 
regulated by various stimuli. For instance, the ERKs are activated by the MAP kinase 
kinases MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and 
MKK6 (Mercer et al., 2006). The JNKs are activated by upstream protein kinases 
that include two dual specificity MAP kinase kinases (MKK4 and MKK7) and multiple 
MAP kinase kinase kinases (MKKKs) (Widmann et al., 1999). The MKKKs 
phosphorylate and activate MKK4 and MKK7 which then cause the activation of 
JNKs by dual phosphorylation on threonine and tyrosine residues within a Thr–Pro–
Tyr motif in protein kinase subdomain VIII (Bode et al., 2007; Boutros et al., 2008; 
Davis, 2000a; Wang et al., 2007) (Figure 1.7). While MKK7 is a specific activator of 
JNKs, MKK4 can also phosphorylate the Thr–Gly–Tyr motif of p38 MAPKs (Derijard 
et al., 1995; Sanchez et al., 1994; Tournier et al., 1997). Interestingly, JNK activation 
in the liver (in vivo model) correlates with decreased p38 MAPK activity (Mendelson 
et al., 1996) suggesting that the two pathways may be regulated differentially.  
The JNKs are encoded by three genes: jnk1, jnk2, jnk3. JNK1 and JNK2 are 
expressed ubiquitously and show variances in their ability to interact with c-Jun. 
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JNK2 in comparison with JNK1, seem to have a much greater affinity to bind with c-
Jun (Bode et al., 2007; Kallunki et al., 1994; Sabapathy et al., 2004).  
JNKs have an important role in the induction of apoptosis, but are also involved in 
enhancing cell survival and proliferation. The divergent roles of JNKs are related to 
the fact that they activate a large number of different substrates which are dependent 
on specific stimulus and cell type (Bode et al., 2007; Gupta et al., 1996). Studies on 
different animal disease models demonstrated specific roles of JNK genes in a huge 
numbers of pathologic conditions including neurodegenerative disorders such as 
Parkinson’s and Alzheimer’s disease (Hunot et al., 2004; Peng et al., 2003), arthritis 
(Han et al., 2002), asthma (Nath et al., 2005; Sumara et al., 2005), as well as in 
cancer development (Kennedy et al., 2003). In relation to the latter, many tumour cell 
lines have been shown to have constitutively active JNK. Moreover, a decline in the 
transforming potential of a number of oncogenes was observed when an anti-sense 
JNK oligonucleotides or dominant negative constructs were employed (Potapova et 
al., 1997; Potapova et al., 2000). The JNK pathway has also been shown to play a 
critical role in Type 1 diabetes (Hirosumi et al., 2002), and in other cardiovascular 
complications such as heart failure as well as mediating hypertrophic responses to 
various forms of cardiac stress (Adams et al., 1998; Kim et al., 1998; Liang et al., 
1997).  
Most of the evidence in support of the above observations has been obtained from 
animal and experimental models. For instance the abolition of JNK expression in 
mice (i.e. JNK deficient mice) with Parkinson’s disease prevents neurodegeneration 
(Hunot et al., 2004). Similarly, inhibition of the JNK pathway with compounds such as 
CEP-1347 exerts neuro-protection potentially through inhibition of JNK but not p38 or 
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ERK1/2 activation. CEP-1347 is now in clinical trials for Parkinson’s disease 
treatment (Peng et al., 2003).  
With regards to cardiovascular diseases, the role of the JNK pathway has also been 
established using various approaches. For instance, overexpression of JNK 
contributes to the development of pathological cardiac hypertrophy (Heineke et al., 
2006). Furthermore, inhibition of endogenous JNK signalling using dominant 
negative JNK1/2 or JNK1/2 -/- in mice has been shown to be augmented cardiac 
growth suporting that JNK1/2 inhibits cardiac hypertrophy (Liang et al., 2003). In 
another study in JNK1/2/3-/- mice, pressure overload reslted in cardiac hypertrophy 
which was not seen in the widltype (Tachibana et al., 2006). Additionally, it has been 
suggested that pharmacological inhibition of JNK1/2 decreases pathological cardiac 
remodeling after myocardial infarction in humans (Muslin 2008) and treatment of 
mice with SP600125, a potent JNK inhibitor, inhibited the development of 
atherosclerosis (Ricci et al., 2004). 
The effects highlighted above may be mediated by different JNK which may vary in 
their functions (Chen et al., 2002; Singh et al., 2009). For instance, JNK2 has been 
shown to have a 25-fold higher binding affinity (with lower Km) for c-Jun (the main 
substrate for JNK) than JNK1 and it has been proposed that JNK2 is the key c-Jun 
activator (Kallunki et al., 1994). Kallunki et al., 1994, also suggested that both 
efficient c-Jun binding and c-Jun phosphorylation are determined by a short region 
on the catalytic c-terminal of the enzyme, which is different between JNK1 and 
JNK2. As a result, c-Jun is more likely to be phosphorylated by JNK2 than by JNK1. 
This is however contradicted by at least one report which suggested that the JNK1 
isoform may be slightly more efficient in phosphorylating c-Jun (Gupta et al., 1996; 
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Hochedlinger et al., 2002) since there is reduced c-Jun phosphorylation in JNK1 
deficient fibroblast. Moreover these cells had higher resistance to UV-induced cell 
death (Hochedlinger et al., 2002). However JNK2 deficient cells revealed elevated 
sensitivity to UV light and had an increase c-Jun phosphorylation. Thus, the two 
isoforms clearly act in opposing ways and there are indications that the specific 
biological functions may probably depend on the stimulation and responding 
tissue/cell type (Sabapathy et al., 2004). 
Depending on the stimulus and cell type, JNKs can phosphorylate a number of 
activator protein-1 (AP-1) components, including c-Jun, JunD, and activating 
transcription factor 2 (ATF2) (Davis, 2000b; Fuchs et al., 1997) which may be 
required, for maximal induction of iNOS, independently or in conjunction with NF-B. 
Activator Protein-1 (AP-1) is a downstream target for JNK and its activity is directly 
increased following phosphorylation of c-Jun by JNKs. This activation augments 
stabilization and overall transcriptional activation (Bode et al., 2007). Furthermore, 
JNKs directly up-regulate c-Jun expression which results in activated AP-1 complex 
and its translocation into the nucleus to initiate gene expression. Other MAPKs may 
be able to up-regulate the Fos family genes by phosphorylation of JNK. The ERKs in 
particular are one of the potential upstream for Fos activation which act through 
ETS-like transcription factor-1 (Elk-1) activation (Kaminska et al., 1999; Whitmarsh et 
al., 1996). This would suggest a complex network of signalling cross-talk which can 
activate AP-1 and subsequent gene transcription (Figure 1.7).  
There is some evidence revealing an important role for JNK in the induction of iNOS 
(Chan et al., 1998; Chiu et al., 2008; Lee et al., 2010; Pawate et al., 2006; Rodriguez 
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et al., 2008). For example in human astrocyte, dominant negative of JNK inhibited 
interleukin-1 (IL-1)-induced iNOS expression (Hua et al., 2002), however this 
dominant negative construct did not show any effect on bovine type I 
collagenstimulated iNOS expression in RAW264.7 murine macrophages (Cho et al., 
2002). The effects of JNK on iNOS expression may be via a post transcriptional 
mechanism through stabilization of iNOS mRNA (Korhonen et al., 2007; Lahti et al., 
2003). Lahti et al., 2003 used the specific JNK inhibitor, SP600125, on LPS-activated 
J77 murine macrophages. The experiments showed this inhibitor has no effect on 
iNOS mRNA expression after 4 hours but reduced transcript levels by up to 90% 
after 8 hours of incubation suggesting that it may be altering the stability on the 
induceed mRNA.  
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Figure 1.7 Representation of the activation of the NF-kB and JNK/AP-1 
pathways. 
Both the NF-kB and JNK/AP-1 pathways are activated by upstream mitogen-
activated protein kinases. AP-1 is formed through activation of a family of Jun/Fos 
proteins. The activated AP-1 complex translocates into the nucleus, initiating gene 
expression. Some of the signalling that activates AP-1 may also activate NF-B  and 
each transcription factor has a specific recognition binding site (kB for NF-B and 
TRE for AP-1) on the iNOS gene promoter which can be activated to induce iNOS 
(Herlaar et al., 1999; Rahman, et al., 1998). 
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1.15 AP-1 
Activator Protein-1 (AP-1) is a transcription factor complex composed of homo- 
and/or hetero-dimers of Jun (c-Jun, JunB and JunD) and Fos (c-Fos, FosB, Fra-1 
and Fra-2) proteins. Fos proteins cannot form homo-dimers but can hetero-dimerize 
with members of the Jun family. The Jun proteins can both homo-dimerize and 
hetero-dimerize with other Jun or Fos members to form transcriptionally active 
complexes (Angel et al., 1991) as shown in Figure 1.8. 
Additionally, Jun proteins can also hetero-dimerize with other transcription factors, 
such as members of the activator transcription factor (ATF) family. The Jun and Fos 
proteins contain a basic-region leucine zipper (bZIP) domain, and are therefore able 
to bind to other bZIP proteins including those from the ATF, MAF, CNC and C/EBP 
(CCAAT/enhancer-binding protein) subfamilies (Chinenov et al., 2001). 
Generally, enhanced expression of c-jun gene, protein and function can be 
maintained by an induction of transcription factors that are related to c-Jun (e.g. Jun-
B, Jun-D), the Fos family members (Fos, FosB, Fra-1/2), or the ATF-family 
members, allowing the formation of functionally different hetero-dimers. Additionally, 
some members of the activating transcription factor and cAMP response element-
binding protein families also dimerize with the core members of the AP-1 family to 
regulate a broad variety of genes by binding to their promoter and enhancer regions. 
Jun and Fos proteins, after dimerization, bind to so-called TPA (12-O-
tetradecanoylphorbol 13-acetate) responsive elements (TRE’s; TGAC/GTCA) in the 
promoter and enhancer regions of target genes (Miller et al., 1984; Mitchell et al., 
1989; Nakamura et al., 1991; Smeal et al., 1989; van Dam et al., 2001). 
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Activation of AP-1 occurs both transcriptionally and post-translationally, and is 
signalled mostly through the mitogen-activated protein kinase (MAPK). The diversity 
of AP-1 proteins and other interacting factors appears to have effect on how specific 
cell types respond to a stimulus (Young et al., 2003). 
AP-1 regulates a variety of cellular processes summarised in Figure1.9, including 
proliferation, differentiation and apoptosis, and contributes to both basal and 
stimulus-activated gene expression. It is activated by growth factors, hormones, 
stress, cytokines, Reactive Oxygen Species (ROS) and ultraviolet radiation (Vesely 
et al., 2009) (Figure 1.10). Regulation of AP-1 activity is critical in deciding cell fate 
and occurs at various levels, including dimer-composition, transcriptional and post-
translational events, and interaction with the other proteins (Eferl et al., 2003).  
It has been demonstrated that the promoter region of iNOS gene from different 
species contain binding site for AP-1 (Lowenstein et al., 1993) and there is evidence 
for an important role of JNK in the induction of iNOS (Chan et al., 1998; Chiu et al., 
2008; Lee et al., 2010; Pawate et al., 2006; Rodriguez et al., 2008) which could be 
mediated through activation of AP-1. Additionally, the JNKs may also regulate iNOS 
expression via post transcriptional mechanism through stabilization of iNOS mRNA 
(Korhonen et al., 2007; Lahti et al., 2003). The role of JNK/AP-1 on iNOS expression 
may however be different in various systems and this will be discuss later in the 
thesis.   
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Figure 1.8 AP-1 transcription dimers 
A cartoon depicting dimerisation of Jun\Fos to form an active AP-1 complex. 
Although members of the Jun and Fos families share a high degree of structural 
homology, the individual AP-1 dimers show significant differences in their DNA 
binding affinity and their capability to activate or suppress gene expression (Wagner 
et al., 2005). TA: transactivating domain; LZ: Leucine Zipper domain; DNA-BD: DNA 
binding domain (Raivich et al., 2006). 
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1.16 Transcriptional regulation of AP-1 family members 
Increasing evidence has suggested the important roles of different AP-1 proteins 
and/or AP-1 dimer formation in various cell systems and their effect in controlling 
diverse cellular functions. ERK, p38, and JNK each selectively regulated AP-1 
subcomponent expression and DNA binding activity (Ding et al., 2008). 
Extracellular stimuli including stress, growth factors, mechanical stretch, G protein-
coupled receptor agonists, cytokines, psychotropic drugs, etc., lead to a wide variety 
of cellular responses such as cellular phenotypic change, growth, apoptosis, 
migration, or gene expressions (Figure 1.9). Most genes that regulate components of 
AP-1 are known as "immediate-early genes" (IEGs), and are induced in response to 
these stimuli (Kim et al., 2003). 
Various toxic and mitogenic stimuli can also induce jun and fos mRNA expression 
rapidly and by several fold above the basal level in a wide variety of tissues and/or 
cell types. In general, the mRNA levels of c-jun, junB, junD, c-fos, and fosB peak 
within 15-30 min of stimulation and return to basal level within 1-2 hours.  
Jun–Jun and Jun–Fos dimers bind with highest affinity to the phorbol 12-O-
tetradecanoate-13-acetate (TPA) response element (TRE) with the consensus 
sequence 5′-TGAG/CTCA-3′ (Angel et al., 1991); although many other ‘AP-1-like 
sites’ have been reported. Binding to any of these sites can be (1) tissue-specific, (2) 
affected by neighbouring sequences, and (3) dependent on interactions with other 
transcription factors or cofactors (Angel et al., 1987). 
Although Jun and Fos proteins are rapidly induced by various stimuli, most cells 
possess a certain amount of pre-existing Jun and Fos proteins that are initial targets 
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for JNK and ERK, MAPKs. Upon their activation, ERKs and JNKs phosphorylate both 
pre-existing and newly synthesized AP-1 proteins. The activated JNKs bind to the 
docking site located in the NH2-terminal region of c-Jun and phosphorylates Ser63 
and -73 located within its transactivation domain (Whitmarsh et al., 1996). Due to its 
higher affinity to the docking site, JNK2 phosphorylates c-Jun with more efficiency 
than JNK1 (Gupta et al., 1996). JunB also contains the JNK docking site but lacks 
NH2-terminal acceptor serine residues and
 therefore appears to be poorly activated 
by JNKs. However, a recent study shows phosphorylation of Thr102 and -104 of 
JunB by JNKs in some cell type (Li et al., 1999).  
In contrast to Jun proteins, which are mainly phosphorylated by JNKs within their 
NH2-terminal region, Fos proteins are mainly
 phosphorylated by ERKs on serine 
and/or threonine residues located within their COOH-terminal domain. Upon 
activation, ERKs translocate into the nuclei and phosphorylate c-Fos on Ser374 
(Chen et al., 1996; Karin, 1996). 
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Figure 1.9 Activation of activator protein-1 (AP-1) and its potential actions 
Various toxins, after interacting with cells, activate different mitogen-activated protein 
kinase (MAPK) signalling pathways, which in turn activate the AP-1 transcription 
factor. Upon activation, AP-1 binds to its target sites located in the promoter regions 
to regulate expression of a wide variety of genes involved in various biological 
processes. ERK, extracellular signal-regulated kinase; JNK, c-Jun NH2-terminal 
kinase (Reddy et al., 2002). 
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1.17 Aims 
The aim of this study is to determine the role of the JNK-AP-1 pathway in the 
induction of iNOS, NO synthesis and L-arginine transport in J774 macrophages and 
rat aortic smooth muscle cells (RASMCs) which both play a critical role in disease 
states associated with over production of NO by iNOS in the body.  
The rational for wanting to conduct these studies is the fact that preliminary studies 
in our group revealed opposing actions of the JNK inhibitor SP600125 when 
compared to dominant negatives a-Fos and TAM-67. In addition the literature also 
indicates inconclusive and contradictory findings about the role of the JNK/AP-1 
pathway on iNOS induction in different cell systems and there are no studies that 
have explored their critical requirement in the regulating L-arginine transport into 
cells. Thus, it is unclear whether the JNKs and/or AP-1 are required for either 
induced NO synthesis and/or L-arginine transport. Moreover, it is not clear whether 
the discrepancies we and others have observed are due to differences in cell types 
and/or experimental approaches using pharmacological vs molecular approaches to 
regulate iNOS induction.  
Studies have therefore been carried out to investigate the critical role of JNK/AP-1 in 
the expression of the inducible L-arginine-NO pathway in both J774 macrophages 
and RASMCs. The planned experiments will use pharmacological inhibitors and the 
dominant negative constructs TAM-67 and a-Fos to confirm previous findings. More 
importantly, the studies will be expanded to include a detailed investigation of the 
activated status of different AP-1 subunits under various experimental conditions. 
This would be with the aim of establishing whether the discrepancies and current 
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controversies relating to the role of JNK/AP-1 in the induction of iNOS/CATs are 
indeed associated with differences in the patterns of activation of various AP-1 
subunits; some of which may be without effect while others may positively or 
negatively regulate iNOS and/or CAT gene expression. 
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Methods 
 
2.1  Cell Culture 
2.1.1 Preparation of complete cell culture growth medium 
Dulbecco’s Modified Eagle’s Medium (DMEM, low glucose- i.e. 1000 mg/ml, without 
sodium pyrivate) supplemented with 10% foetal bovine serum (FBS), 100 units ml-1  
penicillin plus 100 µg ml-1  streptomycin, was used as cultured medium. Once prepared, 
the complete growth medium was kept at 4 °C and used within a period of 2 weeks. 
 
2.1.2 Culture of J774 macrophages 
The murine monocytic macrophage cell line J774 was obtained from the European 
Collection of Animal Cell Cultures and maintained in continuous culture at 37 °C and 
5% CO2 in T-75 tissue culture flasks containing complete growth medium. When 
necessary cells were harvested by gentle scraping and passage every 3-5 days by 
dilution of the suspension of the cells in fresh medium.  
 
2.1.3 Isolation of Rat Aortic Smooth Muscle Cells (RASMCs) 
Vascular smooth muscle cells were isolated from the aorta of male Weister rats 
(250-300g) as described (Wileman et al., 1995) and cultured in complete growth 
medium. Briefly, each aorta was cleaned off fat and other tissues before cutting open 
to expose the lumen, which was gently scraped to remove the endothelial layer. 
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Each aorta was then cut into small (2 mm) segments and transferred into a T-25 
flasks containing complete medium. Segments were allowed to attach to the plastic 
by keeping each flask in the upright position for 6-12 h in a cell culture incubator at 
37 °C/5% CO2. Flasks were then placed flat, allowing the medium to cover the tissue 
explants and observed over 7-14 days. Migrating and proliferating cells were 
harvested and sub-cultured as described below.  
 
2.1.4 Sub-culturing of rat aortic smooth muscle cells 
Proliferating cells that had migrated from the explants were harvested with Trypsin-
EDTA (0.01/0.02 %) made up in Phosphate Buffer Saline (PBS). At first, the culture 
medium was aspirated from flasks and the cells washed with PBS (3 times) to 
remove all the media containing FBS. Trypsin-EDTA was added to the cell 
monolayer and incubated for 5 min in a cell culture incubator. Cells were then 
observed under the microscope to ensure detachment. Five ml of complete growth 
medium was added to the flasks to inactive the trypsin and the cells were dispersed 
into single cultures with a Pasture Pipette before being transferred into sterile T-75 
tissue culture flasks. Cells were passaged weekly and used between passage 3 and 
6. 
 
2.1.5 Identification of Smooth Muscle Cells 
Cells isolated were identified as being smooth muscle by immunostaining using a 
monoclonal anti-α smooth muscle actin antibody and anti-mouse IgG FITC 
53 
 
conjugated secondary antibody (Skalli et al., 1986). Cells were plated in Lab Tec 
wells at sub-confluent density and allowed to grow to 50% - 60% confluency. The 
cells were washed twice with PBS (1X)  fixed with ice-cold methanol for 45 sec and 
rinsed with ice-cold PBS before blocking for 20 min with a solution that contain 5% 
Bovine Serum Albumin (BSA) in 10 ml of 1X PBS. A 1:50 dilution of the anti-α-actin 
antibody was made up in blocking buffer and incubated with cells for 1 h at 37°C. 
Cells were washed four times with PBS changing the wash buffer every 5 min. The 
secondary antibody was diluted 1:50 in blocking buffer and incubated with the cells 
for 1 h at 37°C. Cells were then treated for 15 sec with 30% glycerol. This procedure 
was repeated using 50% and 80% glycerol solution respectively. Finally, the cells 
were mounted in 2-3 drop of glycerol (100%) solution and a cover slip was placed on 
top of the cells. A seal was made using nail varnish and visualised under the UV 
microscope at a magnification of 100x. 
 
2.1.6 Determination of cell number 
Cell number was determined using a haemocytometer with the Trypan Blue 
exclusion assay. Monolayers of cells were trypsinized as described above and 
resuspended in 10 ml of DMEM. 100μl of the cell suspension was mixed with an 
equal volume of Trypan blue and then a total volume of 10 μl was used to fill the 
chamber on both side of the haemocytometer with the cover slip placed on top. The 
haemocytometer was then placed on the microscope stage and viewed. The total 
number of cells was determined by counting the cells in each large square (1mm) on 
both side of the haemocytometer ensuring that only cells touching the two borders 
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were counted. Moreover, cells outside the large square even if they were within the 
field of view were not counted. The cell count per millilitre was determined as follows  
 
 
Where:  
Number of the cells = total cell counted 
Square = the four squares counted on the haemocytometer 
Convension factor = 104, as each square is equal to 10-4 ml 
 
To get the total number of cells harvested, the number of cells determined per 
millilitre was multiplied by the original volume of medium in which the cells were 
suspended: 
           
 
2.1.7 Plating of cells for experimentation 
When required, confluent monolayer of J774 macrophages were scraped with the 
rubber scraper while RASMCs were trypsinised as described above. Cells were then 
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plated at the appropriate density and allowed to grow to the required confluency by 
incubating plates at 37°C/ 5% CO2 in a tissue culture incubator. 
 
2.2 Experimental Protocols 
2.2.1 Regulation of nitric oxide production by drug treatment  
Effects of the selected drugs on NO production were investigated on confluent 
monolayers of cells. When present, drugs were added for 30 min prior to activation 
of cells with LPS and/or IFN- for the required time period. 
 
2.2.2 Determination of nitrite production by the Griess assay 
Nitric oxide production was measured by the standard Griess assay as described by 
Wileman et al., (1995). This assay relies on a diazotization reaction that was 
originally described by Griess in 1879 and detects NO2
- in solution as shown in 
Figure 2.1(Green et al., 1982). 
A 100 μl aliquot of media was removed from each well and transferred to new 96 
well plates. Sodium nitrite standards (1 to 10 pmoles/well) made up in complete 
culture medium were transfer to the outer wells on the same plate and all samples 
were incubated at room temperature for 15 min with 100 μl of Griess reagent 
(Appendix 1). The absorbance of each well was read at 540 nm on a Multiscan 
Ascent (Lab-system) plate reader and the level of nitrite determined using the 
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sodium nitrite standard curve constructed. Figure 2.2 shows an example of a nitrite 
standard curve that was used to determine nitrite concentration.  
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Figure 2.1 Detection of NO2
- in solution by the Griess assay  
Under acidic conditions nitrite reacts with the amino group of sulfanilic acid to form 
the diazonium cation, which couples to α-naphthylamine in the para-position to form 
the azo dye (Green et al., 1982). 
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Figure 2.2 A representative nitrite standard curve  
Sodium nitrite standard were prepared in complete culture medium. A 100 μl aliquot 
from each standard was added in triplicate to the 96 well plates and incubated for 15 
min with an equal volume of the Griess reagents. Absorbance values were taken at 
540 nm on a Multiskan Ascent plate reader.  
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2.2.3 Protein quantification using Bicinchoninic acid (BCA) 
Total cell protein was determined by the BCA assay which is based on the Biuret 
reaction as shown in Figure 2.3. This is a detergent-compatible formulation for the 
colorimetric detection and quantification of total proteins. This method is a 
combination of the reduction of cupric ions [Cu (II)] to cuprous ions [Cu (I)] by 
proteins in an alkaline medium (i.e. biuret reaction) and a selective and sensitive 
colorimetric detection of the cuprous ions. The purple-coloured product is formed by 
the chelation of one Cu (I) ion by two molecules of BCA (Smith et al., 1985; 
Wiechelman et al., 1988)  
For the determination of total cell protein, 10 μl of Double distilled water (DDW) or 
lysis buffer was added to each well containing cells. Protein standards (1-30 μg/ml) 
were made from a 1 mg/ml bovine serum albumen (BSA) stock solution in DDW. 10 
μl of each standard was added in triplicate to wells. The BCA reagent was prepared 
as instructed by the manufactures by mixing reagent A with reagent B at the ratio of 
1:50 volume. [Pierce BCA assay reagent A contains sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide. 
Reagent B contains 4 % (w/v) Copper (II) sulfate pentahydrate (CuSO4 • 5H2O)]  
 A 100 μl aliquot of the BCA reagents was added to each well and the plates 
incubated at room temperature on a shaker for 40 minutes. The absorbance was 
read at 620 nm on a Multiscan Ascent plate reader. The absorbance values of 
samples were then converted to protein using a BSA standards curve (Figure 2.4) 
constructed with each assay. 
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Figure 2.3 Protein detection by the BCA method 
The method combines the reduction of Cu+2 to Cu+1 by protein in an alkaline medium 
with the highly sensitive and selective colorimetric detection of the chelation of Cu+1 
by the BCA reagent to form a BCA Cu+ complex. 
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Figure 2.4 A representative protein standard curve 
Bovine serum albumin standards were prepared in lysis buffer/water. 10 μl of each 
was added in triplicate to the plates. 100 μl of BCA reagent was added to each well 
and incubated for 40 minutes at room temperature. Absorbance values were then 
read at 620 nm using a Multiscan II plate reader and the readings used to construct 
the standard graph. 
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2.2.4 Measurement of [3H]-L-arginine transport  
Transport of [3H]-L-arginine was performed as described (Wileman et al., 1995). 
Cells were washed twice with 200 μl Kreb’s buffer (NaCl, 131 mM; KCl, 5.6 mM; 
NaHCO3, 25 mM; NaH2PO4, 1 mM; D-glucose, 5.5 mM; HEPES, 20 mM; MgCl2, 1 
mM; CaCl2, 2.5 mM) at 37°C. Transport was initiated by the addition of transport 
buffer (Kreb’s buffer containing 1 μCi/ml [3H]-L-arginine plus 100 μM unlabelled L-
arginine) to the cells at 37°C. The reaction was stopped after 2 min by incubating 
plates on ice and washing cells twice with ice cold Kreb’s buffer containing 10 mM 
non-radioactive L-arginine.  
Total cell protein was determined as described above and the content of each well 
transferred into scintillation vials. 4 ml of scintillation fluid was added to each vial, 
vortexed and counted on a Beckman LS6500 β-scintillation counter. The standard 
vials were prepared using 50 μl of Kreb’s buffer alone and 50 μl of Kreb’s buffer 
containing 100 μM L-arginine plus 1 μM Ci/ml [3H]L-arginine. Blank Disintegrations 
Per Minute (DPMs) were subtracted from each sample and the remaining DPMs 
converted to pmoles of L-arginine/μg protein/minute using the equation:  
 
                                                       
R is the amount of L-arginine in cell lysates expressed in pmoles 
5000 is the amount of cold arginine in pmoles in 50 μl of 100 μM solution 
C is DPM in cell lysates 
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X is DPM in 50 μl aliquot of 100 μM L-arginine solution containing 1μ Ci/ml [3H]L-
arginine 
Y is total protein content of cell lysates counted 
2 is for 2 minutes incubation time with [3H]-L-arginine 
 
2.2.5 Determination of cell viability by the MTT assay 
Cell viability was determined by monitoring the metabolism of 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) to purple formazan by viable cells 
(Figure 2.5). This reaction takes place only when mitochondrial reductase enzymes 
are active, and so conversion is directly related to the number of viable cells. The 
production of purple formazan in cells treated with an agent was compared to its 
production in control cells. Toxic concentrations of a compound would lead to a 
reduction in the mitochondrial dehydrogenase ability to metabolise (MTT) to 
formazan and therefore produce a reduced absorbance in the MTT assay. 
For the assay, confluent monolayers of cells were treated according to the 
experimental protocol.  After the incubation time, fresh medium containing 0.5 mg/ml 
of MTT was added to the cells and incubated for 4 h at 37°C in a tissue culture 
incubator. The MTT solution was removed and 100 μl Isopropanol was added to the 
cells and the plate incubated on an orbital shaker for 10 minutes or until all the 
formazan crystals had dissolved. The plates were read on Ascent multiscan plate 
reader at 540 nm. The cell viability in the control cells (untreated cells) was 
considered as 100% and cell viability at each drug concentration was calculated as a 
percentage of the control.  
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Figure 2.5 Detection of formazan by viable cells  
Water soluble tetrazolium salt is converted into an insoluble purple compound, 
formazan, by cleavage of the tetrazolium ring by mitochondrial dehydrogenases into 
purple formazan in viable cells (Mosmann, 1983).  
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2.2.6 Western blotting 
Preparation of cell extracts for Western blot analysis 
Confluent monolayers of cells were incubated under different experimental 
conditions. At the end of each treatment time, wells were washed twice with ice-cold 
PBS and the cells lysed using hot lysis buffer containing TRIS 100 mM (pH 7.4)  and 
10% SDS. The lysates were scraped and transferred into eppendorf tubes. The 
samples were heated for 5 minutes at 95°C and sonicated three times for 30 
seconds each time. Lysis of phospho-proteins was performed using ice-cold lysis 
buffer plus the EDTA-free protease inhibitor cocktail containing: AEBSF, 100 mM/ml; 
Arotinin, 80 μM/ml; Bestatin, 5 mM/ml, E64 protease inhibitor, 1.5 mM/ml; Leupeptin, 
2mM/ml; Pepstatin A, 1 mM/ml diluted 1:200 in lysis buffer.    
Protein quantification was performed as described in the BCA assay and samples 
were kept in the freezer at -20 °C until analysed. 
      SDS-PAGE electrophoresis 
Various target protein were identified from cell lysis by Western blot analysis using 
specific antibodies. Samples were diluted with a 1:1 volume of loading buffer (TRIS 
250 μM; SDS 4%; glycerol 10%, β-mercaptoethanol 2%; bromophenol blue 0.006%; 
pH 6.8) and heated for 5 minutes at 90 °C prior to loading. Resolving and stacking 
gels and buffers were prepared as described in appendix 2.   
Samples were loaded into the wells on the stacking gel and run at a constant voltage 
of 100V in a Bio-Rad Mini-PROTEAN II (Bio-Rad, UK) electrophoresis tank until the 
bromophenol blue front had migrated to the bottom of the gel. The proteins in the gel 
66 
 
were transferred to a polyvinylidene difluoride (PVDF) blotting membrane that was 
pre-soaked in methanol (99.8%) for 15 seconds prior to blotting. The membrane was 
placed in a transfer cell on 3 blotting filter paper and followed by gel and 3 filter 
papers on top. The proteins were transferred in an electroblotter (semi-dry transfer 
systems) (Bio-Rad, UK) for 120 min at 1mA per cm2 of membrane. The gels were 
stained in Coomassie blue reagent after the transferring stage to check the efficiency 
of the protein transferred to the membrane followed by de-staining using a solution of 
methanol (455 ml), DDW (455 ml) and glacial acetic acid (90 ml). The membrane 
was blocked in blocking buffer (washing buffer (1x), 0.1% Tween20 and 5% fat free 
milk or BSA for phospho-proteins) for 1 hour at room temperature to prevent 
nonspecific antibody binding to charged and other molecules on the membrane, thus 
preventing or reducing background noise.  
The membrane was then incubated with the appropriate primary antibody for the 
target protein and for β-actin, which was used to standardise for loading. On the 
following day, the membrane was washed with 1x washing buffer (200ml of 10X 
washing buffer (Appendix 2.7) + 2ml Tween-20 + 1800 ml of DDW) for 30 minutes, 
changing the buffer every 5 minutes. This was followed by a further 90 minute 
incubation of the membrane with the secondary antibody and the antibody for the 
molecular weight marker in blocking buffer. The membrane was washed for another 
30 minutes, changing the wash buffer every 5 minutes. Proteins were detected by 
the enhanced chemiluminescence detection method following the manufacturer’s 
protocol. The membrane was covered with ECL reagent and then exposed to 
photosensitive film for 1 to 5 minutes. The photosensitive film was developed and 
fixed. The developed protein bands on the film were scanned using an Epson 
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(Perfection 2480 Photo) Scanner and the intensities of the protein bands on the 
scanned image were measured using the densitometry software, Syngene Gene 
Tools (version 3.00) and the data expressed as the percentage of the value obtained 
for Control samples.  
 
2.2.7 Stripping the western blot membrane 
If a membrane was needed for another probe after ECL treatment, it was washed 
for 10 min with washing buffer prior to incubation with a stripping buffer (2 g SDS in 
62.5 mM Tris-HCl pH 6.7 plus 700 µl mercaptoethanol) at 50°C for 30 min (on 
shaker). The blotting procedure was repeated and the primary and secondary 
antibody incubations carried out as described above.  
 
2.2.8 Preparation of DH5-α Competent E.coli 
Using a loop, DH5-α cells were transferred directly from frozen stock to growth 
media (TYM; Tryptone, 20 g/l; Yeast Extract, 5 g/l; MgSO4.7H2O, 2.5 g/l; NaCl, 5.8 
g/l; dissolved in DDW) and incubate overnight at 37°C. The following day, 2 ml of an 
overnight culture was incubated with 200 ml TYM. Cells were grown to a density of 
approximately 108 cells/ml for 3 hours at 37°C in a microbiological shaker. The 
cultures were cooled on ice for 10 minutes and recovered by centrifugation at 4100 
rpm for 10 minutes. The supernatant was removed and the pallet re-suspended in 20 
ml of ice-cold frozen storage buffer (potassium acetate, 1M pH 7.5; MnCl2.4H2O, 
8.91 g; CaCl2.2H2O, 1.47 g; potassium chloride, 7.46 g; hexaminecobalt chloride, 
0.80 g; glycerol, 100 ml; DDW, 1 L). Re-suspended cells were then placed on ice for 
68 
 
10 minutes before centrifuging at 4100 rpm for 10 minutes. The supernatant was 
removed and the pallet re-suspended in 14 ml of ice-cold storage buffer containing 
140 μl DMSO per 5 ml of re-suspended cells. Cells were incubated on ice for 15 
minutes before being aliquot into eppendorf tubes and stored at -70°C until needed.  
 
2.2.9 Transformation of E.Coli DH5-α with dominant negative GFP-a-Fos or 
GFP-TAM-67 
Aliquots of competent DH5-α cells were thawed on ice for 15 minutes. Under aseptic 
condition, 200 μl of DH5-α cells were transferred into three vials, labelled and kept 
on ice. Vial 1 contained no plasmid, vial 2 contained the positive control vector 
(PUC19: small, high copy number E.coli plasmid cloning vector) and vial 3 contained 
the plasmid. The suspension in the vials were mixed and incubated on ice for 30 
minutes. Following heat shock for 30-45 seconds at 37°C (in water bath), the 
competent cells were immediately placed on ice for 5 min. 800 μl of liquid broth (LB 
without antibiotics) was added and then cultures incubated for 1 hours in 37°C. 
Cultures were centrifuged at 14,000 rpm for 1 minutes and the supernatant 
discarded. The pellet was re-suspended in 100 μl of LB and transferred on the agar 
plates containing 50 μg/ml Kanamycin. Plates were allowed to stand at room 
temperature for 1 hour before incubating at 37°C overnight for colony growth. A 
mature single colony, resistance to Kanamycin was used to inoculate sterile bottle 
containing 10 ml of LB (with 50 μg/ml Kanamycin). The cultures were incubated 
overnight at 37°C in an orbital shaker. It should be noted that the colour of L-Broth 
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should change from a clear yellow to a cloudy solution indicating the growth of 
bacteria in suspension.   
 
2.2.10 Mini-scale preparation of plasmid DNA (mini-preps) 
A single colony of transformed DH5-α cells from a fresh plate was picked using a 
flamed sterile loop and inoculated into 10 ml LB containing Kanamycin. This was 
then left to incubate in an orbital shaker for 24 hours at 37°C. An aliquot of 1 to 5 ml 
of an overnight recombinant E.Coli culture was pelletted at 12,000 rpm for 1 minute. 
The supernatant was discarded and the pellet re-suspended in 200 μl re-suspension 
solution (Tris-Cl, 50 mM; pH 8.0; EDTA, 10 mM; RNase A, 100 μg/ml) by vortexing in 
order to thoroughly re-suspend the cells. Cells were lysed with 200 μl of lysis solution 
(NaOH, 200mM; SDS, 1%) and mixed immediately by gentle inversion until the 
mixture become clear and viscous. 350 μl of neutralization/binding solution 
(Potassium acetate, 3.0 M; pH 5.5) was added to precipitate the cell debris. Tubes 
were then gently inverted and the debris pelleted by centrifuge at 12,000 rpm for 10 
minutes. Each tube was washed twice with 750 μl wash solution and centrifuged at 
12,000 rpm for 30 seconds to 1 minute to remove residual salts and other 
contaminants. The supernatant was discarded and re-centrifuged again at 12,000 
rpm for 1 to 2 minutes to remove excess ethanol. Finally the DNA was eluted by the 
addition of 100 μl of elution solution (NaCl, 1.6 M; MOPS, 50 mM; pH 7.0; 
Isopropanol, 15%) and centrifuged at 12,000 rpm for 1 minute. The elute containing 
the DNA was collected and stored at -20°C for future use. 
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2.2.11 Preparation of 0.8% agarose for mini-gel 
The quality of the DNA generated was determined on an agarose gel. The gel was 
prepared by dissolving 0.4 g of agarose in 50 ml of 1X gel running buffer (Tris, 90 
mM; EDTA 2.5 mM; Boric acid, 90 mM) and dissolved in a microwave. The mixture 
was poured in the gel tray after being slightly cool and well forming comb inserted 
and left to set properly. The gel was placed in the tank and covered with gel running 
buffer. Plasmid DNA was loaded into the wells and run for 2 hours at 80 volts. The 
gel was stained with ethidium bromide (5μg/ml) added to the running buffer for 1 
hour. Plasmid DNA was visualized in a UV chamber and captured using a Bio 
Imaging System and Gene Genius software program. 
 
2.2.12 Determination of DNA yield 
The quantification of DNA was performed spectrophotometrically. Two micro litres of 
plasmid DNA was diluted in 998 μl of sterile double distilled water and placed in a 
quartz cuvette. The spectrophotometer was blanked against 1 ml of water and the 
optical density of the DNA read at 260 nm. The concentration of DNA was 
determined using the following equation: 
  
 
ODλ260   is the absorbance of the DNA measured 
50    is concentration in μg/ml of DNA in a solution with an ODλ260 of 1 
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2.2.13 Digestion of plasmids by restriction enzymes  
Plasmids (GFP-a-Fos and GFP-TAM-67) were digested with the restriction enzymes 
BamHI and HindIII for a-Fos or BamHI and XhoI for TAM-67 to confirm the presence 
of the inserted fragment. Restriction enzyme digestion was performed in a volume of 
20 μl on 0.2- 1.5 μg of substrate DNA. The mixture was prepared in an eppendorf 
tube with sterile deionised water at a ratio of 16.3 μl; digestion buffer 2 μl; acetylated 
BSA 0.2 μl and DNA at the concentration of 1 μg/ml. This was mixed by gentle 
pipetting and 0.5 µl of restriction enzyme (10 U/μl) added, mixed by a further gentle 
pipetting and centrifuged for a few seconds at 2000 rpm. The tube was incubated in 
a water bath at 37°C for 4 hours before mixing with loading buffer and loaded on to 
the mini gel. (The maps for each plasmid are attached in appendix 4) 
 
2.2.14 Transfection of RASMCs with dominant negative GFP-a-Fos and 
GFP-TAM-67 
Rat aortic smooth muscle cell were transfected using a polycationic peptide (Peptide 
6; Hart et al., 1998) as described by Cui et al (2005). Cells were seeded at a density 
of 4x104 cells per well in 24-well plates and allowed to reach a confluency of 50-
70%. The transfection mixture was prepared by adding 0.75 μl, Lipofectin (stock of 
1mg/ml) to 100 μl of OptiMEM followed by 40 μl of Peptide 6 (stock 0.1 mg/ml). In a 
different tube, 1 μl of 1 mg/ml DNA stock was added to 100 μl OptiMEM which was 
then added to the content of the first mixture and incubated at room temperature in 
the cell culture hood for 3 hours to let the DNA-Peptide 6 complex form. After the 
incubation period the solution was diluted (1:2) to give 2 μg/ml DNA concentration in 
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OptiMEM. The culture medium was removed from each well and replaced with 500 
μl of complex mixture containing the DNA of interest. Plates were incubated for 3 
hours at 37°C in the cell culture incubator to allow the DNA to internalise. After this 
stage, the transfection mixture was removed and cells incubated in fresh culture 
medium for periods of 3, 6, 9, 12, 18 and 24 hours in order to determine  the 
maximum transfection efficiency. After establishing the optimum time for transfection, 
transfected cells were activated with LPS and IFN- for a further 24 hours. Controls 
were cultured in normal complete growth medium without transfection mixture in the 
presence or absence of LPS and IFN-. The transfected cells were observed under 
UV microscope, which showed the green fluorescent colour and also by western 
blotting using a Green Fluorescent Protein (GFP) antibody.  
 
2.2.15 Isolation of total RNA 
Total RNA was prepared from confluent monolayers of cells using the RNA STAT-60 
reagent (AMC Biotechnology) according to the manufacturer’s instructions. 1 ml of 
RNA STAT-60 was added to each T-25 plate and incubated at room temperature for 
3 min to allow lysis and complete dissociation of nucleoprotein complexes. Cell 
lysates were scrapped using a sharp strile scrapper and transferred into eppendorf 
tubes and 200 µl of chloroform per ml of RNA STAT-60 added to each tube. The 
mixture was then incubated for a further 5 min at room temperature. Each tube was 
vortexed for 15-20 seconds and incubated for 10 min at room temperature before 
centrifugation at 4ºC for 10 min at 10,000 rpm. The upper clear aqueous phase 
containing RNA was removed and transferred into a new eppendorf tube. Total RNA 
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was precipitated by adding 500 µl of isopropyl alcohol per ml of RNA STAT-60 to the 
clear supernatant and samples incubated at room temperature for 10 min before 
centrifuging at 4ºC for 10 min at 10,000 rpm. The RNA pellet was washed three 
times with 75% ethanol, centrifuged for 2 min at 8,000 rpm and then air dried in the 
fume cupboard before re-dissolving in 50 µl of DNase free treated water. The 
samples were frozen down at -20 ºC for future use. 
 
2.2.16 RNA treatment and purification  
Ribonucleases are ubiquitous and are often the leading cause of RNA degradation 
during RNA isolation. Before the resulting RNA could be used it must be ensured 
that the extracted RNA is of high quality, intact and is free of DNA contamination. To 
achieve this, the extracted RNA was initially treated with RNase-free DNase to 
eliminate DNA from the RNA sample. This was carried out using the TURBO DNA-
free DNase kit (Applied Biosystems) according to the manufacturer’s protocol. 
Briefly, the RNA was mixed with DNase enzyme in a DNase buffer (Turbo DNase 
free buffer) and incubated in 37 ºC for 30 min. After incubation time, DNase 
inactivation reagent was added and mixed properly. The RNA was then centrifuged 
at 10,000 rpm for 3 min and supernatant transferred into fresh ependorph tubes. The 
samples were then freeze in -20 ºC. 
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2.2.17 Quantification of isolated RNA 
The RNA concentration was assessed using a UV spectrophotometer (Eppendorf 
Biophotometer, Germany) by measuring the absorbance at 260 (OD260) and 280 
(OD280) nm and calculating the concentration as follows:  
RNA concentration (μg/ml) = A λ260 X 40 μg/ml X Dilution Factor 
Where 
Aλ260 is Absorbance of RNA 
40 represents the concentration in μg ml-1 of RNA in a solution with an 
OD λ260 of 1. 
Measurements were carried out in triplicate, and the average value was used. Also 
RNA purity was determining using the ratio of absorbance at 260 nm to the 
absorbance at 280 nm (A260/A280).  
RNA quality was assessed by gel electrophoresis, in order to visualize the discrete 
and intact ribosomal bands of 28S and 18S respectively. Sharp and non-smearing 
bands of the latter will confirm the quality and degree of RNA degradation. Figure 2.6 
is a sample of agarose gel and ribosomal band for both RASMCs and J774 
macrophages. 
 
2.2.18 Reverse Transcription 
To quantify the level of gene expression, reverse transcription in combination with 
polymerase chain reaction (Horikoshi et al., 1992; Murphy et al., 1990) was carried 
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out using the high capacity RNA to cDNA Reverse Transcription kit (Appllied 
Biosystems). 2 μg of total RNA was used per 20 μl reaction mix containing RT buffer 
(10 μl), RT enzyme mix (1 μl) plus Nuclease-free H2O to reach to the volume of 20 
μl. The tubes were briefly centrifuged and incubate in a thermal cycler at 37°C for 60 
min. The reaction stopped by heating at 95°C for 5 min and the samples held at 4°C. 
The cDNA was either analysed or frozen down at -20°C until required.       
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Figure 2.6 Agarose gel electrophoresis of RNA isolates from RASMCs and 
J774 macrophages  
The gel is representative of at least five independent isolations and shows 28s and 
18s ribosomal bands. Panel 1 and 3 representing the RNA before DNase treatment 
and Panel 2 and 4 represent the RNA after treatment.  
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2.2.19 PCR primer design 
Primers for use in PCR analysis of iNOS and CATs (Tables 2.1 and 2.2) were 
designed from respective published sequences obtained from the murine database 
with cross-reference to the National Center for Biotechnology Information (NCBI). 
The sequences retrieved were: iNOS [NOS II – RefSeq; NM_010927.3], CAT-1 
[SLC7A1 – RefSeq; NM_007513.3], CAT-2 [SLC7A2] (gene encoding the spliced 
variants of CAT-2A - RefSeq; NM_001044740.1 and CAT-2B- RefSeq; 
NM_007514.3). Housekeeping genes, glyceraldehyde phosphate dehydrogenase 
(GAPDH- RefSeq; NM_008084.2) for mouse and Ribosomal protein L13a (RPL13a- 
RefSeq; NM_009438) for rat were chosen. Primers were designed with a melting 
temperature (Tm) of 60°C ± 2°C using FASTPCR and Molecular Beacon programs. 
The primer sequences generated (Table 2.1 and 2.2) were checked for hairpins and 
self-complementarity using the Oligoucleotide Properties calculator software and 
specificity was assessed using BLAST and/or ClustaW.   
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2.2.20 Polymerase Chain Reaction (PCR)  
Following the reverse transcription, quantitative Polymerase Chain Reaction (qPCR) 
was carried out using the fluorogenic minor groove binding dye, SYBR green (Figure 
2.7), the most commonly used dye for a variety of detections. It is a double-stranded 
DNA intercalating dye which fluoresces, bound to the DNA. A pair of specific primers 
is required to amplify the target gene with this chemistry. The amount of dye 
incorporated is proportional to the amount of generated target. The dye emits at 520 
nm and this can be detected and related to the amount of target gene (Kubista et al., 
2006; Scipioni et al., 2008).  
The experiments were performed in a reaction mixture (20μl) consisting of 10μl 
Power SYBR green master mix, 2μl each of sense and antisense primers (Forward 
and reverse), 2 μl of template cDNA (1μg/μl cDNA) and 4μl of DNA free water.  
PCRs were performed using a Quantica real time machine (Techne) using the ‘hot-
start’ approach as follows: 
           AmpliTaq Gold polymerase activation at 95°C for 10 min 
Template cDNA denaturing at 95°C for 15 secs 
Annealing between 59 to 61°C depending on the primer used for 30 secs  
Extension at 72°C for 45 secs  
The annealing/extension were allowed to progress through a maximum of 45 cycles. 
This was followed by:  
Dissociation at 56°C - 95°C and Final hold at 4°C 
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Figure 2.7 Structure of SYBR green 
Asymmetric cyanines have two aromatic systems containing nitrogen, one of which 
is positively charged and connected by a methine bridge. The dye has virtually no 
fluorescence when it is free in solution due to vibrations engaging both aromatic 
systems, which convert electronic excitation energy into heat that dissipates to the 
surrounding solvent. On the other hand the dye becomes brightly fluorescent when it 
binds to DNA, presumably due to the minor channel, and to the fact that rotation 
around the methine bond is restricted (Bengtsson et al., 2003; Zipper et al., 2004). 
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2.2.21 Analysing PCR data 
To investigate physiological changes in gene expression levels, relative 
quantification was used to analyse the data generated from qPCR results. This is 
based on the expression level of a target gene versus a housekeeping gene 
(reference or control gene). The relative quantities can thus be compared across 
multiple real time PCR experiments (Orlando et al., 1998). The q-PCR results were 
analysed by the comparative CT method also known as the Delta-Delta CT method 
(2-ΔΔCT). This method involves comparing threshold cycle (Ct) values of both the 
target gene and the housekeeping gene. The latter was used to normalize the 
expression results in both control and activated or treated samples. It is therefore 
necessary that reliable housekeeping genes having minimal variation in expression 
irrespective of the treatment strategies are employed. To further improve our 
amplification profile, we incorporate a mathematical model and analyze our data by 
adjusting for PCR efficiency differences as described (Pfaffl, 2001). 
Figure 2.8 shows a sample of standard curve (panel A) which should be plotted for 
each samples and housekeeping gene. Preparing a standard curve for each gene, 
which needs to be analysed, can provide a good idea of the performance of the 
qPCR. The standard curve should include at least 5 points of dilution. Plotting these 
points on a standard curve, determine the linearity, efficiency, sensitivity and 
reproducibility of the assay. The slope of the standard curve gives the efficiency of 
the PCR reaction by the following equations: 
     Exponential amplification = 10(-1/slope) 
     Efficiency = 10(-1/slope) –1 
If the slope of the standard curve is -3.32 then the PCR is 100 % efficient. 
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With 100 % efficiency, a 2x dilution gives a ΔCt of 1 between each dilution (each 
cycle the amount of amplification is doubled). 
With 100 % efficiency, a 10x dilution gives a ΔCt of 3.2 values between each dilution 
(every 3.2 cycles the amount of amplification is 10 fold higher). 
PCR efficiency between 90 %-110 % is acceptable (slope between 3.1 and 3.58) 
(Kubista et al., 2006; Schmittgen et al., 2008). 
Panel B, an amplification curve, reveals the number of cycles for amplification in 
which the lower a cycle the higher expression. Panel C is the crossing point, which 
shows the CT value.  
Figure 2.9 panel A and B, shows the dissociation peak and background correction 
respectively. 
Figure 2.10 is an example of comparison between control and activated samples for 
iNOS expression.   
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 Figure 2.8 The standard curve, amplification curve and crossing points of the 
PCR 
Panel A is an example of a standard curve and Panel B is demonstrates the cycle for 
the same standard to be amplified. Panel C shows the same cycle with the baseline 
and the threshold cycle (Ct) value. The blue colour line is the baseline which is the 
average background. It is calculated according to the noise level in the early cycles, 
when there is no detectable increase in fluorescence, due to PCR products. The 
threshold (the red colour line) is the level of fluorescence above the baseline, at 
which the signal is not considered to be background. The Ct value is defined as the 
cycle in which there is a significant increase in reporter signal, above the threshold. It 
is consequently related to the initial amount of DNA and shows also the sensitivity of 
the assay. The Ct value is consequently in inverse proportion to the expression level 
of the gene. If the Ct value is low, it means the fluorescence crosses the threshold 
early, meaning that the amount of target in the sample is high. 
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Figure 2.9 The dissociation curve and background correction 
An example of a dissociation curve which demonstrates the peck temperature for 
dissociation of DNA ladder is shown in Panel A. As the temperature of dissociation 
depend on the length and composition of the amplicon, it is consequently possible to 
check how many products of amplification are present in the well. A nice meltcurve 
should show a unique dissociation peak. This temperature is specific for each 
product (primer). Panel B is a sample of background correction.  
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  Figure 2.10 Amplification curve 
An example of expression cycle with different samples (control and activated for 
iNOS). The control expression is in the later cycles (26) and activated cells 
expressed iNOS in the earlier cycles (18-22 according to the treatment).     
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2.2.22 Preparation of Nuclear Extract for ELISA 
Confluent monolayer of RASMCs or J774 macrophages in T-75 flasks were washed 
with 10 ml of ice-cold PBS/PIB (Protease Inhibitor Buffer) [125mM NaF (Sodium 
Fluoride), 250mM β-glycerophosphate, 250mM p-nitrophenyl phosphate (PNPP), 
25mM NaVO3 (Sodium metavanadate) ]. The PBS/PIB was discarded and another 10 
ml of this solution added to cell which were then scraped with a cell scraper. Cells 
were subsequently transferred to pre-chilled 15 ml falcon tube and centrifuge at 300 
rpm for 5 min at 4°C. Supernatants were removed and pellets resuspended in 1 ml of 
ice-cold hypotonic buffer (HB) (20mM Hepes, pH 7.5, 5mM NaF, 1μM Na2MoO4, 
0.1mM EDTA). The mixture was transferred into a pre-chilled 1.5 ml eppendorf tube 
and left on ice for 15 min for cells to swell. After this stage 50 μl 10% Nonidet P-40 
(0.5% final) was added and tubes vortexed vigorously for 10 sec. 
The homogenates were centrifuge for 30 sec at 4°C in a microcentrifuge and the 
supernatant (cytoplasmic fraction) removed, while the pellet was resuspended in 50 
μl complete lysis buffer and left on ice for 30 min on a shaking platform. The tubes 
were centrifuged at 4°C for 10 min at 12,000 rpm and the supernatant (Nuclear 
Extract) transferred  to a fresh tube and stored in -80°C until analysed. 
 
2.2.23 Analysis of AP-1 activation using the TransAM AP-1 kit 
To determine the effect of various experimental procedures on AP-1 activity, a 
TransAM AP-1 kit (Active Motif, Belgium) was used to assess the activated status of 
different AP-1 subunits. This kit contains a 96 well ELISA plate with immobilized 
double-stranded oligonucleotide that contains a TPA Response Element (TRE; 5´-
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TGAGTCA-3´) which specifically binds to phospho subunits of AP-1 in the nuclear 
extract. Phosphorylated and bound to DNA epitopes of AP-1 subunits (c-Jun, JunB, 
JunD, c-Fos, FosB, Fra-1 and Fra-2) were subsequently identified using a primary 
antibody. A secondary HRP-conjugated antibody provides a sensitive colorimetric 
read-out which could be quantified by spectrophotometry.  
For each assay, 10 μg of nuclear extract was diluted in complete lysis buffer (the 
total volume of 20 μl) and added to the binding buffer (30 μl) which was added to the 
wells previously. After one hour incubation at room temperature, plates were washed 
with washing buffer and the primary antibody specific for each subunit, diluted (1:500 
for c-Jun and 1:1000 for the rest of antibodies) and added to the wells. Each plate 
was incubated at room temperature with mild agitation for another hour before 
washing three times with wash buffer. The procedure was followed by the incubation 
with the HRP- conjugated secondary antibody (1:1000 dilution) for a further one 
hour. The wells were washed three times before adding 100 μl developing solution. 
The reaction was stopped after 10 min using 100 μl stop solution and the 
absorbance read on a spectrophotometer in 450 nm. The complete procedure is 
summarised in Figure 2.11. 
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Figure 2.8 The mechanism of TransAM AP-1 family kit 
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2.3 Analysis of data  
All values are expressed as means ± S.E.M of measurement of at least three 
different experiments with replicates in each. Statistics applied to data was one way 
Anova followed by Dunnett’s Multiple Comparison Test for the experiment in which 
one control was compared Treatment conditions. Two way Anova, was used to 
compare multiple data complex in which various concentrations of drugs were 
compared over different time point. 
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Chapter 3 
Effects of JNK/AP-1 inhibition on the expression 
profile of the inducible L-arginine-nitric oxide 
pathway in rat cultured aortic smooth muscle cells 
and the murine J774 macrophages. 
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3.1 Introduction  
The role of the JNK signalling pathway in the induction of iNOS in different cell 
systems has been controversial and inconclusive as highlighted in Chapter 1. Even 
in our group it has been difficult to ascertain the critical role of the JNKs in regulating 
either induced NO synthesis or L-arginine transport. In preliminary unpublished 
observations, it would appear SP600125 regulates the expression of the inducible L-
arginine-NO pathway in J774 macrophages but not in RASMCs even though the 
latter can be regulated by dominant negatives of AP-1 which again show opposing 
effects (unpublished observations). It is not clear whether this could be due, at least 
in part, to the experimental approaches used and/or the cell systems being 
investigated. To ascertain the precise role of the JNK/AP-1 pathway and establish 
whether the discrepancies are due to cell type differences or to limitations of using 
SP600125 as a pharmacological inhibitor, studies have been conducted in this 
chapter that examined the concentration-dependent effects of an additional potent 
JNK inhibitor referred to as JNK inhibitor VIII (N-(4-Amino-5-cyano-6-ethoxypyridin-2-
yl)-2-(2,5-dimethoxyphenyl) in comparison with SP600125.  
Studies were carries out in both RASMCs and J774 macrophages to ensure we 
could identify potential cell type differences. Although additional studies were 
planned for using freshly isolated peritoneal rat macrophages, these were eventually 
not conducted because of the lack of adequate facilities for obtaining these cell from 
infection-free animals. The experiments were intended to eliminate inconsistencies 
that may arise from species as opposed to cell type differences.  
In addition to the pharmacological approach, other experiments were conducted 
exploiting dominant negative constructs for AP-1, which are a-Fos and TAM-67. 
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These constructs contain a transactivation domain, in addition to the bZIP domain, 
that is phosphorylated or dephosphorylated in response to various stimuli. Deletion 
of the major transactivation domain of c-Jun (amino acids 3–122) results in TAM-67 
being produced as a dominant-negative mutant of c-Jun and blocks AP-1 activity 
(Young et al., 1999; Li et al., 2000). a-Fos which is a chimeric protein belongs to the 
c-Fos leucine zipper family and has a designed 25 amino acid acidic protein 
sequence which replaces the DNA-binding region. It heterodimerizes with c-Fos 
dimerization partners, preventing AP-1-DNA binding and as a result blocks the 
activity of AP-1 (Gerdes et al., 2006). Figure 1.10 presents the schematic structure of 
the two dominant negatives. 
Induction of the L-arginine-NO pathway in RASMCs consistently requires LPS and 
IFN- in our laboratory while J774 macrophages require LPS alone. In fact, it would 
appear that the induction of transporter activity in particular is independent of IFN-
signalling in J774 cells (Baydoun et al., 1993), suggesting a difference in the 
signalling for the two processes (i.e. induced NO synthesis and induced L-arginine 
transport).  As an expansion of these previous observations additional studies have 
been carried out exploring the effects of LPS, IFN-and a combination of both on 
iNOS and CAT mRNA expression to determine whether the divergence between 
these agents is reflected at the nuclear and thus functional levels. 
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 Figure 3.1.1 AP-1 Dominant negatives constructs  
The schematic presents the structure of GFP-aFos and GFP-TAM67 mutants. TA: 
transactivating domain; TR: transrepressing domain; DBD: DNA binding domain; LZ: 
leucine zipper dimerization domain; GFP: green fluorescent protein (Bahassi et al., 
2004). 
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3.2 Methods 
All general protocols have been described in Chapter 2 and the methods outlined in 
this section highlight specific details relevant to the experiments carried out for this 
chapter. In all the experiments, control cells were harvested at the maximum time 
course without addition of any inflammatory stimulator or any drug incubation. 
 
3.2.1 Time course of iNOS gene expression, protein induction and NO 
production in RASMCs and J774 macrophages 
 
Cells were cultured to confluency in T-25 flasks and treated either with LPS (100 μg 
ml-1)/ IFN- (100 U ml-1) (RASMCs) or LPS (1 μg ml-1) alone (J774 macrophages) for 
periods of either 3, 6, 12, 18 and 24 hours (RNA analysis) or 0.5, 1, 2, 6, 12, 18 and 
24 hours (protein analysis). Control cells were incubated with complete culture 
medium alone. Total RNA was subsequently extracted, cDNAs generated by  
reverse transcription and analysed by qPCR using 1 μg/ml of cDNA template 
together with rat iNOS specific primers (Tables 2.1 and 2.2).  
For Western blotting, cells were cultured in 6 well plates and treated as above before 
generating lysates for analysis. The medium was used to measure the amount of 
nitrite produced using the Griess assay. 
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3.2.2 Effect of different stimuli on iNOS gene expression, protein induction 
and NO production in J774 macrophages 
 
Monolayers of J774 macrophages were plated in T-25 culture flasks and incubated 
for 24 hours with either LPS (1 μg ml-1), IFN- (1 U ml-1) or LPS plus IFN- together. 
Changes in iNOS mRNA expression were determined on isolated RNA by RT-
qPCR analysis as described above using murine iNOS specific primers (Tables 2.1 
and 2.2). Parallel studies were carried out on 6-well plates and lysates generated 
for western blotting using a monoclonal anti-iNOS antibody.  
 
3.2.3 Effect of SP600125 and JNK inhibitor VIII on nitric oxide production,  
iNOS expression and L-arginine transport in RASMCs and J774 
macrophages 
Confluent monolayer of cells in 96- or 6-well plates were respectively activated for 
24 hours with LPS (100 μg ml-1) and IFN- (100 U ml-1) (RASMCs) or LPS (1 μg ml-
1) alone (J774 macrophages) following a 30 min pre-treatment period with either 
SP600125 (0.1-10 μM) or JNK inhibitor VIII (0.1-10 μM). Controls were incubated 
with culture medium alone. Incubations were terminated 24 hours after activation, 
the medium was removed for nitrite measurement and cell monolayers washed 
three times with ice cold PBS. Lysate were prepared and sample subjected to 
western blotting. In parallel study, confluent monolayers of cells in 96 well plates 
were used to determine the transport of L-[3H]-arginine. 
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3.2.4  Effect of SP600125 and JNK inhibitor VIII on cell viability in RASMCs 
and J774 macrophages 
To examine any potential cytotoxic action of each drug, confluent monolayers of the 
cells in 96 well plates were treated with different concentration of SP600125 (0.1-30 
μM) or JNK inhibitor VIII (0.1-30 μM) for 30 min prior to a 24 hours activation with 
LPS (100 μg ml-1) and IFN- (100 U ml-1) for RASMCs or LPS (1 μg ml-1) alone for 
J774 macrophages. Cells were then incubated for a further 4 hours with MTT (0.5 
mg/ml) and assayed for formazan production and analysis.  
 
3.2.5 Generation of Mini-preps of pGFP-a-Fos and pGFP-TAM-67 
Mini-preps of pGFP-a-Fos and pGFP-TAM-67 were produced from transformed 
DH5- E. Coli. The quality of DNA isolated was determined using a 0.8% agarose 
mini-gel and the quantity estimated spectrophotometrically. Plasmids were digested 
with the restriction enzymes BamHI and HindIII for a-Fos or BamHI and XhoI for 
TAM-67 and then analysed as described in the methods.  Restriction enzyme digest 
was performed in a volume of 20 μl on 1 μg of DNA. The mixture was prepared with 
sterile deionised water, digestion buffer, acetylated BSA and DNA at the 
concentration of 1 μg/ml. Restriction enzymes were added and incubated in a water 
bath at 37°C for 4 hours before mixing with loading buffer and then ran on the mini 
gel.  
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3.2.6 Expression profile of p-GFP-a-Fos and pGFP-TAM-67 transfected into 
RASMCs 
Partially confluent (60-70%) monolayers of RASMCs in 24 well plates transfected 
with pGFP-a-Fos or pGFP-TAM-67 were visualised under the UV microscope at the 
different time point of 3, 6, 18 and 24 hours. Lysates were also prepared at the end 
of each time point and subjected to western blotting for the detection of GFP using 
an anti-GFP primary antibody. 
 
3.2.7 Effect of pGFP-a-Fos and p-GFP-TAM-67 on LPS and IFN- induced nitric 
oxide production, iNOS expression and L-[3H]-arginine transport in 
RASMCs 
Partially confluent (60-70%) monolayers of RASMCs were transfected with either 
pGFP-a-Fos or pGFP-TAM-67 before being activated for 24 hours with LPS (100 μg 
ml-1) and IFN- (100 U ml-1) at 18 hours post transfection as this was the optimum 
time for incubation that did not result in significant cell loss but gave good expression 
of GFP. Cells incubated with culture medium alone or with transfection mix 
containing peptide 6 (to increase the transfection efficiency) were used as respective 
control. Nitric oxide production was determined by the nitrite assay and lysates from 
cell monolayers subjected to western blotting. In parallel plates, uptake of L-[
3
H]-
arginine was monitored in cell monolayers using transport buffer containing 100 µM 
unlabelled L-arginine plus 1 µCi ml-1 of L-[3H]-arginine.  
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3.2.8 The effect of SP600125 on iNOS mRNA expression in RASMCs and J774 
macrophages 
Confluent monolayers of cells were treated with SP600125 (0.3 and 3 μM) for 30 
min prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for RASMCs or 
LPS (1 μg ml-1) alone for macrophages for a further 18 hours. The control cells 
were incubated in complete culture medium in the absence or presence of 
SP600125 for the same period of time but without activation with LPS and IFN-. 
The incubations were terminated at the end of this time, total RNA extracted and 
analysed using iNOS specific primers in the qPCR reaction.  
 
3.2.9 Effect of a-Fos and TAM-67 on iNOS mRNA expression in RASMCs 
Because of the difficulties encountered in transfecting macrophages, studies using 
the dominant negatives were limited to RASMCs which were  grown to partial 
confluency  (60-70%) before being  transfected with pGFP-aFos or pGFP-TAM-67 
for 18 hours and then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 18 hours. The total RNA was extracted and analysed using iNOS specific 
primers.  
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3.3 Results 
 
3.3.1  Identification and biochemical characterization of Rat Aortic Smooth 
Muscle Cells (RASMCs) 
The characteristics of the cells isolated from rat aorta were determined 
morphologically and biochemically to ensure that studies were carried out on the 
required cell types. Cultures isolated exhibited the characteristic spindly morphology 
and Figure 3.1, shows the labelling of the -actin filaments positively identifying 
smooth muscle cells. 
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Figure 3.1  Morphology and -actin staining of RASMCs  
Smooth muscle cells were isolated from rat aorta as described in the methods 
(section 1.2.5) and plated at a density of 50-60% in Lab-Tec wells. Cells were 
allowed to establish over 2 days before staining for -actin as described in the 
methods (Section 2.1.5). This figure is representative of at least five experiments 
carried out at random on various isolates. 
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3.3.2  Time course of iNOS gene and protein expression and NO production 
in RASMCs and J774 macrophages 
Gene expression of iNOS in both RASMCs (Figure 3.2) and J774 macrophages 
(Figure 3.5) was detectable as early as 3 h after activation and increased time-
dependently, reaching a peak at 18 to 24 hours after induction. Similarly, iNOS 
protein was also detectable early and was marginally present in controls which would 
indicate some basal expression even before activation of cells. The levels however 
remained low and stable at the earlier time points increasing significantly at 12 hours 
in RASMCs (Figure 3.3) and 6 hours in macrophages (Figure 3.6), reaching peak 
levels in both cell types at 18 to 24 hours after activation.  Nitrite production reflected 
the trends seen for iNOS gene and protein expression in both cell systems (Figures 
3.4 for RASMCs and 3.7 for J774 macrophages) 
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Figure 3.2 iNOS gene expression profile in RASMCs   
Confluent monolayers of RASMCs were incubated in culture medium alone or in 
medium containing LPS (100 µg ml-1) and IFN- (100 U ml-1) for different time 
periods. Total RNA was isolated from cells and the cDNA prepared before analysing 
by quantitative PCR using iNOS specific primers. The graph reflects fold changes in 
iNOS level in activated cells relative to control. The results are the mean ± SEM of 3 
independent experiments with 3 replicates in each.  
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Figure 3.3 iNOS protein expression profile in RASMCs  
Confluent monolayers of RASMCs were incubated in culture medium alone or in 
medium containing LPS (100 µg ml-1) and IFN- (100 U ml-1) for different time points. 
Lysates were generated at the end of each incubation and subjected to western 
blotting using an anti-iNOS selective antibody. Expression of -actin was also 
determined and used to standardise the loading and expression levels of iNOS. The 
bar graph is a scanning densitometry obtained using a Bio Imaging System and the 
Gene Genius software program (Gene Snap). The results represent percentage 
change in iNOS expression relative to the 24 h activation time point and are the 
mean ± SEM of three separate experiments. Statistical analysis was carried out 
using a one way Anova followed by Dunnett’s multiple comparison test. 
iNOS (130 kDa) 
β-actin (42 kDa) 
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Figure 3.4  Nitrite production profile in RASMCs 
Confluent monolayers of RASMCs were incubated in culture medium alone or in 
medium containing LPS (100 µg ml-1) and IFN- (100 U ml-1) for different time points. 
Accumulated nitrite was determined by the Griess assay as described in the 
methods (Section 2.2.2) and standardised for total protein present in each well. The 
result is expressed as a percentage of the total amount of nitrite accumulated at 24 h 
and is the mean ± SEM of 3 independent experiments with 3 replicates in each.  
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Figure 3.5 iNOS gene expression profile in J774 macrophages  
Confluent monolayers of J774 macrophages were incubated in culture medium alone 
or in medium containing LPS (1µg ml-1) for different time periods. Total RNA was 
isolated from cells and the cDNA prepared before analysing by quantitative PCR 
using iNOS specific primers. The graph reflects fold changes in iNOS level in 
activated cells relative to control. The results are the mean ± SEM of 3 independent 
experiments with 3 replicates in each.  
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Figure 3.6 iNOS induction profile in J774 macrophages 
Confluent monolayers of J774 macrophages were incubated in culture medium alone 
or in medium containing LPS (1µg ml-1) for different time points. Lysates were 
generated at the end of each incubation and subjected to western blotting using an 
anti-iNOS selective antibody. Expression of -actin was also determined and used to 
standardise the loading and expression levels of iNOS. The bar graph is a scanning 
densitometry obtained using a Bio Imaging System and the Gene Genius software 
program (Gene Snap). The results represent percentage change in iNOS expression 
relative to the 24 h activation time point and are the mean ± SEM of three separate 
experiments. Statistical analysis was carried out using a one way Anova followed by 
Dunnett’s multiple comparison test. 
iNOS (130 kDa) 
β-actin (42 kDa) 
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Figure 3.7 Nitrite production profile in J774 macrophages 
Confluent monolayers of J774 macrophages were incubated in culture medium alone 
or in medium containing LPS (1µg ml
-1
) for different time points. Accumulated nitrite 
was determined by the Griess assay as described in the methods (Section 2.2.2) 
and standardised for total protein present in each well. The result is expressed as a 
percentage of the total amount of nitrite accumulated at 24 h and is the mean ± SEM 
of 3 independent experiments with 3 replicates in each.  
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3.3.3 Effect of different stimuli on iNOS gene and protein expression and NO 
production in J774 macrophages  
In order to determine whether J774 macrophages respond differently to LPS or IFN- 
in expressing iNOS and NO, cell were incubated with LPS (1 µg  ml-1), IFN- (1 U ml-
1) or both for 18 hours and qPCR, Western blotting and the Griess assays were 
performed to detect changes in iNOS gene expression, protein induction and nitrite 
production respectively. As shown in Figure 3.8, levels of iNOS mRNA were 
marginal in controls but significantly elevated by up to 800-fold following activation 
with LPS.  IFN- also induced iNOS mRNA but to a much lesser extent (only 160-
fold) than that seen with LPS alone. Both LPS and IFN- together increase the level 
of gene induction by up to 1000 fold.  
The result of the western blots and griess assays reflected a similar pattern in that 
LPS caused a higher induction of iNOS protein expression (Figure 3.9) and NO 
production (Figure 3.10) than IFN- but together produced an even more pronounced 
change than either agent alone. 
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Figure 3.8 Effects of LPS, IFN- and a combination of both on iNOS gene 
expression in J774 macrophages 
Confluent monolayer of J774 macrophages were stimulated with either LPS (1 μg ml-
1), IFN- (1 unit ml-1) or both for 18 hours. Total RNA was isolated from cells and the 
cDNA prepared and analysed by quantitative PCR using iNOS specific primers. The 
graph reflects fold changes in iNOS level in activated cells compared to control. The 
results are representative of 3 independent experiments with 3 replicates in each.   
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Figure 3.9 Effects of LPS, IFN- and a combination of both on iNOS protein 
expression in J774 macrophages 
Confluent monolayer of J774 macrophages in 6 well plate were incubated with either 
LPS (1 μg ml-1), IFN-(1 unit ml-1) or a mixture of both for 18 hours. Lysates were 
generated at the end of the incubation period and subjected to western blotting using 
an anti-iNOS selective antibody. Expression of -actin was also determined and 
used to standardise the loading and expression levels of iNOS. Protein bands were 
quantified by scanning densitometry using a Bio Imaging System and the Gene 
Genius software program. The data is expressed as a percentage of levels detected 
at 24 h post activation and is the mean ± SEM of three separate experiments. 
iNOS (130 kD) 
β-actin (42 kD) 
116 
 
       
    
 
Figure 3.10  Effects of LPS, IFN- and a combination of both on Nitrite 
production in J774 macrophages 
Confluent monolayers of J774 macrophages were incubated with either LPS (1 μg 
ml-1), IFN-1 unit ml-1) or a mixture of both for 18 hours. Accumulated nitrite was 
determined by the Griess assay and standardised for total protein present in the 
well. The result is expressed as pmol nitrite/µg protein/24 hours and is the mean ± 
SEM of 3 independent experiments with 3 replicates in each.  
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3.3.4 Effect of SP600125 on nitric oxide production in RASMCs 
Consistent with all our studies, treatment of RASMCs with LPS (100 μg ml-1) and 
IFN- (100 U ml-1) for 24 h, resulted in the production of NO, which was not 
detectable in control non-activated cells. Under these conditions, activated cells 
produced 0.4 ± 0.01 pmole nitrite µg protein-1 24 h-1. As seen in Figure 3.11, NO 
production was increased marginally by SP600125 at 0.3 μM, declining thereafter to 
the LPS/IFN- stimulated levels. SP600125 (0.1-10 µM) however failed to cause any 
significant inhibition in either basal or activated nitrite release when incubated with 
cells for 30 min prior to activation (Figure 3.11). 
 
3.3.5  Effect of SP600125 on iNOS expression in RASMCs 
To determine the effect of SP600125 on iNOS protein expression, western blot 
analysis was performed on lysates obtained from control and activated cells in the 
absence and presence of increasing concentration of SP600125 (0.1-10 μM). There 
was no detectable expression of iNOS in control non-activated cells. In contrast, 
activation with LPS and IFN- caused the expected induction of iNOS protein which 
remained unaltered in cells treated with increasing concentrations of SP600125 of up 
to 10 µM (Figure 3.12). 
 
3.3.6  Effect of SP600125 on L-[3H]-arginine transport in RASMCs 
Consistent with previous findings (Baydoun, 1999), basal rates of L-[3H]-arginine 
transport were increased in RASMCs exposed to LPS (100 μg ml-1) and INF- (100 U 
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ml-1). In these experiments, L-[3H]-arginine transport increased from control values of 
1 pmoles μg protein-1 min-1 (n=3) to 1.4 ± 0.05 pmole μg protein-1 min-1 (n=3) in 
activated cells. SP600125 at the full concentration range of 0.1 μM to 10 μM failed to 
cause any significant changes in either basal or activated transport rates (Figure 
3.13). 
 
3.3.7  Effect of SP600125 on Cell viability in RASMCs  
Viability studies carried out in parallel with experiments outlined above revealed that 
SP600125 did not cause any significant degrees of cytotoxicity in RASMCs over the 
concentration range of 0.1 μM to 3 μM. At 10 μM, the activated cells reveal a decline 
in viability of 18%, with the higher concentration of 30 μM showing a more significant 
increase in cell toxicity (Figure 3.14). As a result all experiments using SP600125 
were limited to a maximum concentration of 10 µM. 
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Figure 3.11 Effect of SP600125 on NO production in RASMCs 
Confluent monolayers of RASMCs were incubated with increasing concentrations of 
SP600125 for 30 min prior to a further 24 h incubation in culture medium alone or in 
medium containing LPS (100 µg  ml-1) and IFN- (100 U ml-1). Accumulated nitrite 
was determined by the Griess assay and standardised for total protein present in the 
well. The results are expressed as a percentage of the total amount of nitrite 
accumulated at 24 h and are the mean ± SEM of 3 independent experiments with 3 
replicates in each. Statistical analysis was carried out using a one way Anova 
followed by Dunnett’s multiple comparison test. *p<0.05 compared to activated non-
drug treated cells. 
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Figure 3.12  Effect of SP600125 on iNOS expression in RASMCs 
Confluent monolayers of RASMCs were incubated with increasing concentrations of 
SP600125 for 30 min prior to a further 24 h incubation in culture medium alone or in 
medium containing LPS (100 µg ml-1) and IFN- (100 U ml-1). Lysates were 
generated at the end of the incubation period and subjected to western blotting using 
an anti-iNOS selective antibody. Expression of -actin was also determined and 
used to standardise the loading and expression levels of iNOS. The bar graph is a 
scanning densitometry of iNOS expression as a percentage of the levels detected at 
24 h post activation and is the mean ± SEM of three separate experiments. 
Statistical analysis was carried out using a one way Anova followed by Dunnett’s 
multiple comparison test. 
iNOS 
β-actin 
LPS/IFN- 
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Figure 3.13 Effect of SP600125 on L-[3H]-arginine transport in RASMCs  
Confluent monolayers of RASMCs were incubated with increasing concentrations of 
SP600125 for 30 min prior to a further 24 h incubation in culture medium alone or in 
medium containing LPS (100 µg ml-1) and IFN- (100 U ml-1). L-arginine transport 
was monitored over 2 min in Krebs buffer containing 1μCi ml-1 L-[3H]arginine plus 
100 μM unlabelled L-arginine. The data is expressed as percentage of the transport 
rates in the control non treated samples. The results are representative of 3 
independent experiments with 5 replicates in each. Statistical analysis was carried 
out using a one way Anova followed by Dunnett’s multiple comparison test. 
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Figure 3.14  Effect of SP600125 on Cell viability in RASMCs  
Cells were pre-incubated with SP600125 for 30 min prior to incubated in culture 
medium alone or activation with LPS (100 μg ml-1) and INF- (100 U ml-1)  for 24 h. 
The culture medium was removed at the end of this period and cells were incubated 
with MTT (0.5 mg/ml) in 200 μl fresh medium per well at 37°C for 4h. The formazan 
crystals produced from the metabolism of MTT were subsequently solubilised in 100 
μl of Isopropanol. Plates were read at 540 nm using a Multiscan II plate reader. All 
values are a percentage of formazan production in the control non-activated cells 
and are expressed as the mean ± S.E.M of 4 separate experiments with 5 replicate 
in each. Statistical analysis was carried out using a one way Anova followed by 
Dunnett’s multiple comparison test. * p<0.05 and ** p<0.01 compared to activated 
non-inhibitor cells. 
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3.3.8  Effect of SP600125 on NO production in J774 macrophages 
Exposure of J774 macrophages to LPS (1 μg ml-1) resulted in the induction of NO 
production with nitrite levels increasing from none detectable amount under control 
conditions to 0.6 ± 0.01 pmoles nitrite μg protein-1 24 h-1 in activated cells. When 
applied, SP600125 caused a biphasic effect which was a significant up-regulation of 
accumulated nitrite levels at concentrations of 0.3 to 1 μM and a significant 
concentration-dependent inhibition at 3 to 10 μM (Figure 3.15). 
 
3.3.9 Effect of SP600125 on iNOS expression in J774 macrophages 
To verify whether SP600125 affect the level of iNOS expression in J774 
macrophages, western blot analysis was  performed on lysates obtained from control 
and activated cells in the absence and presence of increasing concentration of the 
drug. There was no detectable expression of iNOS in control non-activated cells. In 
contrast, activation with LPS caused the induction of iNOS protein which, as seen 
with nitrite production, was enhanced at 0.1 to 0.3 μM SP600125 and decreased 
thereafter with 10 μM reducing accumulated nitrite levels by 50% (Figure 3.16).  
 
3.3.10  Effect of SP600125 on L-[3H]-arginine transport in J774 macrophages  
Activation of J774 macrophages resulted in a significant increase in L-[3H]-arginine 
transport which was elevated from 1.2 pmoles µg protein-1 min-1 (control; n=3) to 1.7 
pmoles µg protein-1 min-1 (n=3) following LPS treatment. SP600125 did not cause 
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any significant changes on L-arginine transport except at 10 μM where transport rate 
in activated but not controls was reduced by 24% (n=3) (Figure 3.17). 
 
3.3.11  Effect of SP600125 on Cell viability in J774 macrophages  
Similar to the findings in RASMCs, viability studies carried out to determine the 
toxicity of SP600125 in J774 macrophages showed that the compound was only 
cytotoxic at concentrations above 10 µM and as can been seen in Figure 3.18, there 
was a significant reduction in cell viability when SP600125 was used at the 
concentration of 30 μM. Thus, when used, the maximum concentration of the drug 
was limited to 10 µM.   
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Figure 3.15  Effect of SP600125 on NO production in J774 macrophages 
Confluent monolayers of J774 macrophages were incubated with increasing 
concentrations of SP600125 for 30 min prior to a further 24 h incubation in culture 
medium alone or in medium containing LPS (1 µg ml-1). Accumulated nitrite was 
determined by the Griess assay and standardised for total protein present in the well. 
Values are expressed as the mean ± S.E.M of 3 separate experiments with 3 
replicate in each. Statistical analysis was carried out using a one way Anova 
followed by Dunnett’s multiple comparison test. * p<0.05 and ** p<0.01 compared to 
activated non-inhibitor cells. 
126 
 
                                        
 
   
C
on
tr
ol
A
ct
iv
at
ed 0.
1
0.
3 1 3 10
0
50
100
150
*
**
*
          SP600125 Concentration (M)
iN
O
S
e
x
p
re
s
s
io
n
(%
 a
c
ti
v
a
te
d
 c
o
n
tr
o
l)
 
Figure 3.16 Effect of SP600125 on iNOS expression in J774 macrophages 
Confluent monolayers of J774 macrophages were incubated with increasing 
concentrations of SP600125 for 30 min prior to a further 24 h incubation in culture 
medium alone or in medium containing LPS (1 µg ml-1). Lysates were generated at 
the end of the incubation period and subjected to western blotting using an anti-iNOS 
selective antibody. Expression of -actin was also determined and used as a loading 
control in the assay. The bar graph is a scanning densitometry of iNOS expression 
as a percentage of the levels detected at 24 h post activation and is the mean ± SEM 
of three separate experiments. Statistical analysis was carried out using a one way 
Anova followed by Dunnett’s multiple comparison test. *p<0.05 and **p<0.01 
compared to activated, non-inhibitor cells. 
       LPS 
iNOS 
β-actin 
127 
 
       
0.
0
0.
1
0.
3
1.
0
3.
0
10
.0
0
50
100
150
Control
Activated
**
SP600125 concentration (M)
L
-a
rg
in
in
e
 t
ra
n
s
p
o
rt
 (
%
 c
o
n
tr
o
l)
 
 
 
 
Figure 3.17  Effect of SP600125 on L-arginine transport in J774 macrophages  
Confluent monolayers of J774 macrophages were incubated with increasing 
concentrations of SP600125 for 30 min prior to a further 24 h incubation in culture 
medium alone or in medium containing LPS (1 µg ml-1). L-arginine transport was 
monitored over 2 min in Krebs buffer containing 1μCi ml-1 L-[3H]-arginine plus 100 
μM unlabelled L-arginine. Values are expressed as the mean ± S.E.M of 3 separate 
experiments with 5 replicate in each. Statistical analysis was carried out using a one 
way Anova followed by Dunnett’s multiple comparison test. ** p<0.01 compared to 
activated non-inhibitor cells 
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Figure 3.18  Effect of SP600125 on Cell viability in J774 macrophages  
Cells were pre-incubated with SP600125 for 30 min prior to activation with LPS (1 μg 
ml-1). After 24 h activation, the culture medium was removed and cells were 
incubated with MTT (concentration of 0.05 mg/ml) in 200 μl fresh medium per well at 
37°C for 4h. The medium was removed and the formazan crystals produced from the 
metabolism of MTT solubilised in 100 μl of Isopropanol. Plates were read at 540 nm 
using a Multiscan II plate reader. All values are expressed as a percentage of the 
control non-activated cells. Values are expressed as the mean ± S.E.M of 4 separate 
experiments with 5 replicate in each. Statistical analysis was carried out using a one 
way Anova followed by Dunnett’s multiple comparison test. * p<0.05 and ** p<0.01 
compared to activated non-inhibitor cells. 
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3.3.12 Effect of JNK Inhibitor VIII on NO production in RASMCs  
To confirm the role or lack of involvement of JNK in the induction of iNOS and NO 
production in RASMCs further experiments were carried out using an additional 
inhibitor of the JNK pathway. The compound used, referred to as JNK inhibitor VIII, 
is known to block JNK I, II and III (Ki = 2 nM, 4 nM and 52 nM for JNK1, 2 and 3, 
respectively; EC50 of 920 nM) (Ogino et al., 2009; Kluwe et al., 2010). This inhibitor 
however failed to cause any significant changes in either basal or activated nitrite 
release when incubated with cells at concentrations of 0.1 μM to 10 μM for 30 min 
prior to activation (Figure 3.19). This finding, together with the data from the 
SP600125 studies, seems to further support a lack of involvement of the JNK 
pathway in the induction of iNOS in RASMCs. 
 
3.3.13 Effect of JNK Inhibitor VIII on iNOS expression in RASMCs  
To determine the effects of JNK Inhibitor VIII on iNOS protein expression, western 
blot analysis was performed on lysates obtained from control and activated cells in 
the absence and presence of increasing concentration of JNK Inhibitor VIII (0.1-10 
µM). There was no detectable expression of iNOS in control non-activated cells. In 
contrast, activation with LPS and IFN- caused the expected induction of iNOS 
protein which remained unaltered in cells treated with JNK inhibitor VIII as shown in 
figure 3.20.  
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3.3.14 Effect of JNK Inhibitor VIII on L-arginine transport in RASMCs  
Following the nitrite assay, transport of L-[3H]-arginine was conducted on the 
underlying cell monolayers. In these experiments, L-[3H]-arginine transport increased 
from control values of 1 pmoles μg protein-1 min-1 (n=3) to 1.4 pmoles μg protein-1 
min-1 (n=3) in the cells activated with LPS/IFN-. Treatment with JNK inhibitor VIII at 
the full concentration range of 0.1 μM to 10 μM failed to cause any significant 
changes in either basal or activated transport rates (Figure 3.21).  
 
3.3.15 Effect of JNK Inhibitor VIII on Cell viability in RASMCs  
Viability studies carried out in parallel with experiments outlined above, revealed that 
JNK Inhibitor VIII did not cause any significant degrees of cytotoxicity in RASMCs 
over the concentration range of 0.1 μM to 10 μM; however at 30 μM the drug did 
appear cytotoxic, decreasing cell viability by 26% in control and 40% in activated 
cells (treated with LPS and INF-) as shown in Figure 3.22. As a result all 
experiments using JNK inhibitor VIII limited the concentration used to a maximum of 
10 μM. 
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Figure 3.19  Effect of JNK Inhibitor VIII on NO production in RASMCs  
Confluent monolayers of RASMCs were incubated with increasing concentrations of 
JNK inhibitor VIII for 30 min prior to a further 24 h incubation in culture medium alone 
or in medium containing LPS (100 µg  ml-1) and IFN- (100 U ml-1). Accumulated 
nitrite was determined by the Griess assay and standardised for total protein present 
in the well. The results are expressed as a percentage of the total amount of nitrite 
accumulated at 24 h and are the mean ± SEM of 3 independent experiments with 3 
replicates in each. Statistical analysis was carried out using a one way Anova 
followed by Dunnett’s multiple comparison test. 
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Figure 3.20  Effect of JNK Inhibitor VIII on iNOS expression in RASMCs  
Confluent monolayers of RASMCs were incubated with increasing concentrations of 
JNK inhibitor VIII for 30 min prior to a further 24 h incubation in culture medium alone 
or in medium containing LPS (100 µg ml-1) and IFN- (100 U ml-1). Lysates were 
generated at the end of the incubation period and subjected to western blotting using 
an anti-iNOS selective antibody. Expression of -actin was also determined and 
used to standardise the loading and expression levels of iNOS. The bar graph is a 
scanning densitometry of iNOS expression as a percentage of the levels detected at 
24 h post activation and is the mean ± SEM of three separate experiments. 
Statistical analysis was carried out using a one way Anova followed by Dunnett’s 
multiple comparison test. 
iNOS 
β-actin 
LPS/IFN- 
Control     0         0.1        0.3         1           3           10          
                 JNK Inhibitor VIII concentration (µM) 
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Figure 3.21  Effect of JNK Inhibitor VIII on L-arginine transport in RASMCs  
Confluent monolayers of RASMCs were incubated with increasing concentrations of 
JNK Inhibitor VIII for 30 min prior to a further 24 h incubation in culture medium alone 
or in medium containing LPS (100 µg ml-1) and IFN- (100 U ml-1). L-arginine 
transport was monitored over 2 min in Krebs buffer containing 1μCi ml-1 L-[3H]-
arginine plus 100 μM unlabelled L-arginine. The results are representative of 3 
independent experiments with 5 replicates in each. Statistical analysis was carried 
out using a one way Anova followed by Dunnett’s multiple comparison test. 
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Figure 3.22  Effect of JNK Inhibitor VIII on Cell viability in RASMCs  
Cells were pre-incubated with JNK Inhibitor VIII for 30 min prior to activation with 
LPS (100 μg ml-1) and INF- (100 U ml-1). After 24 h activation, the culture medium 
was removed and cells were incubated with MTT (concentration of 0.5 mg/ml) in 200 
μl fresh medium per well at 37°C for 4h. The medium was removed and the 
formazan crystals produced from the metabolism of MTT solubilised in 100 μl of 
Isopropanol. Plates were read at 540 nm using a Multiscan II plate reader. All values 
are expressed as a % of the control non-activated cells. Values are expressed as the 
mean ± S.E.M of 3 separate experiments with 5 replicate in each. Statistical analysis 
was carried out using a one way Anova followed by Dunnett’s multiple comparison 
test. * p<0.05 and ** p<0.01 compared to activated non-inhibitor cells. 
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3.3.16 Effect of JNK Inhibitor VIII on NO production in J774 macrophages  
In contrast to its lack of effect in RASMCs, but consistent with the actions of 
SP600125 in J774 macrophages, JNK inhibitor VIII initially marginally enhanced 
LPS-induced nitrite accumulation at 0.1 μM and 0.3 μM, inhibiting by 23 % and 38%  
at concentrations of 3 μM and 10 μM respectively (Figure 3.23). 
 
3.3.17 Effect of JNK Inhibitor VIII on iNOS expression in J774 macrophages  
Parallel studies were also carried out in J774 macrophages to verify whether JNK 
inhibitor VIII affect the level of iNOS expression in J774 macrophages.  Western blot 
analysis was performed on lysates obtained from control and activated cells in the 
absence and presence of increasing concentration of the drug. In these studies, JNK 
inhibitor VIII was without significant effect at concentrations of ≤1 µM but inhibited 
iNOS expression by 29% and 44% at 3 μM and 10 μM respectively (Figure3.24).  
 
3.3.18 Effect of JNK Inhibitor VIII on L-arginine transport in J774 macrophages  
Consistent with the observations in RASMCs, activation of J774 macrophages 
resulted in a significant increase in L-arginine transport which was elevated from 1.2  
pmoles µg protein-1 min-1 (in control; n=3) to 1.7 pmoles µg protein-1 min-1 (n=3) 
following LPS treatment. JNK inhibitor VIII at concentrations of 3 and 10 μM caused 
a significant down regulation in L-arginine transport in the J774 macrophages 
activated with LPS but not in controls (Figure 3.25). 
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3.3.19 Effect of JNK Inhibitor VIII on Cell viability in J774 macrophages  
Viability studies carried out to determine the toxicity of JNK inhibitor VIII in J774 
macrophages showed that the compound was cytotoxic particularly at 30 μM as 
shown in Figure 3.26. As a result all experiments using JNK inhibitor VIII in J774 
macrophages limited the concentration used to a maximum of 10 μM. 
 
 
 
 
 
 
 
 
137 
 
      
C
on
tr
ol
A
ct
iv
at
ed 0.
1
0.
3 1 3 10
0
25
50
75
100
125
*
*
*
                     JNK Inhibitor VIII concentration (M)
N
it
ri
te
 a
c
c
u
m
u
la
ti
o
n
(%
 a
c
ti
v
a
te
d
 c
o
n
tr
o
l)
 
 
 
 
 
Figure 3.23 Effect of JNK Inhibitor VIII on NO production in J774 macrophages  
Confluent monolayers of J774 macrophages were incubated with increasing 
concentrations of JNK Inhibitor VIII for 30 min prior to a further 24 h incubation in 
culture medium alone or in medium containing LPS (1 µg ml-1). Accumulated nitrite 
was determined by the Griess assay and standardised for total protein present in the 
well. Values are expressed as the mean ± S.E.M of 3 separate experiments with 3 
replicate in each. Statistical analysis was carried out using a one way Anova 
followed by Dunnett’s multiple comparison test. * p<0.05 compared to activated non-
inhibitor cells. 
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Figure 3.24 Effect of JNK Inhibitor VIII on iNOS expression in J774 
macrophages  
Confluent monolayers of J774 macrophages were incubated with increasing 
concentrations of JNK inhibitor VIII for 30 min prior to a further 24 h incubation in 
culture medium alone or in medium containing LPS (1 µg ml-1). Lysates were 
generated at the end of the incubation period and subjected to western blotting using 
an anti-iNOS selective antibody. Expression of -actin was also determined and 
used as a loading control in the assay. The bar graph is a scanning densitometry of 
iNOS expression as a percentage of the levels detected at 24 h post activation and 
is the mean ± SEM of three separate experiments. Statistical analysis was carried 
out using a one way Anova followed by Dunnett’s multiple comparison test. **p<0.01 
and ***p<0.001 compared to activated, non-inhibitor cells. 
iNOS 
β-actin 
    LPS 
Control     0         0.1        0.3       1          3         10          
                 JNK Inhibitor VIII concentration (µM) 
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Figure 3.25  Effect of JNK Inhibitor VIII on L-arginine transport in J774 
macrophages  
Confluent monolayers of J774 macrophages were incubated with increasing 
concentrations of JNK Inhibitor VIII for 30 min prior to a further 24 h incubation in 
culture medium alone or in medium containing LPS (1 µg ml-1). L-arginine transport 
was monitored over 2 min in Krebs buffer containing 1μCi ml-1 L-[3H]-arginine plus 
100 μM unlabelled L-arginine. Values are expressed as the mean ± S.E.M of 3 
separate experiments with 5 replicate in each. Statistical analysis was carried out 
using a one way Anova followed by Dunnett’s multiple comparison test.  
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Figure 3.26  Effect of JNK Inhibitor VIII on Cell viability in J774 macrophages  
Cells were pre-incubated with JNK Inhibitor VIII for 30 min prior to activation with 
LPS (1 μg ml-1). After 24 h activation, the culture medium was removed and cells 
were incubated with MTT (concentration of 0.5 mg/ml) in 200 μl fresh medium per 
well at 37°C for 4h. The medium was removed and the formazan crystals produced 
from the metabolism of MTT solubilised in 100 μl of Isopropanol. Plates were read at 
540 nm using a Multiscan II plate reader. All values are expressed as a percentage 
of the control non-activated cells. Values are expressed as the mean ± S.E.M of 3 
separate experiments with 5 replicate in each. Statistical analysis was carried out 
using a one way Anova followed by Dunnett’s multiple comparison test. * p<0.05 
compared to activated non-inhibitor cells.  
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3.3.20 Mini-preps of a-Fos and TAM-67 characterised by restriction digest  
DH5-α competent cells, were generated as described in the methods (Section 2.2.9) 
and transformed with pGFP-a-Fos and pGFP-TAM-67 (Section 2.2.10). The cultures 
were isolated and purified by mini-prep (Section 2.2.11) and a mini-gel was run to 
observe the purity of the plasmids isolated which as shown in Figures 3.27 (Panel A) 
appears as smear-free bands confirming that the isolates were not degraded.  
Restricting the plasmids with BamHI and HindIII for a-Fos (Figure 3.27, panel B) or 
BamHI and XhoI for TAM-67 (Figure 3.27, panel C) produced single bands of 250 
and 700 kb respectively which correspond to their insert sizes. 
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Figure 3.27 Mini-preps of non-restricted and restricted a-Fos and TAM-67   
The plasmids were either left intact or restricted and then separated on a mini-gel to 
ensure they possessed the correct insert as well as observe their purity.  The figures 
show the unrestricted plasmid (Panel A), plasmids restricted using BamHI & HindIII 
for a-Fos (Panel B) or BamHI and XhoI for TAM-67 (Panel C). The first columns in 
the panels represent the DNA ladder (1kb) and in Panel B the next 2 column are 
undigested plasmid and the rest are digested plasmids showing fragments of 250 bp 
which corresponds to the a-Fos insert. Panel C shows a band of 700 bp 
corresponding to the insert size of TAM-67.    
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3.3.21 Expression profile of transfected pGFP-a-Fos and pGFP-TAM-67 
plasmide in RASMCs 
The optimum transfection time was first established prior to examining the effect of 
plasmids on NO production, iNOS expression and L-arginine uptake. This was 
carried out by examining the expression of each plasmid at various time points after 
the transfection using the GFP-antibody. Lysates from transfected cells were 
analysed by western blot analysis as described, using a primary GFP-antibody as an 
indicator of the expression of GFP. The expression of β-actin was also determined in 
parallel (Figure 3.28) and used to confirm the loading efficiency. Western blotting 
confirmed successful transfection of RASMCs with both a-Fos and TAM-67 as 
expression of the GFP tagged to a-Fos and TAM-67 (panel A and B respectively) 
was detectable over the time course examined, albeit marginally, at 6 hrs reaching a 
peak at 24 hrs. It is worth noting however that incubations of 24 hours cause 
cytotoxicity to cells with many lifting off from the monolayers. To ensure the planned 
experiments could be carried out we did the study for an 18 hour transfection time 
period which as shown in Figure 3.29 revealed high transfection efficiency but with 
little change in either cell morphology or density. 
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Figure 3.28  Expression of GFP in time course study of transfected pGFP-a-
Fos and pGFP-TAM-67 in RASMCs  
Partially confluent RASMCs were transfected with pGFP-a-Fos or pGFP-TAM-67 in 
24 well plates as described in the methods (Section 2.2.14). Lysate of transfected 
cells were analysed by western blotting using a primary GFP-antibody to detect 
pGFP-a-Fos (Panel A) or pGFP-TAM-67 (Panel B). The expression of -actin was 
also determined in parallel and used to determine the loading efficiency. The blots 
are representative of 2 individual experiments. 
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               (A)                  a-Fos after 18 hours                                                                                                                                                                                                                                                                                                                                      
a           a(B)                             TAM-67 after 18 hours  
 
 
Figure 3.29   Visualisation of Transfected RASMCs with pGFP-a-Fos and   
pGFP-TAM-67 at 18 hours 
Partially confluent RASMCs were transfected with pGFP-a-Fos (panel A) or pGFP-
TAM-67 (panel B) in 24 well plates as described in the methods (Section 2.2.15). 
Cells were visualised under UV light 18 hours post transfection using a Nikon EFD3, 
LABOPHOT-2 florescence microscope at 40x magnifications. The photographs are 
representative of 3 individual experiments.          
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3.3.22 Effect of pGFP-a-Fos and pGFP-TAM-67 on LPS and IFN- induced NO 
production in RASMCs  
Partially confluent monolayers of RASMCs were transfected with pGFP-a-Fos or 
pGFP-TAM-67 for 18 hours and activated for 24 h with LPS (100 μg ml-1) and IFN- 
(100 U ml-1). Nitric oxide production was determined by the nitrite assay as 
described in the methods (section 2.2.2). The data obtained  from these studies 
suggest opposing effects of the dominant constructs in that pGFP-a-Fos caused a 
marginal but significant increase (18%) of NO production in activated cells, while 
pGFP-TAM-67 significantly suppressed induced NO production, reducing the later by 
45% (Figure 3.30). Neither pGFP-a-Fos nor pGFP-TAM-67 caused any significant 
changes in basal nitrite levels in control non-activated cells.  
 
3.3.23 Effect of pGFP-a-Fos and pGFP-TAM-67 on LPS and IFN- induced iNOS 
expression in RASMCs  
To determine whether the changes on NO production observed above were 
associated with changes in iNOS expression, partially confluent monolayers of 
RASMCs transfected with pGFP-a-Fos or pGFP-TAM-67 for 18 h and activated for 
24 h with LPS (100 μg ml-1) and IFN- (100 U ml-1) were lysed and subjected to 
western blotting. As shown in Figure 3.31 iNOS bands were not detectable in control 
non-activated cells but present in cells exposed to LPS and IFN-. More importantly, 
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level of the enzyme increased by 24% in cells expressing pGFP-a-Fos but reduced 
by 27% in cells expressing pGFP-TAM-67. 
3.3.24 Effect of pGFP-a-Fos and pGFP-TAM-67 on LPS and IFN- induced L-
arginine transport in RASMCs  
In parallel with the study on NO production and iNOS expression, experiments were 
also carried out examining the effect of either pGFP-a-Fos or pGFP-TAM-67 on L-
arginine transport in both control and activated RASMCs. The data shown in Figure 
3.32 reveal that transport of L-arginine was not altered in a-Fos transfected cells 
when compared to the controls. In contrast, activated cells expressing TAM-67 
showed a significant reduction in L-arginine transport, with the induced rates 
decreasing from 1.6 ± 0.01 pmoles μg protein-1 min-1 (n=3) to the basal control rates 
of 1.3 ± 0.015 pmoles μg protein-1 min-1 (n=3). Transport into control cells was 
unaffected suggesting a selective action of TAM-67 on the induction process. 
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Figure 3.30 Effect of pGFP-a-Fos and pGFP-TAM-67 on LPS and IFN- induced 
NO production in RASMCs  
50- 70% confluent monolayers of RASMCs were transfected with pGFP-a-Fos (panel 
A) or pGFP-TAM-67 (panel B) and activated for 24 h with LPS (100 μg ml-1) and IFN-
 (100 U ml-1). Cells incubated with culture medium alone or with transfection mix 
containing peptide 6 were used as controls. Nitric oxide production was determined 
by the nitrite assay. Values are expressed as the mean ± S.E.M of 3 separate 
experiments with 3 replicate in each. Statistical analysis was carried out using a one 
way Anova followed by Dunnett’s multiple comparison test. * p<0.05 and *** p<0.01 
compared to activated non-transfected cells. 
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Figure 3.31 Effect of pGFP-a-Fos and pGFP-TAM-67 on LPS and IFN- induced 
iNOS expression in RASMCs  
50-70% confluent monolayers of RASMCs were transfected with pGFP-TAM-67 or 
pGFP-a-Fos and activated for 24 h with LPS (100 μg ml-1) and IFN- (100 U ml-1). 
iNOS expression was determined by western blotting using a specific anti-iNOS 
monoclonal antibody as described in the methods. Expression of -actin was also 
determined and used to standardise the loading and expression levels of iNOS. 
Protein bands were quantified by scanning densitometry using a Bio Imaging System 
and the Gene Genius software program. The data is expressed as a percentage of 
value obtained for samples from activated cells and is the mean ± SEM of three 
separate experiments. Statistical analysis was carried out using a one way Anova 
followed by Dunnett’s multiple comparison test. ** p<0.01 compared to activated 
non-transfected cells. 
 
 
 
 
 
 
 
152 
 
                           
C
on
tr
ol
a-
Fo
s 
C
on
tr
ol
A
ct
iv
at
ed
a-
Fo
s 
A
ct
iv
at
ed
0
50
100
150
**
iN
O
S
e
x
p
re
s
s
io
n
(%
 a
c
ti
v
a
te
d
 c
o
n
tr
o
l)
 
 
                    
C
on
tr
ol
TA
M
-6
7 
C
on
tr
ol
A
ct
iv
at
ed
TA
M
-6
7 
A
ct
iv
at
ed
0
50
100
**
iN
O
S
e
x
p
re
s
s
io
n
(%
 a
c
ti
v
a
te
d
 c
o
n
tr
o
l)
 
iNOS 
β-actin 
iNOS 
β-actin 
a-Fos 
TAM-67 
153 
 
 
Figure 3.32 Effect of pGFP-a-Fos and pGFP-TAM-67 on LPS and IFN- induced 
L-arginine transport in RASMCs  
Partially confluent monolayers of RASMCs were transfected with pGFP-a-Fos or 
pGFP-TAM-67 and activated for 24 h with LPS (100 μg ml-1) and IFN- (100 U ml-1). 
Transport of L-arginine was measured over 2 minutes in Krebs buffer containing 
1μCi ml-1 L-[3H]-arginine plus 100 μM unlabelled L-arginine. Values are expressed 
as the mean ± S.E.M of 3 separate experiments with 5 replicate in each. Statistical 
analysis was carried out using a one way Anova followed by Dunnett’s multiple 
comparison test. * p<0.05 compared to activated non-transfected cells. 
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3.3.25  Effect of SP600125 on iNOS gene expression in RASMCs 
The data presented in sections 3.3.4, 3.3.5 and 3.3.6 for SP600125 on iNOS, NO 
synthesis and L-arginine transport would suggest that this compound does not affect 
the induction of the L-arginine-NO pathway in RASMCs. However, the studies 
conducted focused on changes in protein expression and function. To determine 
whether SP600125 regulated gene expression or exerted any effects at the 
transcriptional level, two different concentration of SP600125 (0.3 and 3 μM) were 
examined on iNOS mRNA expression. Consistent with the other data, SP600125 
failed to cause any significant change in iNOS mRNA levels induced by LPS and 
IFN- (Figure 3.33) confirming the lack of effect of this inhibitor on iNOS expression, 
at least in RASMCs.  
 
3.3.26  Effect of SP600125 on iNOS gene expression in J774 macrophages 
In contrast to its lack of effects in RASMCs, SP600125 caused a significant inhibition 
of iNOS mRNA induction in J774 macrophages at the same concentration of 3 µM 
that also significantly suppressed protein levels and NO production. Interestingly, 
there appeared to be a marginal increase in iNOS mRNA at 0.3 µM, aligning with the 
small increase in nitrite levels detected with the Griess assay. The increases in 
mRNA levels were however not statistically significant (Figure 3.34).  
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3.3.27 Effect of pGFP-a-Fos and pGFP-TAM-67 on LPS and IFN- induced iNOS 
gene expression in RASMCs 
To investigate the effect of AP-1 dominant negative construct on iNOS gene 
expression, RASMCs were transfected with a-Fos for 18 hours and activated with 
LPS/IFN- for another 18 hours as described previously. The results of the qPCR 
analysis revealed a pattern reflective of those demonstrated at the expressional and 
functional levels in that a-Fos enhanced while TAM-67 suppressed iNOS mRNA 
expression when compared to the levels induced by LPS and IFN-Figures 3.35 
and 3.36).  
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Figure 3.33 The effect of SP600125 on iNOS gene expression in RASMCs 
Confluent monolayers of RASMCs were incubated with SP600125 (0.3-3 uM) for 30 
min prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for 18 hours. 
Total RNA was isolated from cells and cDNA was prepared before analysing by 
quantitative PCR using iNOS specific primers. The graph reflects fold changes in 
iNOS level in activated cells containing SP600125 compared to activated cells 
without SP600125. The results are representative of 3 independent experiments with 
3 replicates in each and the values are expressed as the mean ± S.E.M of 3 
separate experiments.  
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Figure 3.34  The effect of SP600125 on iNOS gene expression in J774 
macrophages 
Confluent monolayers of J774 macrophages were incubated with SP600125 (0.3-3 
μM) for 30 min prior to activation with LPS (1 μg ml-1) for a further 18 hours. Total 
RNA was isolated from cells and cDNA was prepared before analysing by 
quantitative PCR using iNOS specific primers. The graph reflects fold changes in 
iNOS level in activated cells containing SP600125 compared to activated cells 
without SP600125. The results are representative of 3 independent experiments with 
3 replicates in each and the values are expressed as the mean ± S.E.M of 3 
separate experiments. Statistical analysis was carried out using a one way Anova 
followed by Dunnett’s multiple comparison test. ** p<0.01 compared to activated 
non-inhibitor cells. 
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Figure 3.35 The effect of pGFP-a-Fos construct on iNOS expression in 
LPS/IFN- stimulated RASMCs 
Partially Confluent monolayers of RASMCs were transfected with pGFP-a-Fos for 18 
hours prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a further 18 
hours. Controls were treated with transfection mixture in the absence or presence of 
LPS/IFN-and also another control for the experiment which was activated but 
without transfection. Total RNA was isolated from cells and cDNA was prepared 
before analysing by quantitative PCR using iNOS specific primers. Values are 
expressed as the mean ± S.E.M of 3 separate experiments. Statistical analysis was 
carried out using a one way Anova followed by Dunnett’s multiple comparison test. * 
p<0.05 compared to activated non-transfected cells. 
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Figure 3.36 The effect of pGFP-TAM-67 construct on iNOS expression in 
LPS/IFN- stimulated RASMCs 
Partially Confluent monolayers of RASMCs were transfected with pGFP-TAM-67 for 
18 hours prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a further 
18 hours. Controls were treated with transfection mixture in the absence or presence 
of LPS/IFN-Control for the experiment was not transfected but activated. Total 
RNA was isolated from cells and cDNA was prepared before analysing by 
quantitative PCR using iNOS specific primers. Values are expressed as the mean ± 
S.E.M of 3 separate experiments. Statistical analysis was carried out using a one 
way Anova followed by Dunnett’s multiple comparison test. * p<0.05 compared to 
activated non-transfected cells. 
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3.4 Discussion  
The studies outlined in this thesis were carried out to establish a clear role for 
JNK/AP-1 pathway in the induction of iNOS and CATs in inflammatory condition. 
Two different cell types were chosen according to their relation to iNOS expression; 
Smooth muscle cells which play a key role in vascular tone regulation and are 
reported to be the key site for iNOS expression in vascular inflammation (Knowles et 
al., 2004) were isolated from rat aorta, characterised and routinely used in the 
studies at early passage numbers (between 3 and 6 passages). J774 macrophages 
were the other cell type used because (i) of their role in host immunity in which iNOS 
derived NO plays a critical role and (ii) they have been widely characterised and 
used for studies on iNOS induction in a multitude of laboratories. 
To determine the profile of iNOS induction, experiments were carried out in order to 
establish the time course of induction in response to stimulation with LPS/IFN- in rat 
aortic smooth muscle cells or LPS in J774 macrophages. In RASMCs, iNOS 
expression was evident as early as 30 min after activation with LPS/IFN-The 
marginal levels of the enzyme protein detected at this stage increased in a time 
dependent manner reaching a peak at 24 hours after stimulation of cells. This 
pattern was also consistent for nitrite level which was detectable at significant 
amounts much later as this requires accumulation in the culture medium for 
detection. These results are consistent with other studies in which control smooth 
muscle cells produced little amount of nitrite (approximately 0.01 pmol µg protein-1 
24 h-1) and activation with LPS/IFN- significantly induced this process (Gross et al., 
1992; Petit et al., 1990). In J774 macrophages the pattern was almost the same and 
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the cells respond to LPS stimulation by expressing iNOS and producing nitric oxide 
in a time-dependent manner. However with LPS, there was a marked increase in 
iNOS protein expression after 30 min indicating a rapid response of the cells to 
inflammatory stimulation. A similar effect has also been reported in macrophages 
(Cattell et al., 1990), lung epithelial cells (Robbins et al., 1994), hepatocytes (Smith 
et al., 1997), epithelial cell line (Taylor et al., 1998) and skeletal myoblasts (Adams et 
al., 2002) showing a rapid increase in iNOS expression and NO released. 
Interestingly, in other in vitro cell culture models such as mouse astrocytes, induction 
of iNOS does not peak until 48 hours after stimulation (Di Rosa et al., 1990; Da Silva 
et al., 1997) while in vivo iNOS protein may peak within 3 hours, declining back to 
basal levels 24 h after stimulation (Sunday et al., 2006). The reasons for these 
discrepancies are unclear but highlight the differences and complex nature of iNOS 
induction in different systems. With the rapid in vivo effects, it is possible that the 
tissues/ cells may already be primed or may have other essential components for 
rapid induction which are missing in the in vitro models. 
In RASMCs two stimulants, LPS and IFN- are needed for maximum iNOS induction. 
This may relate to the fact that LPS alone is not enough for iNOS expression and 
IFN- is needed for iNOS mRNA stabilisation (Bergeron et al., 2006; Flodstrom et al., 
1997; Vodovotz et al., 1993). In fact LPS can induce the iNOS gene but the stability 
of the latter may require other elements which can be induced by IFN- By 
comparison, macrophages appear to require only LPS for full induction of iNOS 
indicating that these cells may not require IFN- to stabilise the gene once induced. 
This area however requires further studies to fully elucidate the manner in which 
both message and protein expression are controlled in the two systems. 
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As indicated earlier, and also highlighted above, macrophages respond differently to 
smooth muscle cells in terms of the stimuli required for the induction of the L-
arginine-NO pathway. The different stimuli used in our studies mediate different 
effects in the two systems with IFN-, for example, failing to cause significant 
induction of NO synthesis when compared to LPS. Similarly, IFN- caused only 
partial induction of iNOS mRNA expression, with transcript levels well below those 
seen with LPS or the combination of LPS and IFN- Worth noting is the fact that the 
combination did not cause much of an increase in iNOS mRNA above that seen with 
LPS alone strengthening the suggestion that latter is able to fully induce iNOS 
expression. 
Apart from our data, there are several contradictory reports in the literature on the 
regulation of iNOS induction and NO production in different systems using either 
LPS and/or IFN- For instance, Hammermann et al (2000) have demonstrated that 
both LPS and IFN- could independently induce expression of iNOS in rat lung 
macrophages but the combination of the two did not produce any additive or 
synergistic effects. In contrast, LPS alone (Shi et al., 2006) or IFN- alone (Chan et 
al., 1998) have been shown to have little or no effect on iNOS in macrophages 
respectively. To further highlight these contradictions, IFN- alone has been shown 
to induce iNOS expression in J774 macrophages (Bergeron et al., 2006; Reis et al., 
2001) and RAW264.7 macrophages (Xiong et al., 2003). Clearly the regulation of 
iNOS expression by inflammatory mediators is complex and effects produced may 
be species, cell type or even stimuli dependent. Each system should therefore be 
fully validated in its own right.   
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To determine the role of JNK/AP-1 on the induction of iNOS (and L-arginine 
transport), pharmacological and molecular interventions were exploited. 
Pharmacologically, SP600125 and JNK inhibitor VIII, which have been widely 
reported as being potent inhibitors of the JNK pathway, were used. SP600125, as 
already mentioned, is a selective and reversible inhibitor of the JNKs, inhibiting JNK-
1, JNK-2 JNK-3 with relatively equal potency (IC50 of 40 nM for JNK1 and 2 vs 90 
nm for JNK3). It exerts its effects by inhibiting the phosphorylation of c-Jun 
(Bogoyevitch et al., 2008). The inhibition is competitive with respect to ATP, 
exhibiting over 300-fold greater selectivity for JNK as compared to ERK1 and p38 
MAP kinases. It is worth noting that other studies have reported that SP600125 may 
act on other pathways (Stempin et al., 2008; Stempin et al., 2004). For instance, in 
J774 macrophages SP600125 induces p38 MAPK phosphorylation (Stempin et al., 
2008). This effect is however observed at higher concentrations comparing to ours. 
JNK inhibitor VIII is a cell-permeable pyridinylamide compound that also acts as an 
ATP-competitive, reversible inhibitor of JNK (Ki = 2 nM, 4 nM and 52 nM for JNK1, 2 
and 3, respectively) and displays excellent selectivity over 72 other kinases. It 
inhibits c-Jun phosphorylation with an IC50 of 920 nM in some cell systems 
(Szczepankiewicz et al., 2006) and at present there are no other non-selective 
effects reported for other pathways. 
Using these inhibitors it would appear that the requirement of JNK for iNOS and CAT 
induction may be cell type specific since both inhibitors seem to have different 
effects in the different cell systems used in this thesis. SP600125 had no significant 
inhibitory effect on iNOS expression, NO production or L-arginine transport in 
smooth muscle cells; but showed a biphasic action on iNOS expression and NO 
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production in J774 macrophages, enhancing these processes at lower 
concentrations while inhibiting at higher concentrations. Transport of L-arginine 
however remained unaffected except at 10 μM where induced transport rate was 
inhibited, suggesting that SP600125 may regulate induced but not basal/control CAT 
activity. In this regard experiments conducted looking at changes in CAT mRNA 
expression when SP600125 applied to clarify the role of JNK pathway in transport 
system which will discuss in chapter 4.  
To ensure that the lack of effect with SP600125 in RASMCs was not simply reflective 
of the compound itself parallel studies were carried out using JNK inhibitor VIII, 
which as described above is another know selective and highly potent inhibitor the 
JNKs and capable of inhibiting all isoforms of the kinase. Consistent with SP600125, 
JNK inhibitor VIII did not cause any changes in nitric oxide production, iNOS 
expression or L-arginine transport in RASMCs but suppressed all three processes in 
J774 macrophages indicating that activation of the JNK pathway may be critical in 
these cells but not in the former.  
At present it is not clear why SP600125 exhibited a biphasic effect in J774 
macrophages. It could be speculated that the potentiation reflects the true selective 
inhibition of JNK since these effects were observed with low concentrations of the 
drug. The inhibitory effects produced at the higher concentration range may reflect 
actions at targets other than JNK. This would however indicate a degree of non-
selectivity in the actions of SP600125 and would need further confirmation. It is 
worth noting however that other studies have used concentrations of SP600125 up 
to 50 µM to suppress iNOS expression in Bv-2 cells (Svensson et al,. 2010) and in 
the RAW 264.7 murine macrophages (Jung et al., 2007; Kim et al., 2007), It is also 
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claimed that the inhibitions were independent of both p38 MAPK or ERKs, 
suggesting some degree of selectivity. 
Other than differences in selectivity at the extreme concentrations, another 
alternative explanation for the biphasic actions of SP600125 could be that the cells 
express different isoforms of JNK of which one may be positively coupled to iNOS 
and another isoform may negatively regulate iNOS expression. Thus, inhibition of the 
latter would enhance LPS-induced iNOS expression while inhibition of the former 
would result in suppression in the induction of iNOS. Also there is a possibility that 
AP-1, the downstream targets for JNK, may act in a different way when JNK is 
inhibited in various cell system or different drugs may cause activation or 
suppression of different subunits of this transcription factor. This interesting 
speculation led us to go further and investigate the regulation by SP600125 of AP-1 
and its subunits more closely and the results are discussed in chapter 5.   
Biphasic responses to SP600125 have previously been reported in the macrophage 
cell line RAW 264 (Lahti et al., 2003) where SP600125 enhanced nitrite production 
at 0.1 µM but caused an inhibition at 1µM.  
In order to conclusively confirm  the role of the JNK pathway and thus  AP-1 in  the 
induction of  iNOS and NO production,  additional experiments were carried out 
using two dominant negative constructs of AP-1, a-Fos and TAM-67. a-Fos is a 
chimeric protein which belongs to a class of transcription factors containing the c-Fos 
leucine zipper and a designed 25 amino acid acidic protein sequence which could 
replace the DNA-binding region and hetero-dimerises with c-Fos dimerisation 
partners, to prevent AP-1 DNA binding (Gerdes et al., 2006). TAM-67 is another 
dominant negative which blocks AP-1 activity. Deletion of the major transactivation 
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domain of c-Jun (amino acids 3–122) results in TAM-67 formation. However, TAM-
67 does have a bZIP domain and can, therefore, dimerise with other members of the 
Jun and Fos families, and with other bZIP proteins. Therefore, dimers containing 
TAM-67 are able to bind DNA, but have little or no transactivational activity (Li et al., 
2000; Young et al., 1999). 
In this study both dominant negatives were used in RASMCs in order to establish the 
role of JNK and thus AP-1 in our systems. Studies in J774 macrophages have not 
yet been carried out as transfection of these cells appears to be more difficult, giving 
a very low transfection efficiency.  
The transfection strategy used involved exploiting a polycationic peptide (Peptide 6) 
which binds DNA and introduces this into cells through specific integrin binding sites. 
Peptide 6 has many advantages over other transfection systems, for instance those 
that utilise viruses. Firstly, peptide 6 is easy to synthesise to a high degree of purity; 
sequences can be designed on the basis of known ligands, or new peptides can be 
selected for a particular cell type (Hart et al., 1998).  
Transfection of pGFP-a-Fos or pGFP-TAM-67 with peptide 6 caused a time 
dependent increase in GFP expression reaching a peak at 24 hours. However, there 
appear to be many dead and floating cells when the 24 h transfected cells are 
activated with LPS and IFN- for a further 24 h. This therefore limits experiments that 
can be carried out in the 24 h transfected cells. To reduce the cytotoxic effect of 
Peptide 6 as much as possible and also have enough transfected cells before 
activation, a series of experiments were performed at different time point after 
transfection and based on the amount of GFP band and also the fact that after 24 
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hours the number of dead cells were increased, it was established that 18 hours 
after transfection may be the optimum time to activate cells.  
Transfection of RASMCs with either a-Fos or TAM-67 for 18 h prior to activation 
modified induced iNOS expression and NO production. What is interesting is the fact 
that a-Fos enhanced while TAM-67 inhibited both processes. From these 
observations, it is likely that some components of the JNK/AP-1 pathway may down-
regulate induction of iNOS and NO production under normal physiological conditions. 
Thus when blocked by a-Fos we get an enhancement not only in iNOS but also in 
NO synthesis.  
TAM-67, in contrast to a-Fos, significantly reduced NO production and iNOS 
expression. Transport of L-arginine also declined. These observations may be of 
significant interest as the findings may highlight the differential regulation by the 
JNK/AP-1 pathway of the expression of the inducible L-arginine-NO pathway. It is 
not unreasonable to hypothesise that proteins targeted by a-Fos down-regulate while 
those targeted by TAM-67 up-regulate expression of iNOS and CATs. Thus inhibition 
of one enhances while inhibition of the other decreases NO synthesis and L-arginine 
transport. This hypothesis was further investigated by examining changes in AP-1 
subunit activity in cell transfected with these dominant negatives in paralles with 
those treated with SP600125 in chapter 5.  
One other alternative explanation that could account for the actions of TAM-67 is the 
fact that it may interact with bind the p65 subunit of NF-B and in doing so inhibit NF-
B (Young et al., 1999; Young et al., 2003) which is reported to be critical for the 
induction of iNOS (Goldring et al., 1995; Kone et al., 1995; Xie et al., 1994). This 
novel action of TAM-67 however remains to be confirmed in our cell system.  
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Not only TAM-67 but even c-Jun has been shown to interact with the p65 subunit of 
NF-B to enhance binding to B and AP-1 sites (Stein et al., 1993; Smith et al., 
1999).  
The NF-B family contains five members; p105 (constitutively processed to p50), 
p100 (processed to p52 under tightly regulated conditions), p65 (also known as Rel 
A), Rel B and c-Rel. These NF-B subunits form homodimers and heterodimers to 
make NF-B transcription factors (Simmonds et al., 2008; Uwe Reuter et al., 2002). 
These subunits may be able to cross-talk with AP-1 subunits or with the dominant 
negatives of AP-1.  
Consistent with a role for NF-B, previous work has shown that the three non-
consensus AP-1 sites in the 5'-flanking region of the iNOS promoter were not 
involved in enhancing iNOS transcription by LPS (Lowenstein et al., 1993; Xie et al., 
1992). It is instead suggested that an alternative transcription factor, NF-B, may be 
the critical regulator of iNOS transcription induced by LPS. Moreover, JNK has been 
shown to bind the c-Rel component of NF-B and to enhance NF-B activation 
(Meyer et al., 1996). Although DBD-c-Jun would be expected to inhibit AP-1 activity, 
it is not known whether it would also be capable of inhibiting any NF-B-c-Jun 
interaction, because the mutated c-Jun still contains the bZIP region that is capable 
of binding the p65 subunit (Li et al., 2000; Stein et al., 1993; Young et al., 1999). 
More specifically in the smooth muscle cells, there is no clear evidence confirming 
that JNK/AP-1 has effect on iNOS induction; however it has been suggested that NF-
B activation alone is not sufficient for complete induction of iNOS. NF-B activity 
was induced by TNF-α (Tumour necrosis factor-α), but TNF-α alone cannot induce 
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iNOS promoter activity, protein expression, or nitrite production (Perrella et al., 1996; 
Zhang et al., 2000). It is clear that further work looking at possible cross-talk between 
JNK and NF-B in inducing iNOS and/or L-arginine transport in our cell systems is 
required.  
 To confirm that the inhibitors and dominant negatives of the AP-1 pathway regulate 
iNOS induction, additional studies were carried out examining changes in gene 
expression. The data confirm that in smooth muscle cells, SP600125 caused no 
significant change in mRNA or protein level. On the other hand in macrophages, 
higher concentration of SP600125 down regulated iNOS mRNA levels which is in 
agreement with the data on protein expression. The dominant negatives also 
exhibited the same effect on gene induction as those seen on protein level. a-Fos 
caused up-regulation while TAM-67 decreased iNOS transcript levels.  
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3.5 Summary 
Taken together our data demonstrate the regulation of the expression profile of iNOS 
gene and protein, as well as nitric oxide production and L-arginine transport by LPS 
and IFN- in both RASMCs and J774 macrophages. Of importance is the fact that 
these were regulated differently in the two cell systems in terms of the stimulus 
needed and of the potential cellular events that lead to the inductions. In RASMCs, 
both LPS and IFN- are required while in the macrophages only LPS was essential. 
Moreover, IFN- even when added was without significant effect when compared to 
LPS. In RASMCs, the induction of iNOS and NO synthesis was insensitive to 
pharmacological inhibition while sensitive to AP-1 dominant negatives. Even with 
these constructs the effects produced varied and was dependent on the dominant 
negative used. TAM-67 which inhibits c-Jun activation partially blocked enzyme 
protein and mRNA expression while a-Fos which blocks c-Fos enhanced both 
processes. In J774 macrophages the pharmacological inhibitors did show their 
inhibitory effects and confirm the role of JNK/AP-1 in these cells. All the data 
obtained, reveal a different regulation mechanism in various cell systems. The 
importance of these observations is further discussed in Chapter 5 and the findings 
in their entirety put into context to explain these divergent actions. 
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 Chapter 4  
The expression profile of Cationic Amino acid 
Transporters and their regulation by JNK/AP-1 
inhibition 
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4.1 Introduction 
This chapter has focused on establishing the profile of expression of CATs in 
RASMCs and J774 macrophages and has further explored how the induction of 
these proteins may be regulated by SP600125, a-Fos or TAM-67 at the 
transcriptional level. These studies parallel those on iNOS mRNA expression 
described in Chapter 3 and should further shed light on the transporters that may 
be involved with L-arginie entry and thus substrate supply for iNOS in the two cell 
types.  
As highlighted in the main introductory chapter, L-arginine uptake into cells may be 
mediated by several different carrier proteins of which the CATs may be the most 
predominant. While CAT-2A is generally associated with uptake of cationic amino 
acids (CAAs) into the liver (where it functions to pool these amino acids into the 
liver after meals), CAT-1 has often been known as the key physiological transporter 
of the CAAs within the vasculature; with CAT-2B associated with L-arginine uptake 
into cell under pathological/inflammatory conditions. Indeed, there was a 
consensus that CAT-1 is ubiquitous while CAT-2B may only be expressed in select 
cells and tissues following exposure to pro-inflammatory mediators. Previous 
studies in our group have, however, revealed the presence of all three cationic 
amino acid transporters (CAT-1, 2A and 2B) in control RASMCs (Baydoun et al., 
1999), suggesting that these transporters may be present as a family within the 
same cell systems under normal physiological conditions. Whether they respond in 
the same way to stimulation by inflammatory mediators or whether the induction of 
their respective genes occurs in a similar manner remains to be elucidated. Studies 
described in this chapter were therefore aimed at addressing these issues, at least 
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in part, by exploring how transcripts for each protein may be regulated by LPS and 
IFN- and by inhibitors of the JNK/AP-1 pathway.   
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4.2 Methods 
 
4.2.1 Time course of CAT gene expression in RASMCs and J774 macrophages 
Cells were cultured to confluency in T-25 flasks and treated either with LPS (100 μg 
ml-1)/ IFN- (100 U ml-1) (RASMCs) or LPS (1 μg ml-1) alone (J774 macrophages) 
for periods of 3, 6, 12, 18 and 24 hours. Control cells were incubated with complete 
culture medium alone. Total RNA was subsequently extracted, cDNAs generated 
using RT-PCR reaction and qPCR performed using 1 μg/ml of cDNA template, 
employing CAT-1, CAT-2A or CAT-2B  specific primers (Tables 2.1 and 2.2). 
Expression of RPL-13 or GAPDH was also determined using its specific primers 
and these were used to standardise the loading and expression levels of the CATs 
in RASMCs and J774 macrophages respectively. 
 
4.2.2 Effect of different stimuli on CAT gene expression in J774 macrophages 
Confluent monolayers of J774 macrophages in T-25 culture flasks were incubated 
for 18 hours with either LPS (1 μg ml-1), IFN- (1 U ml-1) or LPS plus IFN- together. 
Changes in CAT-1, CAT-2A or CAT-2B expression were determined on isolated 
RNA  by qPCR analysis using individual CAT specific primers (Tables 2.1 and 2.2).  
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4.2.3 Effect of SP600125 on CAT gene expression in RASMCs and J774 
macrophages 
Confluent monolayers of cells were treated with SP600125 (0.3 and 3 μM) for 30 
min prior to an 18 hour activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for 
RASMCs or LPS (1 μg ml-1) for macrophages. The control cells were incubated in 
complete culture medium in the absence and presence of SP600125 for the same 
period of time but without activation with LPS and IFN-. The incubations were 
terminated at the end of this period, total RNA extracted and analysed using CAT-
1, CAT-2A or CAT-2B specific primers in the qPCR reaction.  
 
4.2.4 Effect of a-Fos and TAM-67 on CAT gene expression in RASMCs 
To determine the effect of AP-1 dominant negative construct on CATs expression 
in the RASMCs, the cells were cultured in T-25 cultured flask to partial confluency 
(60-70%) before being  transfected with pGFP-aFos or pGFP-TAM-67 for 18 hours 
and then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a further 18 
hours. The total RNA was extracted and analysed using CAT-1, CAT-2A or CAT-2B 
specific primers in a qPCR reaction. 
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4.3 Results 
 
4.3.1 Time course of CAT mRNA expression induced by LPS and IFN- in 
RASMCs 
Time course of CAT mRNA induction was conducted in parallel with the studies on 
iNOS gene expression. Changes in CATs expression were determined on isolated 
total RNA by qPCR analysis using CAT specific primers (Tables 2.1 and 2.2). The 
association curve for primers shows the melting temperature for each primer and 
also revealed if there is just one product in the PCR. Figure 4.1 revealed different 
melting temperature for each CAT primers which were: 81.5°C for CAT-1 (panel A), 
81°C for CAT-2A (Panel B) and 77.5°C for CAT-2B (Panel C). Moreover, there was 
only the existence of one detectable peak in the association curves, confirming the 
existence of just one PCR product. 
Figure 4.2 demonstrate that after stimulation with LPS and IFN-, there was a 
reduction in CAT-1 expression, which was evident as early as 3h reaching a 
minimum level at 12 hours and staying reduced over 24 hours in the continued 
presence of LPS. In contrast, mRNA expression of CAT-2A and CAT-2B increased 
following LPS stimulation. Interestingly, the CAT-2A gene increased only marginally 
(less than 2 Fold increase) (Figure 4.3) while CAT-2B mRNA increased significantly 
after 6 hours, reaching a peak of about 14 fold increase above basal levels at 18 
hours and remaining at the elevated level over 24 hours of induction (Figure 4.4). 
These findings confirm that CAT-2B may be the main transporter of L-arginine in the 
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induced cells and this could potentially also be the case in inflammatory condition 
where iNOS and L-arginine transport are induced. 
 
4.3.2 Time course of CAT mRNA expression induced by LPS in J774 
macrophages 
As with the RASMCs, time course of CAT mRNA induction was conducted in parallel 
with the studies for iNOS in J774 macrophages. Figure 4.5 is the association curve 
confirming the presence of just one product for each primer (Panel A for CAT-1; 
Panel B for CAT-2A; Panel C for CAT-2B). It also reveals a different melting 
temperature for each CAT primer which were: 86°C for CAT-1, 80.5°C for CAT-2A 
and 78°C for CAT-2B.  
Figures 4.6 to 4.8 demonstrate the trends for CAT expression in time point assays 
and reveal that CAT-1 mRNA was not significantly altered by incubations with LPS 
over the time course studied (Figure 4.6). In contrast, both CAT-2A and CAT-2B 
transcripts were significantly elevated by LPS from 3 hours onwards reaching peak 
expression after 24 hours of induction (Figure 4.7 and 4.8). Worth noting is the fact 
that in these cells induction of CAT-2A was much higher (80 Fold above basal; 
Figure 4.7) than that seen for CAT-2B which was only elevated 30 fold above the 
basal control levels (Figure 4.8). 
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4.3.3 Effect of different stimuli on CATs mRNA expression in J774 
macrophages 
To verify whether different stimuli show varying profiles of CAT gene expression in 
J774 macrophages, the cells were incubated for 18 hours with either LPS (1 μg ml-1), 
IFN- (1 U ml-1) or LPS plus IFN- together. The total RNA isolated was subjected to 
qPCR analysis using specific primer for each CAT. As shown in Figure 4.9 Panel A, 
after stimulation with LPS, there was no significant changes in the CAT-1 gene 
expression and this trend was the same when IFN- was used independently. The 
combination of both also failed to cause any changes in the CAT-1 gene expression 
levels. Panels B and C reveal that while LPS, as already reported above, was able to 
enhance CAT-2A and CAT-2B mRNA expression, IFN- alone failed to cause 
significant changes in CAT-2A mRNA but enhanced that for CAT-2B by 
approximately 10 % of the levels caused by LPS or the combination of both LPS and 
IFN- (Figure 4.9). 
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Figure 4.1 Representative association curves for CAT-1, CAT-2A and CAT-2B 
Using a specific primer for each cationic amino acid transporters in RASMCs, 
qPCR was conducted and association curves obtained. Each product has its 
specific melting temperature which also indicates the existence of just one product. 
Panel A reveals the melting temperature for CAT-1, Panel B for CAT-2A and Panel 
C for CAT-2B. 
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Figure 4.2 CAT-1 gene expression profile in RASMCs following treatment 
with LPS and IFN- 
Confluent monolayer of RASMCs were stimulated with LPS (100 μg ml-1) and IFN- 
(100 U ml
-1
) for different time periods. Total RNA was isolated from cells and the 
cDNA prepared before analysing by quantitative PCR using CAT-1 specific primers. 
The graph reflects fold changes in CAT-1 level in activated cells compared to 
control. Expression of RPL-13 was also determined and used to standardise the 
loading and expression levels of CAT-1. The data is the mean ± SEM of three 
separate experiments. Statistical analysis was carried out using a one way Anova 
followed by Dunnett’s multiple comparison test. **p<0.01 compared to control, non-
activated results. 
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Figure 4.3 Time course of CAT-2A gene expression induced by LPS and IFN- 
in RASMCs 
Confluent monolayer of RASMCs were stimulated with LPS (100 μg ml-1) and IFN- 
(100 U ml-1) for different time periods. Total RNA was isolated from cells and the 
cDNA prepared before analysing by quantitative PCR using CAT-2A specific 
primers. The graph reflects fold changes in CAT-2A level in activated cells 
compared to control. Expression of RPL-13 was also determined and used to 
standardise the loading and expression levels of CAT-2A. The data is the mean ± 
SEM of three separate experiments.  
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Figure 4.4Time course of CAT-2B gene expression induced by LPS and IFN- 
in RASMCs 
Confluent monolayer of RASMCs were stimulated with LPS (100 μg ml-1) and IFN- 
(100 U ml-1) for different time periods. Total RNA was isolated from cells and the 
cDNA prepared before analysing by quantitative PCR using CAT-2B specific 
primers. The graph reflects fold changes in CAT-2B level in activated cells 
compared to control. Expression of RPL-13 was also determined and used to 
standardise the loading and expression levels of CAT-2B. The data is the mean ± 
SEM of three separate experiments. Statistical analysis was carried out using a one 
way Anova followed by Dunnett’s multiple comparison test. *p<0.05 and **p<0.01 
compared to control, non-activated results. 
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Figure 4.5 Representative association curves for CAT-1, CAT-2A and CAT-2B 
Using a specific primer for each cationic amino acid transporters in J774 
macrophages, qPCR was conducted and association curves obtained. Each 
product has its specific melting temperature which also indicates the existence of 
just one product. Panel A reveals the melting temperature for CAT-1, Panel B for 
CAT-2A and Panel C for CAT-2B. 
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Figure 4.6 CAT-1 gene expression profile in J774 macrophages following 
treatment with LPS  
Confluent monolayer of J774 macrophages were stimulated with LPS (1 μg ml-1) for 
different time periods. Total RNA was isolated from cells and the cDNA prepared 
before analysing by quantitative PCR using CAT-1 specific primers. The graph 
reflects fold changes in CAT-1 level in activated cells compared to control. 
Expression of GAPDH was also determined and used to standardise the loading 
and expression levels of CAT-1. The data is the mean ± SEM of three separate 
experiments. Statistical analysis was carried out using a one way Anova followed 
by Dunnett’s multiple comparison test. 
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Figure 4.7 CAT-2A gene expression profile in J774 macrophages following 
treatment with LPS  
Confluent monolayer of J774 macrophages were stimulated with LPS (1 μg ml-1) for 
different time periods. Total RNA was isolated from cells and the cDNA prepared 
before analysing by quantitative PCR using CAT-2A specific primers. The graph 
reflects fold changes in CAT-2A level in activated cells compared to control. 
Expression of GAPDH was also determined and used to standardise the loading 
and expression levels of CAT-2A. The data is the mean ± SEM of three separate 
experiments. Statistical analysis was carried out using a one way Anova followed 
by Dunnett’s multiple comparison test. *p<0.05 and **p<0.01compared to control, 
non-activated results. 
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Figure 4.8 CAT-2B gene expression profile in J774 macrophages following 
treatment with LPS  
Confluent monolayer of J774 macrophages were stimulated with LPS (1 μg ml-1) for 
different time periods. Total RNA was isolated from cells and the cDNA prepared 
before analysing by quantitative PCR using CAT-2B specific primers. The graph 
reflects fold changes in CAT-2B level in activated cells compared to control. 
Expression of GAPDH was also determined and used to standardise the loading 
and expression levels of CAT-2B. The data is the mean ± SEM of three separate 
experiments. Statistical analysis was carried out using a one way Anova followed 
by Dunnett’s multiple comparison test. *p<0.05 and **p<0.01compared to control, 
non-activated results. 
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Figure 4.9 Effect of different stimuli on CAT gene expression in J774 
macrophages 
Confluent monolayers of J774 macrophages were incubated with either LPS (1 μg    
ml-1), IFN- (1 U ml-1) or a combination of both for 18 hours. RNA was generated at 
the end of the incubation period and the cDNA prepared before analysing by 
quantitative PCR using CAT-1 (panel A), CAT-2A (panel B) or CAT-2B (panel C) 
specific primers. Expression of GAPDH was also determined and used to 
standardise the loading and expression levels of CATs. The data is the mean ± 
SEM of three separate experiments. Statistical analysis was carried out using a one 
way Anova followed by Dunnett’s multiple comparison test. **p<0.01 compared to 
control, non-activated results. 
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4.3.4  Effect of SP600125 on CAT gene expression in RASMCs and J774 
macrophages 
To determine the effect of JNK inhibition  on CAT mRNA expression, both RASMCs 
and J774 macrophages were incubated with two different concentration of 
SP600125 (0.3 and 3 μM)  for  30 min prior to stimulation with LPS (100 μg ml-1) and 
IFN- (100 U ml-1) or LPS (1 μg ml-1) for RASMCs and J774 macrophages 
respectively. The total RNA was extracted and the cDNA prepared by reverse 
transcription before subjecting to quantitative PCR analysis using CAT specific 
primers. In RASMCs, stimulation with LPS and IFN- caused a reduction in the CAT-
1 gene expression as already reported earlier but of importance is the fact that 
SP600125 did not cause any significant changes to transcript levels in control or 
activated cells at both 0.3 μM and 3 μM (Figure 4.10). Although there appeared to be 
a marginal increase with 0.3 μM this was statistically not significant. Similarly, 
SP600125 did not alter CAT-2A or CAT-2B mRNA expression either in controls or in 
LPS and IFN- treated cells (Figure 4.11 and Figure 4.12). In J774 macrophages 
neither CAT-1 (Figure 4.13) nor CAT-2A (Figure 4.14) mRNA levels were affected by 
SP600125 (0.3-3 µM) in control and activated cells. In contrast CAT-2B mRNA 
induction was suppressed by approximately 34 % at 3 μM SP600125 (Figure 4.15). 
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Figure 4.10 Effect of SP600125 on CAT-1 expression in RASMCs 
Confluent monolayers of RASMCs were incubated with SP600125 (0.3-3 μM) for 
30 min followed by activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 18 hours. The controls were in the absence and presence of SP600125 
without stimulation with LPS/IFN-. The total RNA was extracted and the cDNA 
prepared by reverse transcription before subjecting to quantitative PCR analysis 
using CAT-1 specific primer. Expression of RPL-13 was also determined and used 
to standardise the loading and expression levels of CAT-1. The data is the mean ± 
SEM of three separate experiments. Each control and activated group was 
analysed separately using one-way ANOVA.  
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Figure 4.11  Effect of SP600125 on CAT-2A expression in RASMCs 
Confluent monolayers of RASMCs were incubated with SP600125 (0.3-3 μM) for 
30 min followed by activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 18 hours. The controls were in the absence and presence of SP600125 
without stimulation with LPS/IFN-. The total RNA was extracted and the cDNA 
prepared by reverse transcription before subjecting to quantitative PCR analysis 
using CAT-2A specific primers. Expression of RPL-13 was also determined and 
used to standardise the loading and expression levels of CAT-2A. The data is the 
mean ± SEM of three separate experiments. Each control and activated group was 
analysed separately using a one-way ANOVA.  
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Figure 4.12  Effect of SP600125 on CAT-2B expression in RASMCs 
Confluent monolayers of RASMCs were incubated with SP600125 (0.3-3 μM) for 30 
min followed by activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a further 
18 hours. The controls were in the absence and presence of SP600125 without 
stimulation with LPS/ IFN-. The total RNA was extracted and the cDNA prepared by 
reverse transcription before subjecting to quantitative PCR analysis using CAT-2B 
specific primers. Expression of RPL-13 was also determined and used to 
standardise the loading and expression levels of CAT-2B. The data is the mean ± 
SEM of three separate experiments. Each control and activated group was analysed 
separately using a one-way ANOVA. 
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Figure 4.13  Effect of SP600125 on CAT-1 expression in J774 macrophages 
Confluent monolayers of J774 macrophages were incubated with SP600125 (0.3-3 
μM) for 30 min followed by activation with LPS (1 μg ml-1) for a further 18 hours. 
The controls were in the absence and presence of SP600125 without stimulation 
with LPS/IFN-. The total RNA was extracted and the cDNA prepared by reverse 
transcription before subjecting to quantitative PCR analysis using CAT-1 specific 
primer. Expression of GAPDH was also determined and used to standardise the 
loading and expression levels of CAT-1. The data is the mean ± SEM of three 
separate experiments. Each control and activated group was analysed separately 
using a one-way ANOVA. 
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Figure 4.14  Effect of SP600125 on CAT-2A expression in J774 macrophages 
Confluent monolayers of J774 macrophages macrophages were incubated with 
SP600125 (0.3-3 μM) for 30 min followed by activation with LPS (1 μg ml-1) for a 
further 18 hours. The controls were in the absence and presence of SP600125 
without stimulation with LPS/IFN-. The total RNA was extracted and the cDNA 
prepared by reverse transcription before subjecting to quantitative PCR analysis 
using CAT-2A specific primer. Expression of GAPDH was also determined and 
used to standardise the loading and expression levels of CAT-2A. The data is the 
mean ± SEM of three separate experiments. Each control and activated group was 
analysed separately using a one-way ANOVA. 
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Figure 4.15 Effect of SP600125 on CAT-2B expression in J774 macrophages 
Confluent monolayers of J774 macrophages macrophages were incubated with 
SP600125 (0.3-3 μM) for 30 min followed by activation with LPS (1 μg ml-1) for a 
further 18 hours. The controls were in the absence and presence of SP600125 
without stimulation with LPS/IFN-. The total RNA was extracted and the cDNA 
prepared by reverse transcription before subjecting to quantitative PCR analysis 
using CAT-2B specific primer. Expression of GAPDH was also determined and used 
to standardise the loading and expression levels of CAT-2B. The data is the mean ± 
SEM of three separate experiments. Each control and activated group was analysed 
separately using a one-way ANOVA. *p<0.05 compared to activated, non SP600125 
results. 
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4.3.5  Effect of a-Fos and TAM-67 on CAT gene expression in RASMCs 
To determine the effect of the AP-1 dominant negative construct on CAT mRNA 
expression in RASMCs, cells were transfected with pGFP-a-Fos or pGFP-TAM-67 
for 18 hours prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 18 hours. The RNA was extracted and the cDNA prepared by reverse 
transcription before subjecting to qPCR analysis applying specific CAT primers. 
Figure 4.16 reveals the effect of a-Fos (panel A) and TAM-67 (panel B) on CAT-1 
expression. Consistent with the findings above, activated cells expressed less 
amount of CAT-1 compared to controls and these trends were not altered by either 
a-Fos (Figure 4.16, panel A) or TAM-67 (Figure 4.16, panel B) were the levels of 
expression changed. Similarly, CAT-2A mRNA in control and activated cells was 
also unaffected by transfection with either a-Fos (Figure 4.17, panel A) or TAM-67 
(Figure 4.17, panel B). CAT-2B which is highly expressed when cells were activated 
with LPS and IFN- was not affected by transfection with a-Fos (Figure 4.18, panel 
A), but suppressed following transfections with TAM-67. This was however only 
evident in activated cells and was not statistically significant when compared to the 
non transfected cells (Figure 4.18, panel B).  
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Figure 4.1 Effect of a-Fos and TAM-67 on CAT-1 gene expression in RASMCs 
Partially confluent monolayers of RASMCs were transfected with either a-Fos or 
TAM-67 for 18 hour prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 18 hours. The control cells were obtained in the absence and presence 
of dominant negative construct with or without activation. The total RNA was 
extracted and the cDNA prepared by reverse transcription before subjecting to 
quantitative PCR analysis using CAT-1 specific primers. Expression of RPL-13 was 
also determined and used to standardise the loading and expression levels of CAT-
1. The data is the mean ± SEM of three separate experiments. Each control and 
activated group was analysed separately using a one-way ANOVA program followed 
by Dunnett’s multiple comparison test.  
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Figure 4.2 Effect of a-Fos and TAM-67 on CAT-2A gene expression in 
RASMCs 
Partially confluent monolayers of RASMCs were transfected with either a-Fos or 
TAM-67 for 18 hour prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 18 hours. The control cells were obtained in the absence and presence 
of dominant negative construct with or without activation. The total RNA was 
extracted and the cDNA prepared by reverse transcription before subjecting to 
quantitative PCR analysis using CAT-2A specific primers. Expression of RPL-13 
was also determined and used to standardise the loading and expression levels of 
CAT-2A. The data is the mean ± SEM of three separate experiments. The data is 
the mean ± SEM of three separate experiments. Each control and activated group 
was analysed separately using a one-way ANOVA followed by Dunnett’s multiple 
comparison test. 
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Figure 4.3 Effect of a-Fos and TAM-67 on CAT-2B gene expression in 
RASMCs 
Partially confluent monolayers of RASMCs were transfected with either a-Fos or 
TAM-67 for 18 hour prior to activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 18 hours. The control cells were obtained in the absence and presence 
of dominant negative construct with or without activation. The total RNA was 
extracted and the cDNA prepared by reverse transcription before subjecting to 
quantitative PCR analysis using CAT-2B specific primers. Expression of RPL-13 
was also determined and used to standardise the loading and expression levels of 
CAT-2B. The data is the mean ± SEM of three separate experiments. The data is 
the mean ± SEM of three separate experiments. Each control and activated group 
was analysed separately using a one-way ANOVA followed by Dunnett’s multiple 
comparison test. 
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4.4 Discussion  
The signalling mechanism that regulates iNOS expression and L-arginine transport 
in different cell systems may not be similar. The differential regulation of these two 
processes is however not unusual since previous studies have shown that upstream 
signalling molecules such as tyrosine kinases can regulate the expression of iNOS 
whilst having no effect on the increase in the transport of L-arginine although the 
latter was induced in parallel with iNOS by the same activating agents (Baydoun et 
al., 1999). However in smooth muscle cells for example it has been shown that 
increase in L-arginine transport activity and nitrite accumulation occurred in parallel 
(Wileman et al., 1995). This up-regulation in L-arginine transport is correlated with 
enhanced expression of cationic amino acid transporters (CATs) which provides 
substrate supply during enhanced synthesis of nitric oxide (Cui et al., 2005). To 
clarify the transporter responsible for L-arginine transport in inflammatory condition in 
our experiments, the expression profile of CATs was studied. In the next step the 
role of JNK/AP-1 pathway on the expression of the CATs was established.  
To determine the profile of CATs gene expression, it should be noted that Cat1 and 
Cat2 genes have distinct expression patterns from one another (Kakuda et al., 
1998). Cat2 is expressed from multiple promoters (Finley et al., 1995) and encodes 
two spliced variants (MacLeod, 1996) that are different in their transport kinetic 
properties (Van Winkle et al., 1995). 
Many of studies have been performed to identify the role of different CATs in the 
various cell types. In this thesis we have established the profile of expression of the 
different CATs in both smooth muscle cell and in J774 macrophages and further 
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explored how these are regulated by different stimuli used in the studies. The data 
obtained has confirmed previous studies showing that RASMCs express transcript 
for CAT-1, CAT-2A and CAT-2B under basal condition (Baydoun et al., 1999). 
However these observations are in contrast with those made in other cell systems 
such as J774 macrophages (Kakuda et al., 1999), astrocytes (Stevens et al., 1996) 
and cardiac Myocytes (Simmons et al., 1996a) where CAT-1 was the only 
constitutively expressed isoform. In these systems CAT-2A (cardiac myocytes) 
and/or CAT-2B (macrophages, astrocytes and cardiac myocytes) were detected only 
after activation of the cells with pro-inflammatory mediators suggesting that CAT-1 
may be the physiological transporters while CAT-2A and CAT-2B may be 
responsible for L-arginine entry into the cells under inflammatory condition.  
In the current studies, CAT-2B was augmented when the cells were stimulated with 
LPS/IFN-, which has the same trend as iNOS expression (chapter 3) and confirms 
the parallel regulation of iNOS and L-arginine transporters but more importantly 
indicates that CAT-2B may be the critical carrier for L-arginine in the induced cells. 
This inducible carrier is usually co-expressed with CAT-1, and its expression has 
been documented in lung, brain (Deves et al., 1998), activated cells such us 
macrophages (Closs et al., 2000), astrocytes (Stevens et al., 1996) and aortic 
vascular smooth muscle cells (Baydoun et al., 1999). Its up-regulation in our system 
is consistent with other reports showing its induction together with iNOS (Hattori et 
al., 1999; Schwartz et al., 2002) and the claims that CAT-2B may have a specific role 
in delivering substrate to iNOS (Closs et al., 2000; Hammermann et al., 2001).  
In smooth muscle cells CAT-2A expression was also increased but using one way 
ANOVA statistical analysis, the change was not significant. It can be concluded that 
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CAT-2A may make a negligible contribution to the total entry of L-arginine into 
RASMCs. This may not be surprising since CAT-2A, when compared to CAT-2B or 
even CAT-1, has a lower affinity for L-arginine (Closs et al., 1993a; Closs et al., 
1997).  
The change in the expression profile of CATs in RASMCs activated with LPS/IFN- is 
interesting since the current data indicate a down regulation in CAT-1 expression. 
The consequences of these changes would be that CAT-1 makes a small 
contribution to L-arginine uptake in activated RASMCs while CAT-2B plays the 
critical role in maintaining substrate supply into the cells and play a considerable role 
in parallel when iNOS in expressed. In this regard, it has been suggested that after 
stimulation with LPS or cytokines, iNOS and CAT-2 genes are co-induced and BH4 
acts as a co-factor that up-regulates both iNOS and CAT-2 mRNA (Schwartz et al., 
2002). It has also been reported that iNOS activity may be reduced in macrophages 
from CAT-2 knockout mice (Nicholson et al., 2001). This has led to the suggestion 
that there may be a clear cooperation between CAT-2 and iNOS in that sustained 
production of NO the latter may be controlled by CAT activity. It is worth noting 
however that our previous studies have shown that this may not be the case. Our 
group has demonstrated that over expression of iNOS in cells (HEK-293 cells) which 
do not constitutively express the enzyme does not necessarily result in enhanced 
transporter activity (Cui et al., 2005). Thus while continued substrate supply to NOS 
may be essential for sustaining NO production, enhanced NOS activity does not 
necessarily result in increased substrate supply into the cells. This is at least the 
case in the transfected cells but the expression levels of iNOS in this model may be 
different to those attained following induction of cell/tissues in vitro and/or in vivo.  
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Moreover, induction with inflammatory mediators may also co-induce other factors 
such as BH4 that are essential for optimal NOS activity. This may not be the case for 
cells transfected with the iNOS construct. 
The decline in CAT-1 mRNA expression is of interest as it indicates that this 
particular transcript may not be stable when cells are induced by inflammatory 
mediators. The findings are consistent with other studies indicating the fact that CAT-
1 mRNA is completely abolished or reduced in parallel with the augmentation in 
CAT-2 mRNA expression (Schwartz et al., 2002). These authors have also 
suggested that up-regulation of an individual CAT may cause a decline on the other 
transporters’ mRNA (Schwartz et al., 2002). The decrease in CAT-1 expression 
following induction of rat cardiac myocytes suggests that CAT-2B may be the more 
important carrier of L-arginine in these cells. 
Unlike RASMCs, the pattern of expression and regulation of CATs in J774 
macrophages was different in some aspects. For instance, CAT-1 did not alter after 
stimulation with LPS while CAT-2A and CAT-2B both revealed a significant increase 
in mRNA expression level. These findings are in agreement with the data obtained in 
RAW264.7 macrophages (Huang et al., 2006) and in rat mesangial kidney cells in 
which stimulation with LPS did not cause any up or down regulation in CAT-1 gene 
expression (Schwartz et al., 2003).  
It may be speculated that in J774 macrophages both CAT-2A and CAT-2B are 
required for complete substrate supply of L-arginine but the low affinity of CAT-2A for 
L-arginine strongly implies that CAT-2B is again the critical carrier in induced cells.  
Similar data was obtained in macrophages previously revealing a role for CAT-2 but 
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not CAT-1 in L-arginine transport when cell were exposed to Helicobacter pylori.  
Moreover, knockdown of Cat-2 gene in macrophages was shown to prevent 
stimulated L-arginine uptake (Chaturvedi et al,. 2010). There are several studies also 
emphasising the important role of CAT-2 in macrophages and this protein is now 
widely accepted as the key transporter for substrate supply at least into induced cells 
expressing iNOS (Lai et al., 2008; Niese et al., 2010; Rothenberg et al., 2006; 
Thompson et al., 2008). To further support this notion, it has been shown that in 
macrophages induction of CAT-2B occurs in parallel with the marked decrease in the 
expression of CAT-1 suggesting that the former may be the critical transporter of L-
arginine and may act as the main supplier of substrate into the cells (Kakuda et al., 
1999). In addition, it has been shown that NO production was significantly decreased 
in macrophages obtained from Cat-2 -/- mice (Nicholson et al., 2001). 
In the J774 macrophages, additional studies were carried out to determine the 
manner in which CAT expression was modulated by LPS, IFN- and the combination 
of both. The reason for wanting to do these experiments is because IFN- in 
preliminary studies did not appear to significantly regulate basal L-arginine transport 
in J774 cells but yet was critical in RASMCs. We therefore questioned whether in the 
macrophages IFN- does in fact control CAT gene expression. These studies were in 
parallel with the same study on iNOS and NO induction discussed in chapter 3. 
Consistent with the functional data, there was no significant change in CAT-1 
expression when cells were subjected to IFN- alone and this is consistent with the 
report by Wanasen et al. (2007) in murine macrophages showing that CAT-1 mRNA 
is not affected by IFN- treatment. Interestingly, in our studies, LPS but not IFN- 
caused an up-regulation in CAT-2A expression. It seems that even in the same cell 
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system, various pro-inflammatory conditions do not have the same effect. At the 
same time, CAT-2B showed an up-regulation with all three different stimulations but 
still lower for IFN- treated alone.  
The effect of IFN- on CAT-2B was shown previously where this stimulant alone 
increases CAT-2B expression (Wanasen et al., 2007). On the other hand, some 
studies suggested no effect for IFN- on CAT-2 expression in macrophages (Sweet 
et al., 1998). Again, it always should be noted that which stimulants in which cell 
system is being used.  
Following the initiation of the preliminary studies, complementary experiments were 
conducted to identify the role of JNK/AP-1 on cationic amino acid transporters 
expression in both RASMCs and J77 macrophages. The findings showed that in 
RASMCs, SP600125 had little effect on CAT function and transcript expression. This 
suggests that the JNK-AP-1 pathway may not be critical for the activity of these 
proteins in either controls or induced cells. However in J77 macrophages the drug 
caused a significant decline in CAT-2B induction without affecting levels of CAT-1 or 
CAT-2A and this effect was seen only at the concentration of 3 µM which also 
partially blocked L-arginine transport rates in induced cells. Thus, taken together, 
these findings now clearly demonstrate that CAT-2B may be the critical transporter 
of L-arginine following induction of cells with pro-inflammatory mediators. Moreover, 
these results show for the first time the selective regulation of CAT-2B but not CAT-1 
or CAT-2A induction by the JNK-AP-1 pathway.  
Not very much is known about the promoter region of CAT-1, CAT-2A and CAT-2B, 
as these have not been fully characterised. Because NF-B plays an essential role in 
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the iNOS expression, there are some studies on the role of this transcription factor 
which suggested that NF-B is an essential transcription factor not only for the 
induction of iNOS, but also for the L-arginine transport system (Kagemann et al., 
2007) which  may relate to up-regulation of CATs specifically CAT-2B (Chu et al., 
2005; Hammermann et al., 2000; Yang et al., 2005). Also two NF-B sites were 
identified on mouse CAT-2 gene promoter (Finley et al., 1995) which can indicate a 
role for NF-B in transport system. It should also be noted that in most of these 
studies there was no significant effect of NF-B on CAT-1 or CAT-2A (Chu et al., 
2005; Hammermann et al., 2000; Huang et al., 2004; Visigalli et al., 2004; Yang et 
al., 2005) which again reveals the important role of NF-B in parallel with induction of 
iNOS. Still there is not much evidence available on the full control of CATs induction 
or on the role of different MAPKs on these transporters. There are some studies in 
macrophages which indicate a role for ERK1/2 and p38 MAPK in transport of L-
arginine and CAT-2B regulation (Caivano, 1998) and in RASMCs it shown that p38 
MAPK but not ERK may regulate CATs expression (Baydoun et al., 1999). On the 
other hand, there are studies suggesting a role for ERK (p42/44 MAPK) in CAT-1 
expression (Casanello et al., 2007; Vasquez et al., 2004).  
In contrast to ERK and p38 MAPK, there is little data on the requirement of JNK/AP-
1 signalling in CATs regulation. Parallel studies were therefore conducted to 
determine the role of this pathway in CAT expression and function using a-Fos and 
TAM-67. The a-Fos construct did not alter expression profile of the CATs nor did it 
cause any effect on L-arginine transport (Chapter 3, results). This observation, at 
glance, indicates that AP-1 may not be involved in regulating transport of L-arginine 
in RASMCs. This may indeed be the case since TAM-67 also causes little change in 
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either CAT-1 or CAT-2A mRNA expression and only marginally altered that for CAT-
2B. This trend is consistent with the functional changes reported in Chapter 3 and 
would indicate that induction of L-arginine transport is not only dependent on CAT-
2B upregulation but also partially regulated by the JNK-AP-1 pathway at the very 
best. At the moment there is just one study available that shows PKC-dependent 
stimulation of CAT2 expression. This apparently requires the activation of 
MEK/ERK1/2 signalling which in turns leads to the activation of AP-1 (visigalli et al., 
2010).  
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4.5 Summary 
In this chapter the profile of CAT expression and their regulation by SP600125, 
TAM-67 and a-Fos were examined. The data has generated some interesting 
findings, showing in RASMCs CAT-1 mRNA declined when cells were exposed to 
LPS and IFN- while that for CAT-2B was enhanced with no effect on CAT-2A. In 
addition none of the transcripts were affected by the JNK inhibitor SP600125 or a-
Fos but CAT-2B was marginally reduced by TAM-67 and this is consistent with the 
reductions in transport rates seen under identical conditions.   
In J774 macrophages, CAT-2A and CAT-2B mRNA increased after stimulation with 
LPS while CAT-1 decreased. JNK inhibition with SP600125 reduced CAT-2B 
without affecting CAT-1 or CAT2A levels which strongly confirming that the 
transporter for enhanced L-arginine transport in these cells is again CAT-2B and 
that the induction of this protein may be critically regulated, at least in part, by JNK 
activation. Further studies with the AP-1 dominant negatives were not carried out 
because of limitations in transfecting macrophages but these studies are essential. 
 
 
 
 
 
 
 
 
216 
 
 
 
Results 
 
 
 
 
217 
 
 
 
 
Chapter 5 
The expression and activation profile of JNK isoforms 
and AP-1 subunits in RASMCs and J774 macrophages 
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5.1 Introduction 
 
As observed in chapters 3 and 4 there was a difference in responses of smooth 
muscle cells and macrophages to JNK inhibition using pharmacological inhibitors or 
to AP-1 suppression using dominant negative constructs. 
In order to get a clearer understanding of the role of the JNK/AP-1 pathway in the 
induction of iNOS and/or CATs in the two cell systems,  further studies were carried 
out determining the expression and activation profile of both JNK isoforms and of the 
different AP-1 subunits. Moreover, the effects of SP6000125 on these proteins were 
also investigated in both cell types but studies exploring the effects of the AP-1 
dominant negative constructs (a-Fos and TAM-67) were limited to the smooth 
muscle cells as J774 macrophages could not be transfected.   
As it mentioned earlier there are three JNK isoforms in which two of them are 
present in most cell systems, therefore we first explored the expression profile of 
these two isoforms and meantime the phosphorylation of JNK when using LPS/LPS-
IFN- in RASMCs and J774 macrophages. After this stage using an ELISA based kit 
we determined the activation of all seven AP-1 subunits (c-Jun, JunB, JunD, c-Fos, 
FosB, Fra-1 and Fra-2). This study helps to clarify the pattern of how these subunits 
work together in our cell systems. 
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5.2   Methods 
 
5.2.1  Detection of JNK1, JNK2 and phospho-JNK expression in RASMCs and 
J774 macrophages 
Confluent monolayers of RASMCs or J774 macrophages were plated in 6 well 
plates and activate with LPS (100 μg ml-1) and IFN- (100 U ml-1) or with LPS (1 μg 
ml-1) alone respectively for the period of 1, 5, 15, 30, 60, 120 min. Control cells 
were incubated with complete culture medium alone. The incubation was 
terminated by lysaing the cells and western blot analysis was performed using anti-
JNK1 or anti-JNK2 or anti-phospho-JNK. The membrane was stripped and re-
probed for detection of -actin as a control of loading. 
 
5.2.2  Effect of SP600125 on JNK phosphorylation status in RASMCs and J774 
macrophages  
Confluent monolayers of RASMCs or J774 macrophages were plated in 6 well 
plates and treated with SP600125 (0.3-3 μM) for 30 min following activation with 
LPS (100 μg ml-1) and IFN- (100 U ml-1) or with LPS (1 μg ml-1) alone respectively 
for a further 30 min. The control cells were incubated in medium alone or treated 
with the same concentrations of SP600125 in the absence of any stimulants. The 
incubation was terminated by lysaing the cells and western blot analysis was 
performed using an anti-JNK1, anti-JNK2 or anti-phospho-JNK antibody. The 
membrane was stripped and re-probed for  -actin which was used as a control of 
loading. 
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5.2.3  Expression profile of AP-1 subunits in RASMCs and J774 macrophages 
stimulated with LPS/IFN-or LPS   
Confluent monolayers of RASMCs or J774 macrophages were serum starved for 
24 hours prior to activation. The cells were then subjected for 5, 15, 30, 60, 120 min 
to LPS (100 μg ml-1) and IFN- (100 U ml-1) for RASMCs or LPS (1 μg ml-1) alone 
for macrophages. The control cells did not contain any stimulants. The incubations 
were terminated and nuclear extractions carried out as described in the methods 
(section 2.2.23). 10 μg of nuclear extract was analysed using a TransAM AP-1 
family kit from Active Motif (Belgium) as described.   
 
5.2.4  The effect of JNK inhibitor (SP600125) on the activity of AP-1 subunits  
in RASMCs and J774 macrophages  
Confluent monolayers of RASMCs or J774 macrophages were serum starved for 
24 hours prior to 30 min incubation with SP600125 (0.3-3 uM). The cells were then 
stimulated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for RASMCs or LPS (1 μg 
ml-1) for macrophages for either 30 min or 2 hours. Parallel controls were set up in 
the presence and absence of SP600125. Nuclear extracts were subsequently 
prepared as described in the methods. 10 μg of nuclear extract was analysed using 
a TransAM AP-1 family kit from Active Motif (Belgium). 
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5.2.5  The effect of pGFP-a-Fos and pGFP-TAM-67 on the activation of AP-1 
subunits in RASMCs  
Partially confluent (60-70%) monolayers of RASMCs were serum starved for 24 
hours before transfection with pGFP-a-Fos or pGFP-TAM-67 for another 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. Nuclear extracts were subsequently prepared as described 
in the methods.10 μg of nuclear extract was analysed using a TransAM AP-1 family 
kit from Active Motif (Belgium).  
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5.3 Results 
 
5.3.1  Detection of JNK1, JNK2 and phospho-JNK expression in RASMCs 
To determine which JNK isoform is expressed and phosphorylated in RASMCs, 
western blot was performed on lysates generated from controls and from cells 
activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) at time points of 1, 5, 15, 30, 
60 and 120 min. The data revealed the presence of both JNK1 and JNK2; with JNK1 
showing one isoform at 46 kDa and JNK2 shows two band at 46 and 54 kDa. JNK1 
appeared to be more predominantly expressed when compared to JNK2 (Figure 
5.1). During the time course the total level of JNK1 and JNK2 remained unaffected. 
There was also very low and almost undetectable phospho-JNK in controls but this 
increased time-dependently in activated cells after 15 min, reaching a peak within 30 
min and sustained over 60 min before declining 2 hours after activation (Figure 5.1).  
 
5.3.2  Effect of SP600125 on JNK phosphorylation status in RASMCs 
To determine whether SP600125 can affect phosphorylation of JNK in RASMCs, 
cells were pre-incubated  with the drug at 0.3 and 3 μM for 30 min  prior to  activation 
with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a further 30 min. Lysates generated 
were subjected to western blotting for phospho-JNK. Expression of total JNK1 and 
JNK2 were also determined in parallel. Under these conditions, the total level of 
JNK1 and JNK2 remain unaffected but SP600125 significantly decreased phospho-
JNK at 0.3 μM and virtually abolished its expression at 3 μM (Figure 5.2). 
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5.3.3  Detection of JNK1, JNK2 and phospho-JNK in J774 macrophages 
In parallel with the studies carried on RASMCs, experiments were conducted in J774 
macrophages to determine which JNK isoform may be expressed and activated 
through phosphorylation. Western blot analysis confirmed the expression of JNK1 at 
46 kDa and two isoforms of JNK2 at 46 and 54 kDa respectively. There was 
marginal expression of phospho-JNK in controls and this was increased in a time-
dependent manner following activation with LPS (1 μg/ml). The increase was 
significant after 15 min reaching a peak at 30 min but beginning to decline after 60 
min of activation (Figure 5.3). 
 
5.3.4 The effect of SP600125 on JNK phosphorylation status in J774 
macrophages 
The effect of SP600125 on JNK phosphorylation  in macrophages was studied using 
two concentration of the inhibitor (0.3 and 3 μM) prior to stimulation with LPS (1 μg 
ml-1) for 30 min. Consistent with the findings in RASMCs, SP600125 significantly 
reduced phosphorylation of JNK at 0.3 μM and virtually abolished its expression at 3 
μM (Figure 5.4). Thus, in both cells types, JNK isoforms are expressed and activated 
following stimulation with inflammatory mediators and this was sensitive to inhibition 
by SP6000125 but with the latter only able to regulate iNOS and induced NO 
production in the macrophages.  
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Figure 5.1 Expression and activation of JNK in control and LPS/IFN- 
activated RASMCs 
Confluent monolayers of RASMCs were incubated in culture medium alone or in 
medium supplemented with LPS (100 μg ml-1) and IFN- (100 U ml-1). Incubations 
were carried out over the time points indicated and lysates generated for western 
blotting using an anti-phospho-JNK and a non phospho-antibody selective for JNK1 
or JNK2. -actin expression was routinely determined to establish loading variability. 
The blots are representative of 3 experiments and the bar graphs are scanning 
densometry of the bands expressed as a % of the maximum levels obtained after 30 
min activated. 
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Figure 5.2 The effect of SP600125 on JNK phosphorylation in RASMCs 
Confluent monolayers of RASMCs were incubated with SP600125 (0.3 -3 μM) for 30 
min prior to stimulation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for  a further 30 
min. Lysates were generated at the end of the incubation period and subjected to 
western blotting using an anti-phospho-JNK or a non-phospho-JNK1 or JNK2 
selective antibodies. -actin expression was routinely determined to establish 
loading variability. The blots are representative of 3 experiments and the bar graphs 
are scanning the bands comparing the data with activated no SP600125 group. 
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Figure 5.3 The time point study of JNK phosphorylation following LPS 
activation of J774 macrophages 
Confluent monolayers of J774 macrophages were incubated in culture medium alone 
or in medium supplemented with LPS (1 μg ml-1). Incubations were carried out over 
the time points indicated and lysates generated for western blotting using an anti-
phospho-JNK or a non phospho-antibody selective for JNK1 or JNK2. -actin 
expression was routinely determined to establish loading variability. The blots are 
representative of 3 experiments and the bar graphs are scanning densometry of the 
bands expressed as a % of the maximum levels obtained after 30 min activated. 
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Figure 5.4 The effect of SP600125 on JNK phosphorylation in J774 
macrophages 
Confluent monolayers of J774 macrophages were incubated with SP600125 (0.3 -3 
μM) for 30 min prior to stimulation with LPS (1 μg ml-1) for  a further 30 min. Lysates 
were generated at the end of the incubation period and subjected to western blotting 
using an anti-phospho-JNK or a non-phospho-JNK1 or JNK2 selective antibodies. -
actin expression was routinely determined to establish loading variability. The blots 
are representative of 3 experiments and the bar graphs are scanning the bands 
comparing the data with activated no SP600125 group. 
 
 
 
 
 
 
 
 
231 
 
 
 
        
 
 
 
   
 
 
 
 
 
 
P-JNK 
JNK1 
JNK2 
-actin 
      LPS            -           -           -           +          +           + 
  SP600125     0         0.3        3           0         0.3         3 
0
50
100
%
 A
c
ti
v
a
te
d
 c
o
n
tr
o
l
     LPS           -            -            -            +          +            + 
SP600125      0         0.3          3            0         0.3          3 
p-JNK 
232 
 
5.3.5  Expression profile of AP-1 subunits in activated RASMCs and J774 
macrophages   
As an extension to the studies above, further experiments were conducted looking at 
the expression and activation profile of different AP-1 subunits with a view to 
understanding how the subunits may be regulated under our experimental conditions 
and potentially identify AP-1 components that may mediate the divergent results 
already highlighted. Confluent monolayers of cells were activated with LPS (100 μg 
ml-1) and IFN- (100 U ml-1) for RASMCs and LPS (1 µg ml-1) for J774 macrophages 
at different time points ranging from 5 min to 2 hours. The cells were then harvested 
for nuclear extraction (methods, section 2.2.23) and the latter used to identify 
different AP-1 subunits and their activated status using the TransAM kit as described 
in the methods (section 2.2.24).  
The assays carried out confirm the expression of c-Jun, Jun-B, Jun-D, c-Fos, Fos-B, 
Fra-1 and Fra-2 in both cell types. Of these, only c-Jun, Jun-D and Fra-1 showed 
clear evidence of significant activation when cells were exposed to either LPS and 
IFN- (RASMCs) or LPS alone (J774 macrophages). Activation of c-Jun was evident 
after 30 min in RASMCs and after 15 min in the macrophages. Activation was 
sustained over 60 min, declining thereafter (Figure5.5 and 5.12). Similarly, Jun-D 
activation was prominent after 30 min in macrophages (Figure 5.14) and 1 hour in 
RASMCs (Figure 5.7). Jun-D remained activated for up to 2 hours after stimulation in 
both cell systems as did Fra-1 (Figures 5.10 and 5.17). Interestingly, Jun-B which 
may play a prominent role in the induction of iNOS in some systems, did not appear 
to be activated in either cell type as its activation and DNA binding was not 
significantly different between control and activated samples analysed (Figures 5.6 
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and 5.13). Similarly, c-Fos, Fos-B and Fra-2 did not show any significant changes in 
activation from control basal levels especially in RASMCs (Figure 5.8, 5.9 and 5.11). 
There were no significant changes in both c-Fos and Fra-2 (Figure 5.15 and 5.18) 
but FosB on the other hand was highly activated after 1 hour in J774 macrophages 
(Figure 5.16). 
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Figure 5.5 The effect of LPS/IFN- stimulation on c-Jun activation in RASMCs 
RASMCs were activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) over the time 
periods indicated on the graph. Nuclear extracts were prepared and subjected to 
analysis as described in the methods (Section 2.2.23). 10 μg of nuclear content was 
used in an AP-1 family DNA binding kit using phospho-c-Jun antibody and HRP-
conjugated secondary. The absorbance was read at 450 nm. The results are 
representative of 3 independent experiments. Statistical analysis using a one way 
Anova followed by Dunnett’s multiple comparison test was performed. *p<0.05 and 
**p<0.01 compared to control, non-activated results.  
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Figure 5.6 The effect of LPS/IFN- stimulation on JunB activation in RASMCs 
RASMCs were activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) over the time 
periods indicated on the graph. Nuclear extracts were prepared and subjected to 
analysis as described in the methods (Section 2.2.23). 10 μg of nuclear content was 
used in an AP-1 family DNA binding kit using JunB antibody and HRP-conjugated 
secondary. The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed.  
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Figure 5.7 The effect of LPS/IFN- stimulation on JunD activation in RASMCs 
RASMCs were activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) over the time 
periods indicated on the graph. Nuclear extracts were generated and subjected to 
analysis as described in the methods (Section 2.2.23). 10 μg of nuclear content were 
used in an AP-1 family DNA binding kit using JunD antibody and HRP-conjugated 
secondary. The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed. **p<0.01 compared to control, 
non-activated results.  
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Figure 5.8 The effect of LPS/IFN- stimulation on c-Fos activation in RASMCs 
RASMCs were activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) over the time 
periods indicated on the graph. Nuclear extracts were generated and subjected to 
analysis as described in the methods (Section 2.2.23). 10 μg of nuclear content was 
used in an AP-1 family DNA binding kit using c-Fos antibody and HRP-conjugated 
secondary. The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed.  
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Figure 5.9 The effect of LPS/IFN- stimulation on FosB activation in RASMCs 
RASMCs were activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) over the time 
periods indicated on the graph. Nuclear extracts were generated and subjected to 
analysis as described in the methods (Section 2.2.23). 10 μg of nuclear content was 
used in an AP-1 family DNA binding kit using FosB antibody and HRP-conjugated 
secondary. The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed.  
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Figure 5.10 The effect of LPS/IFN- stimulation on Fra-1 activation in RASMCs 
RASMCs were activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) over the time 
periods indicated on the graph. Nuclear extracts were prepared and subjected to 
analysis as described in the methods (Section 2.2.23). 10 μg of nuclear content was 
used in an AP-1 family DNA binding kit using Fra-1 antibody and HRP-conjugated 
secondary. The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed. *p<0.05 and **p<0.01 compared 
to control, non-activated results.  
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Figure 5.11 The effect of LPS/IFN- stimulation on Fra-2 activation in RASMCs 
RASMCs were activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) over the time 
periods indicated on the graph. Nuclear extracts were prepared and subjected to 
analysis as described in the methods (Section 2.2.23). 10 μg of nuclear content was 
used in an AP-1 family DNA binding kit using Fra-2 antibody and HRP-conjugated 
secondary. The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed.  
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Figure 5.12 The effect of LPS stimulation on c-Jun activation in J774 
macrophages 
J774 macrophages were activated with LPS (1 μg ml-1) over the time periods 
indicated on the graph. Nuclear extracts were prepared and subjected to analysis as 
described in the methods (Section 2.2.23). 10 μg of nuclear content was used in an 
AP-1 family DNA binding kit using phospho-c-Jun antibody and HRP-conjugated 
secondary. The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed. *p<0.05 and **p<0.01 compared 
to control, non-activated results. 
 
242 
 
              
JunB
Control 5 15 30 60 120
0.00
0.25
0.50
0.75
1.00
1.25
Time (min)
R
e
la
ti
v
e
 a
c
ti
v
it
y
 
 
 
  
 
Figure 5.13 The effect of LPS stimulation on JunB activation in J774 
macrophages 
J774 macrophages were activated with LPS (1 μg ml-1) over the time periods 
indicated on the graph. Nuclear extraction prepared and subjected to analysis as 
described in the methods (Section 2.2.23). 10 μg of nuclear content was used in an 
AP-1 family DNA binding kit using JunB antibody and HRP-conjugated secondary. 
The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed.  
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Figure 5.14 The effect of LPS stimulation on JunD activation in J774 
macrophages 
J774 macrophages were activated with LPS (1 μg ml-1) over the time periods 
indicated on the graph. Nuclear extracts were prepared and subjected to analysis as 
described in the methods (Section 2.2.23). 10 μg of nuclear content was used in an 
AP-1 family DNA binding kit using JunD antibody and HRP-conjugated secondary. 
The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed. *p<0.05 and **p<0.01 compared 
to control, non-activated results. 
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Figure 5.15 The effect of LPS stimulation on c-Fos activation in J774 
macrophages 
J774 macrophages were activated with LPS (1 μg ml-1) over the time periods 
indicated on the graph. Nuclear extracts were prepared and subjected to analysis as 
described in the methods (Section 2.2.23). 10 μg of nuclear content was used in an 
AP-1 family DNA binding kit using c-Fos antibody and HRP-conjugated secondary. 
The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed.  
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Figure 5.16 The effect of LPS stimulation on FosB activation in J774 
macrophages 
J774 macrophages were activated with LPS (1 μg ml-1) over the time periods 
indicated on the graph. Nuclear extracts were prepared and subjected to analysis as 
described in the methods (Section 2.2.23). 10 μg of nuclear content was used in an 
AP-1 family DNA binding kit using FosB antibody and HRP-conjugated secondary. 
The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed. *p<0.05 compared to control, 
non-activated results. 
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Figure 5.17 The effect of LPS stimulation on Fra-1 activation in J774 
macrophages 
J774 macrophages were activated with LPS (1 μg ml-1) over the time periods 
indicated on the graph. Nuclear extracts were prepared and subjected to analysis as 
described in the methods (Section 2.2.23). 10 μg of nuclear content was used in an 
AP-1 family DNA binding kit using Fra-1 antibody and HRP-conjugated secondary. 
The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed. *p<0.05 and **p<0.01 compared 
to control, non-activated results. 
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Figure 5.18 The effect of LPS stimulation on Fra-2 activation in J774 
macrophages 
J774 macrophages were activated with LPS (1 μg ml-1) over the time periods 
indicated on the graph. Nuclear extracts were prepared and subjected to analysis as 
described in the methods (Section 2.2.23). 10 μg of nuclear content was used in an 
AP-1 family DNA binding kit using Fra-2 antibody and HRP-conjugated secondary. 
The absorbance was read at 450 nm. The results are representative of 3 
independent experiments. Statistical analysis using a one way Anova followed by 
Dunnett’s multiple comparison test was performed. 
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5.3.6  The effect of JNK inhibition on AP-1 subunits activity in RASMCs and 
J774 macrophages  
Following from the above observations, studies were subsequently carried out 
investigating the effects of SP600125 at concentration of 0.3 μM and 3 μM on the 
activation of various AP-1 subunits by LPS (100 µg ml-1) and IFN- (100 U ml-1) in 
RASMCs or LPS alone (1 µg ml-1) in J774 macrophages. Nuclear fractions were 
extract at different time point (30 min and 2 hours). The extracts were then used to 
identify different AP-1 subunits and their activated status using the TransAM kit as 
described in the methods (section 2.2.24). 
SP600125 significantly inhibited c-Jun activation in both RASMCs and J774 
macrophages. This was seen at the concentrations used and in both controls and 
activated cells (Figure 5.19 and 5.26). In contrast to its effects on c-Jun, SP600125 
up-regulated Fra-1 in both cell systems (Figures 5.24 and 5.31) but selectively 
increased JunD (Figures 5.21) and c-Fos (Figures 5.22) in RASMCs. Fos-B on the 
other hand was selectively up-regulated in a non-concentration-dependent manner in 
control J774 macrophages (Figures 5.30) while Fra-2 remained unaffected in both 
cell types (Figures 5.25 and 5.32). What is even more interesting is the observation 
that JunB activity was significantly enhanced by SP600125 in both control and 
activated RASMCs (Figure 5.20) and J774 macrophages (Figure 5.27) even though 
the activity of this subunit was not altered by LPS or LPS and IFN-. In RASMCs, 
FosB (Figure 5.23) and in J774 macrophages JunD (Figure 5.28) and c-Fos (Figure 
5.29) did not reveal any changes after incubation with SP600125. 
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Figure 5.19  Effect of SP600125 on activation of c-Jun in RASMCs  
RASMCs were incubated with SP600125 (0.3 μM and 3 μM) for 30 min prior to 
activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for either 30 min or 2 hours. 
Nuclear extracts were prepared and analysed using the TransAM kit as described in 
the methods using a phospho-c-Jun antibody (methods, section 2.2.24). The activity 
of the subunit was measured and expressed as relative activity. Results are the 
mean ± SEM of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test performed. * p<0.05 and **p<0.01 
compared to control or activated, non-drug results.  
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Figure 5.20  Effect of SP600125 on activation of JunB in RASMCs  
RASMCs were incubated with SP600125 (0.3 μM and 3 μM) for 30 min prior to 
activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for either 30 min or 2 hours. 
Nuclear extracts were prepared and analysed using the TransAM kit as described in 
the methods using a JunB antibody. The activity of the subunit was measured and 
expressed as relative activity. The results are the mean ± SEM of 3 independent 
experiments. Statistical analysis using two way Anova followed by multiple 
comparison test performed. * p<0.05, **p<0.01 and ***p<0.001compared to control 
or activated, non-drug results.  
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Figure 5.21  Effect of SP600125 on activation of JunD in RASMCs  
RASMCs were incubated with SP600125 (0.3 μM and 3 μM) for 30 min prior to 
activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for either 30 min or 2 hours. 
Nuclear extracts were prepared and analysed using the TransAM kit as described in 
the methods using a JunD antibody. The activity of the subunit was measured and 
expressed as relative activity. The results are the mean ± SEM of 3 independent 
experiments. Statistical analysis using two way Anova followed by multiple 
comparison test performed. * p<0.05, **p<0.01 and ***p<0.001compared to control 
or activated, non-drug results.  
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Figure 5.22  Effect of SP600125 on activation of c-Fos in RASMCs  
RASMCs were incubated with SP600125 (0.3 μM and 3 μM) for 30 min prior to 
activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for either 30 min or 2 hours. 
Nuclear extracts were prepared and analysed as described in the methods (Section 
2.2.23). TransAM kit was run using c-Fos antibody. The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed. * p<0.05 and **p<0.01compared to control or 
activated, non-drug results.  
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Figure 5.23  Effect of SP600125 on activation of FosB in RASMCs  
RASMCs were incubated with SP600125 (0.3 μM and 3 μM) for 30 min prior to 
activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for either 30 min or 2 hours. 
Nuclear extracts were prepared and analysed as described in the methods (Section 
2.2.23). TransAM kit was run using FosB antibody. The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed.  
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Figure 5.24  Effect of SP600125 on activation of Fra-1 in RASMCs  
RASMCs were incubated with SP600125 (0.3 μM and 3 μM) for 30 min prior to 
activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for either 30 min or 2 hours. 
Nuclear extracts were prepared and analysed as described in the methods (Section 
2.2.123). TransAM kit was run using Fra-1 antibody. The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed. * p<0.05, **p<0.01 and ***p<0.001compared to 
control or activated, non-drug results.  
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Figure 5.25  Effect of SP600125 on activation of Fra-2 in RASMCs  
RASMCs were incubated with SP600125 (0.3 μM and 3 μM) for 30 min prior to 
activation with LPS (100 μg ml-1) and IFN- (100 U ml-1) for either 30 min or 2 hours. 
Nuclear extracts were prepared and analysed as described in the methods (Section 
2.2.23). TransAM kit was run using Fra-2 antibody. The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed.       
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Figure 5.26  Effect of SP600125 on activation of c-Jun in J774 macrophages  
J774 macrophages were incubated with SP600125 (0.3 μM and 3 μM) for 30 min 
prior to activation with LPS (1 μg ml-1) for either 30 min or 2 hours. Nuclear extracts 
were prepared and analysed as described in the methods (Section 2.2.23). TransAM 
kit was run using phospho-c-Jun antibody (Section 2.2.24). The activity of the 
subunit was measured and expressed as relative activity. The results are the mean ± 
SEM of 3 independent experiments. Statistical analysis using two way Anova 
followed by multiple comparison test performed. * p<0.05, and **p<0.01compared to 
control or activated, non-drug results.  
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Figure 5.27  Effect of SP600125 on activation of JunB in J774 macrophages  
J774 macrophages were incubated with SP600125 (0.3 μM and 3 μM) for 30 min 
prior to activation with LPS (1 μg ml-1) for either 30 min or 2 hours. Nuclear extracts 
were prepared and analysed as described in the methods (Section 2.2.23). TransAM 
kit was run using JunB antibody (Section 2.2.24). The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed. ** p<0.01, and ***p<0.001compared to control 
or activated, non-drug results.  
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Figure 5.28  Effect of SP600125 on activation of JunD in J774 macrophages  
J774 macrophages were incubated with SP600125 (0.3 μM and 3 μM) for 30 min 
prior to activation with LPS (1 μg ml-1) for either 30 min or 2 hours. Nuclear extracts 
were prepared and analysed as described in the methods (Section 2.2.23). TransAM 
kit was run using JunD antibody (Section 2.2.24). The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed.  
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Figure 5.29  Effect of SP600125 on activation of c-Fos in J774 macrophages  
J774 macrophages were incubated with SP600125 (0.3 μM and 3 μM) for 30 min 
prior to activation with LPS (1 μg ml-1) for either 30 min or 2 hours. Nuclear extracts 
were prepared and analysed as described in the methods (Section 2.2.23). TransAM 
kit was run using c-Fos antibody (Section 2.2.24). The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed.  
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Figure 5.30  Effect of SP600125 on activation of FosB in J774 macrophages  
J774 macrophages were incubated with SP600125 (0.3 μM and 3 μM) for 30 min 
prior to activation with LPS (1 μg ml-1) for either 30 min or 2 hours. Nuclear extracts 
were prepared and analysed as described in the methods (Section 2.2.23). TransAM 
kit was run using FosB antibody (Section 2.2.24). The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed. ***p<0.001compared to control or activated, 
non-drug results.  
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Figure 5.31  Effect of SP600125 on activation of Fra-1 in J774 macrophages  
J774 macrophages were incubated with SP600125 (0.3 μM and 3 μM) for 30 min 
prior to activation with LPS (1 μg ml-1) for either 30 min or 2 hours. Nuclear extracts 
were prepared and analysed as described in the methods (Section 2.2.23). TransAM 
kit was run using Fra-1 antibody (Section 2.2.24). The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed. **p<0.01 and ***p<0.001compared to control or 
activated, non-drug results.  
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Figure 5.32  Effect of SP600125 on activation of Fra-2 in J774 macrophages  
J774 macrophages were incubated with SP600125 (0.3 μM and 3 μM) for 30 min 
prior to activation with LPS (1 μg ml-1) for either 30 min or 2 hours. Nuclear extracts 
were prepared and analysed as described in the methods (Section 2.2.23). TransAM 
kit was run using Fra-2 antibody (Section 2.2.24). The activity of the subunit was 
measured and expressed as relative activity. The results are the mean ± SEM of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test performed.  
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5.3.7  The effect of a-Fos and TAM-67 on activation of AP-1 subunits in 
RASMCs  
To determine the effect of AP-1 dominant negatives construct on DNA binding 
activity of each subunit in RASMCs, the cells were transfected with either pGFP-a-
Fos or pGFP-TAM-67 for 18 hours as described before. The cells were then 
activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a further 30 min or 2 
hours and nuclear extract generated for analysis using the TransAM AP-1 family kit 
as described in the methods (section 2.2.24).  
In these studies, transfection of RASMCs with a-Fos caused a reduction in the 
activation of c-Jun (Figure 5.33), c-Fos (Figure 5.36) and FosB (Figure 5.37) but did 
not alter JunB (Figure 5.34), JunD (Figure 5.35), Fra-1 (Figure 5.38) or Fra-2 (figure 
5.39). By comparison, TAM-67 had no effect on the activation of JunB (Figure 5.41), 
JunD (Figure 5.42), FosB (Figure 5.44), or Fra-2 (Figure 5.46) but inhibited c-Jun 
(Figure 5.40) and c-Fos (Figure 5.43) while enhancing the activation of Fra-1 but 
only in control non-activated cells (Figure 5.45).   
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Figure 5.33  Effects of a-Fos on c-Jun activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with a-Fos for 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. The nuclear extracts were prepared and analysed using a 
TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed. *p<0.05 and **p<0.01 
compared to non-transfected results.  
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Figure 5.34  Effects of a-Fos on JunB activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with a-Fos for 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. The nuclear extracts were prepared and analysed using a 
TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed.  
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Figure 5.35  Effects of a-Fos on JunD activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with a-Fos for 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. The nuclear extracts were prepared and analysed using a 
TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed.  
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Figure 5.36  Effects of a-Fos on c-Fos activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with a-Fos for 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. The nuclear extracts were prepared and analysed using a 
TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test performed. *p<0.05, **p<0.01 and 
***p<0.001 compared to non-transfected results.  
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Figure 5.37  Effects of a-Fos on FosB activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with a-Fos for 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. The nuclear extracts were prepared and analysed using a 
TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed. *p<0.05, **p<0.01 and 
***p<0.001 compared to non-transfected results.  
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Figure 5.38  Effects of a-Fos on Fra-1 activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with a-Fos for 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. The nuclear extracts were prepared and analysed using a 
TransAM kit as described in the methods (section 2.2.24) and the activity of Fra-1 
was measured using the specific antibody. The results are representative of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test was performed. *p<0.05 compared to non-transfected 
results.  
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Figure 5.39  Effects of a-Fos on Fra-2 activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with a-Fos for 18 hours. 
The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) for a 
further 30 min or 2 hours. The nuclear extracts were prepared and analysed using a 
TransAM kit as described in the methods (section 2.2.24) and the activity of Fra-2 
was measured using the specific antibody. The results are representative of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test was performed.  
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Figure 5.40  Effects of TAM-67 on c-Jun activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with TAM-67 for 18 
hours. The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 30 min or 2 hours. The nuclear extracts were prepared and analysed 
using a TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed. *p<0.05, **p<0.01 and 
***p<0.001 compared to non-transfected results. 
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Figure 5.41  Effects of TAM-67 on JunB activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with TAM-67 for 18 
hours. The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 30 min or 2 hours. The nuclear extracts were prepared and analysed 
using a TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed. 
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Figure 5.42  Effects of TAM-67 on JunD activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with TAM-67 for 18 
hours. The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 30 min or 2 hours. The nuclear extracts were prepared and analysed 
using a TransAM kit as described in the methods (section 2.2.24). The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed. 
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Figure 5.43  Effects of TAM-67 on c-Fos activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with TAM-67 for 18 
hours. The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 30 min or 2 hours. The nuclear extracts were prepared and analysed 
using a TransAM kit as described in the methods (section 2.2.24. The results are 
representative of 3 independent experiments. Statistical analysis using two way 
Anova followed by multiple comparison test was performed. *p<0.05 compared to 
non-transfected results. 
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Figure 5.44  Effects of TAM-67 on FosB activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with TAM-67 for 18 
hours. The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 30 min or 2 hours. The nuclear extracts were prepared and analysed 
using a TransAM kit as described in the methods (section 2.2.24) and the activity of 
FosB was measured using the specific antibody. The results are representative of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test was performed.  
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Figure 5.45  Effects of TAM-67 on Fra-1 activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with TAM-67 for 18 
hours. The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 30 min or 2 hours. The nuclear extracts were prepared and analysed 
using a TransAM kit as described in the methods (section 2.2.24) and the activity of 
Fra-1 was measured using the specific antibody. The results are representative of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test was performed. *p<0.05 compared to non-transfected 
results. 
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Figure 5.46  Effects of TAM-67 on Fra-2 activation in RASMCs 
Partially confluent monolayers of RASMCs were transfected with TAM-67 for 18 
hours. The cells were then activated with LPS (100 μg ml-1) and IFN- (100 U ml-1) 
for a further 30 min or 2 hours. The nuclear extracts were prepared and analysed 
using a TransAM kit as described in the methods (section 2.2.24) and the activity of 
Fra-2 was measured using the specific antibody. The results are representative of 3 
independent experiments. Statistical analysis using two way Anova followed by 
multiple comparison test was performed. 
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5.4 Discussion   
 
The JNK pathway plays important roles in many different cellular processes, 
including apoptosis as well as enhancing cell survival and proliferation (Bode et al., 
2007; Gupta et al., 1996). Furthermore, the JNKs have also been implicated in a 
variety of pathologic conditions, like cancer (Wagner et al., 2009), cardiac 
hypertrophy and heart failure (Ramirez et al., 1997), neurodegenerative disorders 
such as Parkinson’s and Alzheimer’s disease (Saporito et al., 2002), type I diabetes,  
arthritis and asthma (Sumara et al., 2005). Other than the above, the JNKs have also 
been implicated in inflammation especially under conditions associated with the over 
production of nitric oxide where JNK activation has been examined. Interestingly the 
data presented in Chapter 3 of this thesis however failed to implicate JNK signalling 
in smooth muscle cells but did confirm a role for these kinases in the J774 
macrophage cell line. The observations in the latter cell type would be in agreement 
with other studies showing that JNK regulates iNOS expression for example in RAW 
264.7 macrophages (Ci et al., 2010; Jung et al., 2007), glial cells (Pawate et al., 
2006), human vascular smooth muscle cells (Sinha-Hikim et al., 2010) and murine 
microglia BV-2 cells (Yoshioka et al., 2010) and one study at least has shown that 
JNK is necessary for IL-1 induced iNOS and NO production in rat glomerular 
mesangial cells (Guan et al., 1999). Consistent with our findings however is the 
report by Finder et al. (2001) which failed to implicate JNK in the induction of iNOS 
using IL-1β in the same smooth muscle cell type.  
There are clearly inconsistencies in the findings from various laboratories and the 
reasons for these discrepancies are unclear but raise questions about the 
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experimental approaches used or even the possibility that expression and activation 
of various JNKs may vary under different experimental conditions. 
Most cells express two JNK genes, jnk1 and jnk2, which are alternatively spliced 
variants and yield both the p54 and p46 proteins of the α and β isoforms (Davis, 
2000b; Gupta et al., 1996). These are activated by the MAPK kinase 4 (MKK4) and 
MAPK kinase 7 (MKK7) which are upstream of JNK1 and JNK2 respectively. The 
latter are activated through phosphorylation at threonine (Thr-183) and tyrosine (Tyr-
185) residues (Chen et al., 2002; Davis, 2000a; Lawler et al., 1998; Takatori et al., 
2008, Derljard et al., 1994) and translocation into the nucleus, where JNK 
phosphorylates its target transcription factors including AP-1 (Dong et al., 1998).  
Recent studies have demonstrated that the JNK isoforms differ in their functions 
(Chen et al., 2002; Singh et al., 2009). Some studies have shown that JNK2 has a 
25-fold higher binding affinity for c-Jun than JNK1, suggesting that JNK2 is the major 
c-Jun activator (Kallunki et al., 1994). However, other experiments have suggested 
that the JNK1 isoform may be slightly more efficient in phosphorylating c-Jun (Gupta 
et al., 1996; Hochedlinger et al., 2002). It seems that the different JNK isoforms may 
have evolved for specific biological functions, probably depending on the stimulation 
and responding tissue/cell type (Sabapathy et al., 2004). Moreover it has been 
suggested that different JNKs may show varied regulatory effects on c-Jun, with  
JNK1  acting as a  positive regulator of c-Jun while JNK2 may negatively regulate 
the same protein in vivo (Sabapathy et al., 2004b). This is however contradicted by 
reports claiming that JNK2 normally increases the expression of c-Jun and JunD 
mRNA and can play a positive role in c-Jun expression in 1MN-PP1 and three MEF 
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lines. Thus, it also suggested that JNK1 and JNK2 are positive regulators of c-Jun 
expression in some but not all cell systems (Jaeschke et al., 2006).  
This could explain, at least in part, some of the discrepancies already highlighted 
relating to iNOS expression and additional experiments were therefore undertaken to 
determine the expression profile of the JNKs in both RASMCs and J774 
macrophages. These studies were to confirm whether these proteins are indeed 
expressed and, more importantly, activated following stimulation of cells with pro-
inflammatory mediators. In addition, the effect of the JNK inhibitor SP600125 was 
also examined to ascertain whether this compound did inhibit JNK activation. It was 
important to establish this in RASMC as the lack of effect of the SP600125 in these 
cells could reflect a lack of inhibition of JNK activation. Parallel experiments in 
RAMSCs examined the effects of the dominant negatives a-Fos and TAM-67.  
In response to stress, JNK phosphorylation on both Thr-183 and Thr-185 residues by 
MKK4/7 (Derijard et al., 1994) leads to phosphorylation of JNK substrates, include c-
Jun (Verheij et al., 1996; Xia et al., 1995), ATF-2 (Westwick et al., 1995), c-Myc 
(Yamamoto et al., 1999), Bcl2 (Deng et al., 2001; Kim et al., 1999) and p53 (Fuchs 
et al., 1998; Milne et al., 1995) which among them c-Jun participate in the activation 
and formation of the AP-1 complex (Karin et al., 1995; Shaulian et al., 2002). The 
JNKs were shown to bind to the delta domain of c-Jun and phosphorylate it on 
serines 63 and 73, leading to its activation (Kallunki et al., 1994).  
In our studies, western blots showed that both RASMCs and J774 macrophages 
expressed JNK1 at 46 kDa and two isoforms of JNK2 at 46 and 54 kDa. Activation of 
both cell types resulted in the time-dependent expression of phospho-JNK which 
was detected using a phospho-specific antibody against Thr-183 and Tyr-185 
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residues. Phosphorylation was rapid with the phospho proteins becoming detectable 
as early as 5 min and peaking after 30 min of activation. This is consistent with other 
findings in human lung carcinoma A549 cells (Chittezhath et al., 2008), J774 
macrophages (Lahti et al., 2003; Nieminen et al., 2006) and pancreatic stellate cells 
(Masamune et al., 2004); however, interestingly, other reports have demonstrated 
rapid peak phosphorylation of JNK in rat vascular smooth muscle cells within 5 
minutes of stimulation with interleukin-1β (Jiang et al., 2004) or after balloon injury 
(Kim et al., 1998).  
What is important however, are the observations that JNK is indeed expressed in 
RASMCs as well as J774 cells and can be phosphorylated by pro-inflammatory 
mediators that induce iNOS expression. It is therefore even more curious that the 
latter could not be inhibited by SP600125 in RASMCs and the next series of 
experiments examined whether JNK phosphorylation could be blocked by this 
compound.  
In these studies, both cell types were incubated with the inhibitor at two different 
concentrations (0.3 and 3 μM) and then activated 30 min later for a further 30 min 
(peak JNK phosphorylation time point) before generating lysates for western blotting. 
The reason for choosing these concentrations was because at 0.3 µM SP600125 
enhanced while at 3 µM inhibited NO production and iNOS expression in the 
macrophages. Thus we wanted to see if this biphasic effect correlated with any 
biphasic regulation of JNK phosphorylation. Interestingly, phospho-JNK expression 
was partially inhibited at 0.3 µM and completely abolished at 3 µM SP600125.  This 
is not consistent with the biphasic trends seen with iNOS and NO and it is unclear 
why SP600125 would enhance iNOS/NO production, albeit marginally, at lower 
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concentrations and suppress at higher concentrations but yet inhibit JNK 
phosphorylation at both concentrations. The possibility that SP600125 may affect 
other pathways distinct from the JNKs which are perhaps positively or negatively 
coupled to iNOS expression and/or NO production remains to be established. The 
effect of this inhibitor on p38 MAPK or ERK was previously discussed and reveals a 
certain degree of non-specificity for SP600125. 
Our findings however support other studies which have reported the inhibitory effect 
of SP600125 on JNK phosphorylation for instance in J774 macrophages (Nieminen 
et al., 2006) or other cell types (Chansard et al., 2007; Saito et al., 2010; Wang et al., 
2007) and this effect may, at least in part, account for the inhibitions seen in the 
macrophages. It was intriguing however why despite inhibiting JNK phosphorylation 
in RASMCs, SP600125 was without any significant effect on either iNOS expression 
or NO synthesis in these cells. Further studies were therefore carried out examining 
the expression profile and changes in the activated status of different AP-1 subunits 
in the presence and absence of SP600125. This was to determine whether 
SP600125 did regulate the sequential activation of AP-1 and, more importantly, the 
pattern of activation of the different subunits which could have an impact on the 
actual biological response produced. 
As already explained earlier (Chapter 1), AP-1 consists of distinct subunits which 
include members of Jun (c-Jun, JunB, JunD) and the Fos families (c-Fos, FosB, Fra-
1 and Fra-2). These proteins have different transactivation potentials and each may 
be linked with various specific stages of a cellular process, rather than the entire 
process (Keklikoglu, 2004). There is a vast amount of data suggesting various roles 
for each AP-1 subunits and their effects may vary between different cell types and/or 
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affected differently by different stimulants, experimental approaches and various 
other factors (Young et al., 2003).  
AP-1 responds to a wide range of physiological and pathological extracellular stimuli 
encountered by the cell. Stimuli such as hormones, cytokines, growth factors, stress 
signals, infections, and radiation or chemical carcinogens activate AP-1 (Angel et al., 
2002; Hess et al., 2004). AP-1 activity plays critical roles in the activation of several 
cytokines (Linard et al., 2003). AP-1 member proteins have different transactivation 
potentials and each protein may be linked with various specific stages of a cellular 
process, rather than the entire process (Keklikoglu, 2004). There is a huge amount 
of different studies suggesting various roles for each AP-1 subunits. The differences 
may reflect variations between different cell types, stimulant used, experimental 
approaches and various other factors.  
Of the different AP-1 subunits, c-Jun is activated by JNKs through phosphorylation 
on serines 63 and 73 following binding of JNK to its delta domain (Kallunki et al., 
1994). Once activated c-Jun regulates various cellular processes including growth, 
proliferation, differentiation and apoptosis, and also contribute to basal and stimulus-
activated gene expression including that for iNOS (Young et al., 2003).  
By comparison, JunB exhibits weaker DNA binding and homo-dimerization affinity 
than c-Jun and has been shown, depending on the promoter sequence and 
dimerization partner, to act both as a transactivator or transrepressor (Passegue et 
al., 2000). JunD on the other hand mediates some functions such as inhibition of 
fibroblast proliferation and although activated by JNK (Yazgan et al., 2002) may not 
be entirely dependent on the latter for its activation. In fact there are reports that JNK 
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may not completely drive JunD phosphorylation but rather requires the activation of 
the ERKs to induce full JunD activity (Smart et al., 2006). Similarly, Kuntzen at al. 
(2005) showed that JunD activation may not be mediated through JNK as this was 
insensitive to SP600125 inhibition.  
In our studies, both RASMCs and J774 macrophages expressed all subunits of AP-
1. What was interesting however was the pattern of activation of each following 
stimulation of cells and also the manner in which each subunit was modified by 
SP600125. These experiments were carried out using the TransAM AP-1 family kit 
to measure the DNA-binding activity of the subunits based on an ELISA assay. 
Basically, AP-1 subunits in the nuclear extracts would bind to specific 
oligonucleotides containing TPA-responsive elements (TREs) immobilized into a 96-
well plate and since this only occurs with activated proteins, the assay allows for the 
detection of the active phosphorylated subunits (Ahmad et al., 2007; Mukhopadhyay 
et al., 2008; Shimizu et al., 2008; Xie et al., 2005; Zhang et al., 2009). 
The results obtained from these studies revealed that the activity of c-Jun increased 
rapidly in J774 macrophages following 15 min stimulation with LPS and reached a 
maximum level at 30 min, declining gradual thereafter. The trend of c-Jun activation 
in J774 macrophages was similar to that seen in RASMCs with the only difference 
being that responses in RAMSCs were delayed, peaking at 60 min after activation. 
This time frame is consistent with similar activation of c-Jun observed in smooth 
muscle cells following mechanical stretch (Mitchell et al., 2004). Similarly, the rapid 
activation of c-Jun in J774 macrophages has been reported previously not only in 
response to LPS but also to IL-1 and TNF-α (Tengku-Muhammad et al., 2000). LPS 
has also been shown to enhance c-Jun activity in RAW264.7 cells (Chen et al., 
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2008; Dudhgaonkar et al., 2009; Lee et al., 2009a) as well as in HCT-116 (Lee et al., 
2007), microglia cells (Jung et al., 2006), smooth muscle cells (Gonzalo et al., 2011; 
Lin et al., 2009) and RASMCs (MacKenzie et al., 2003). More importantly, the  rapid 
induction of c-Jun demonstrate its critical role in inflammatory conditions and since 
its activation may be JNK dependent, it indicates that JNK could be an “immediate 
early gene” along with other AP-1 family members (Franciscovich et al., 2008; Guo 
et al., 2007; Hartwig et al., 2008) especially c-Jun (Wainford et al., 2009).  
JunD, the other subunit of AP-1 was also rapidly activated in J774 macrophages at 
the 30 min time point, reaching a maximum at 1 hour and a slight decline was 
observed after 2 hours. Similarly, Fra-1 and FosB DNA-binding activities were also 
enhanced at 30 min with that for FosB peaking at 60 min and declining thereafter 
while Fra-1 remained elevated over two hours. JunB, c-Fos and Fra-2 were 
unaltered. In parallel with these observations, RASMCs exposed to LPS and IFN- 
showed increased Fra-1 activation after 30 min and that of JunD after 1 hour, 
increasing to a maximum at 2 hours. Interestingly, c-Fos was virtually unaltered as 
was JunB and FosB; and although Fra-2 appeared to be enhanced, this was not 
statistically significant when compared to the non-activated cells. These findings 
summarised in Tables 5.1 and 5.2 for clarity, highlight a sequential activation and 
further indicate differences in the activation pattern of the different subunits.  
The consequence of the sequential activation is unclear but there is at least one 
report that JunD, which we found was activated after c-Jun, can stabilise c-Jun 
mRNA expression. Also worth noting is the fact that the basal levels of both JunB 
and c-Fos in macrophages were significantly higher than in RASMCs which may 
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relate to the roles of these proteins in normal physiological cellular functions such as 
differentiation and proliferation in macrophages (Cho et al., 2002).  
These observations are the first to report the expression and activation profile of 
these sub-components of AP-1 in vascular smooth muscle cells. Indeed there is very 
little published literature on either the profile of expression or activation of any of the 
AP-1 subunits we have investigated and the data we have generated for this thesis 
should therefore further enhance our understanding of the role and activation of 
these subunits. 
Some of our observations described above are consistent with, for instance the 
activation of JunD in cytokine stimulated A549 cells (Chittezhath et al., 2008); the 
activation of FosB in RAW264.7 macrophages by LPS and IFN- (Okada et al., 
2003) and the lack of c-Fos stimulation by IL-6 (Tengku-Muhammad et al., 2000). 
The activation of JunD in the J774 macrophages has been reported but others 
studies which have looked at changes in JunD mRNA expression level have shown 
no changes when  cells were exposed to LPS (Tengku-Muhammad et al., 2000); and 
the activation of FosB contrasts with its lack of activation in human aortic smooth 
muscle cells exposed to LPS and CD14 (Patel et al., 2006) as does the lack of 
stimulation of c-Fos which Tengku-Muhammad et al. (2000) claims is enhanced by 
LPS stimulation of J774 macrophages. Similarly, our findings for JunB contracts with 
those reported by Tengku-Muhammad et al. (2000) who claimed the induction of 
JunB mRNA in macrophages within 1 hour  of exposure to LPS (Tengku-Muhammad 
et al., 2000) and with others in rat myometrial smooth muscle cells (Mitchell et al., 
2004) or in human aortic smooth muscle cells where JunB activation and expression 
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was elevated respectively by mechanical stretch  and by exposure to LPS and CD14 
(Patel et al., 2006).  
However it should be noted that in some of these studies the induction or mRNA 
expression and not activation was measured. The reasons for these discrepancies 
are unclear but highlight the need for establishing the actual changes that occur to 
the AP-1 subunits under different conditions, especially when trying to correlate this 
with changes in biological functions.  
The important point about the findings discussed above is the fact that various AP-1 
subunits that may be critical for the induction of iNOS are not only expressed but 
also activated in both RASMCs and J774 macrophages. Thus the fact that 
SP600125 selectively blocked this process in the macrophages but not in the smooth 
muscle cells raises a critical question of whether the AP-1 subunits are regulated 
differentially by this compound in the two cell systems. 
SP600125 is known to inhibit the c-Jun transactivation domain (Bogoyevitch et al., 
2008) and acts as a reversible ATP-competitive inhibitor with equal potency towards 
JNK1, JNK2 and JNK3. It has a high degree of selectivity (300-fold) for these 
proteins when compared to its effects on the extracellular signal regulated kinases 
(ERKs) and p38 MAPKs (Bogoyevitch et al., 2004; Maroney et al., 2001). To 
determine the effects of SP600125 on the activation of the various AP-1 subunits, 
the drug was used at the two concentrations of 0.3 µM and 3 µM discussed 
previously and at two incubation time points which covered the peak activation time 
points (30 min and 2 hours) of the different subunits. In these studies, SP600125 
concentration-dependently blocked c-Jun DNA binding activity without affecting FosB 
or Fra-2 in RASMCs and JunD, c-Fos or Fra-2 in J774 macrophages. Interestingly, 
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SP600125 significantly enhanced JunB, JunD, c-Fos and Fra-1 activity in RASMCs 
while in activated macrophages JunB was the most affected. In these cells 
SP600125 caused an increase in JunB actrivity which was not further enhanced by 
LPS, suggesting that SP600125, on its own, is able to activated JunB significantly. 
Similarly, the up-regulation of Fra-1 in RASMCs and FosB and Fra-1 in J774 
macrophages again appear to be a direct response to SP600125. These changes in 
both cell types are again summarised in Tables 5.1 and 5.2 and summarised 
diagrammatically in Figure 6.1 for clarity. 
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Table 5.1 Changes in activation of AP-1 subunits, iNOS and L-arginine 
transport in RASMCs treated with LPS + IFN-, SP600125, a-Fos or 
TAM-67. 
 
 
(↑ = increase; ↓ = decrease and – = no changes) 
LPS/IFN- treatment up-regulated c-Jun, JunD and Fra-1 as well as induce iNOS 
expression and L-arginine transport. Addition of SP600125 in the presence of LPS/ 
IFN- caused a significant decline in c-Jun, enhanced JunD and c-Fos level but did 
not reveal any effect on basal iNOS or L-arginine transport. SP600125 independently 
elevated level of JunB and Fra-1 in the absence of LPS and IFN- treatment. 
Transfection of RASMCs with a-Fos or TAM-67 and incubation with LPS/IFN-
caused reductions respectively in c-Jun, c-Fos, FosB and Fra-1 and in c-Jun, c-
Fos. However TAM-67 up-regulated the induction of Fra-1. a-Fos transfection 
resulted in iNOS/L-arg enhancement while TAM-67 reduced these processes.  
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RASMCs LPS/INF- SP600125 
-LPS/INF- 
SP600125 
+LPS/INF- 
a-Fos 
+LPS/INF- 
TAM-67 
+LPS/INF- 
c-Jun ↑ ─ ↓ ↓ ↓ 
JunB ─ ↑ ↑ ─ ─ 
JunD ↑ ─ ↑ ─ ─ 
c-Fos ─ ─ ↑ ↓ ↓ 
FosB ─ ─ ─ ↓ ─ 
Fra-1 ↑ ↑ ↑ ↓ ↑ 
Fra-2 ─ ─ ─ ─ ─ 
iNOS ↑ ─ ↑ ─ ↓ 
L-arginine ↑ ─ ↑ ─ ↓ 
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Table 5.2 Changes in activation of AP-1 subunits, iNOS and L-arginine 
transport in J774 macrophages treated with LPS, SP600125. 
 
 
(↑ = increase; ↓ = decrease and – = no changes)          
LPS treatment up-regulates c-Jun, JunD, FosB and Fra-1 and resulted in the 
induction of iNOS expression and L-arginine transport. Addition of SP600125 caused 
a significant decline in c-Jun and in iNOS expression and L-arginine transport. The 
other AP-1 subunits were not affected. Treatment with SP600125 alone elevated 
level of JunB, FosB and Fra-1 above basal. No changes were observed in JunD, c-
Fos and Fra-2 expression.   
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J774 macrophages LPS SP600125 
-LPS 
SP600125 
+LPS 
c-Jun ↑ ─ ↓ 
JunB ─ ↑ ↑ 
JunD ↑ ─ ─ 
c-Fos ─ ─ ─ 
FosB ↑ ↑ ─ 
Fra-1 ↑ ↑ ↑ 
Fra-2 ─ ─ ─ 
iNOS ↑ ─ ↓ 
L-arginine ↑ ─ ↓ 
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The significance of the observations described above and how they relate to the 
regulation of iNOS or NO production are as yet unclear. It has, however, been 
reported that the activation of c-Jun may be essential for these processes to occur 
and inhibition of this molecule could result in the blockade of iNOS expression and 
subsequently NO synthesis. This could explain the results obtained in the J774 
macrophages where inhibition of c-Jun activation by SP600125 was clearly 
demonstrated. Should this argument hold, the same outcome should also have been 
observed in RASMCs where c-June DNA-binding activity was evidently blocked by 
SP600125. However, there was no suppression of iNOS expression or NO 
production in smooth muscle cells despite the inhibition of c-Jun activity.  
In RASMCs, the situation may be more complex because inhibition of c-Jun was 
accompanied by a parallel up-regulation in the activity of several other subunits 
including JunD and c-Fos while in LPS-activated J774 macrophages there were no 
notable changes or increase in any other subunits. It is therefore possible that in 
RASMCs there may be some compensation for the inhibition of c-Jun by subunits 
with enhanced activity. As a result of this, any inhibitory actions that may have been 
mediated by the blockade of c-Jun may be masked by opposing compensatory 
actions of others especially where these are positively coupled to the induction of 
iNOS. Some of the key candidates for consideration include JunB, JunD, c-Fos and 
Fra-1. In this regard, it is worth noting that there is at least one report in cytokine-
treated C6 glial cells claiming that JunD and Fra-1 may be the critical AP-1 subunits 
required for iNOS gene expression (Giri et al., 2002). Both of these are not only 
activated by LPS and IFN- in the RASMCs but their activities were also further 
enhanced by SP600125. Thus even with c-Jun inhibited the activation of JunD and 
294 
 
Fra-1 may compensate for the effects of SP600125 on c-Jun especially as they can 
both dimerise into an active AP-1 complex (Nadori et al., 1997; Tkach et al., 2003). 
JunD can also complex with Fra-2 and has been implicated in the induction of iNOS 
following LPS and IFN-treatment of the A549 human lung epithelial cells (Kristof et 
al., 2001).  
Interestingly, in C6 cells it would appear Fra-1 and JunB rather than c-Jun and c-Fos 
may be required following stimulation of these cells with LPS and TNF-α (Lee et al. 
2003). We can however discount an involvement of Fra-2 or complexes involving this 
subunit as it was not activated by LPS and IFN-nor was its activity induced by 
SP600125. Similarly, although activated by SP600125, JunB was not altered in the 
presence of LPS and IFN- and unlikely to be associated with the induction of iNOS 
in this cell system. Other active complexes which could be formed and potentially 
regulate the activation of the iNOS gene include complexes with c-Fos that do not 
involve c-Jun which could be just as critical for the induction of iNOS and will be 
addressed further below when discussing the effects of the dominant negative a-Fos.  
The discussions above although largely speculative, could be substantiated using 
more direct and selective approaches such as exploiting siRNA technology, over 
expression of individual AP-1 subunits or both. However, these experiments 
although identified could not be carried out because of the time limitation. Instead 
further studies were conducted by investigating the effects of dominant negative 
constructs of AP-1. One of the dominant negatives used was a-Fos which is an 
engineered chimeric protein containing the c-Fos leucine-zipper and a designed 25 
amino acid acidic protein sequence that replaces the DNA-binding region 
(Bobrovnikova-Marjon et al., 2004; Bonovich et al., 2002; Gerdes et al., 2006). It has 
295 
 
also been shown to inactivate the DNA binding of the Fos-Jun hetero-dimer and 
potentially inhibit Jun-dependent transactivation (Manna et al., 2004; Olive et al., 
1997).  
Transactivation minus c-jun dominant negative AP-1 (TAM-67) is the other dominant 
negative construct which acts against c-Jun and has the ability to form dimers with 
wild-type AP-1 proteins because of its DNA binding domain and leucine-zipper 
region (bZIP). However TAM-67 lacks the transactivation domain of c-Jun (amino 
acids 1–122) and thus functions as a dominant negative to block wild-type c-Jun 
activity (Dhar et al., 2004; Feng et al., 2002; Wu et al., 2003; Young et al., 2006). In 
exerting its effects, TAM-67 can act by (i) forming a homo-dimer which binds to DNA 
and blocks the 12-O-tetradecanoylphorbol-13-acetate response element (TRE), (ii) 
quenching DNA activation by directly binding to the latter but without activating 
transcription and (iii) squelching through formation of a heterodimer with wild-type 
transcription factors with the complex formed failing to bind to DNA (Thompson et al., 
2002).  
In this thesis, each dominant negative was transfected into RASMCs using an 
integrin binding peptide with an RGD domain for integrin and a poly-lysine tail for 
DNA binding (Hart et al., 1998). The non-transfected or cells incubated with the 
transfection mix lacking the cDNA construct were used as controls. The data from 
these studies confirm that a-Fos could significantly suppress both c-Fos and FosB 
activity with a smaller but significant inhibition of c-Jun. In contrast JunB, JunD, Fra-1 
and Fra-2 remained virtually unaltered. These results show a good degree of 
selectivity of a-Fos for the Fos subunits and the fact that when transfected into cells 
enhanced both iNOS and NO production strongly suggests that the Fos proteins may 
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be negatively coupled to these processes and their inhibition results in enhanced 
expression of iNOS and thus NO synthesis. This would indeed agree with the report 
by Okada et al. (2003) showing that over expression of c-Fos in macrophages 
suppressed rather than enhanced iNOS expression, indicating that c-Fos may be 
negatively coupled to the induction of iNOS. In contrast, other reports have indicated 
that c-Fos rather than c-Jun may be more relevant for inducing the expression of 
iNOS in some cell systems. This is further supported by observation in terminal 
bronchiole lesions in rats exposed to cigarette smoke where expression of iNOS was 
associated with a significant enhancement of c-Fos expression (Chang et al., 2001).  
In contrast to the actions of a-Fos, TAM-67 significantly inhibited c-Jun DNA-binding 
activity and marginally suppressed that of c-Fos without affecting any of the other 
subunits. These effects are not unpredictable as TAM-67 is a dominant negative of 
c-Jun and the latter often complexes with c-Fos. As a result, suppression of c-Jun 
may impact on the activation of c-Fos. In this regard, it has been reported that TAM-
67 is able to interact with all proteins which combine with c-Jun (Thompson et al., 
2002) and can augment c-Fos activity (Brown et al., 1994) as well as block the DNA 
binding of a Fos-Jun hetero-dimer (Olive et al., 1997). Since c-Jun may be critical for 
iNOS induction, its inhibition by TAM-67 without any up-regulation of other subuints 
that could compensate for its inhibition may result in the inhibition of iNOS 
expression and reveals the true effects of c-Jun. This would be consistent with the 
inhibition of iNOS expression by TAM-67 in gastric epithelial cells (Cho et al., 2009).    
Finally, unlike SP600125, neither a-Fos nor TAM-67 caused any significant 
elevations in the activities of the AP-1 subunits. The only indication of this was with 
Fra-1 following transfections with TAM-67 but the increases were marginal and only 
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evident in control non-activated cells. Thus, the effects of the dominant negatives 
would appear to be more selective and less complex. This could explain the clear 
trends obtained and trends that perhaps were masked in RASMCs when treated with 
the pharmacological inhibitor (SP600125) due to induction of parallel effects that 
could have potentially compensated for the inhibitory actions of the compound. This 
raises a serious issue which is often overlooked in research exploiting purely 
pharmacological interventions. As demonstrated in this thesis, compounds such as 
SP600125 may exert effects beyond their expected pharmacological actions and this 
is often overlooked resulting in conclusions which may not be truly representative of 
their pharmacological actions. Multiple approaches that combine pharmacological 
and molecular tools may therefore be the preferred approach and this need to be 
given some attention in experimental designs. Figure 5.47 simply demonstrated this 
events and their role in iNOS gene induction.  
As mentioned in chapter 3 and 4, the role of JNK/AP-1 on iNOS expression was 
studied in parallel with L-arginine transport and also cationic amino acid transporters 
responsible for transport of this amino acid. There are not many studies on the 
signalling mechanism controlling CAT expression. Visigalli et al. (2004) suggested a 
mechanism in which stimulation by PKCα activation through ERK1/2/AP-1 pathway 
lead the arginine transport through system y+ and induction of CAT-2A and CAT-2B 
expression in endothelial cells. On the other hand Baydoun et al. (1999) showed no 
involvement of PKC on transport of L-arginine but the important role of p38 MAPKs 
in rat aortic smooth muscle cells. 
In this thesis we have shown (Chapter 3) that transport in RASMC is not affected by 
SP600125 but it was in J774 macrophages even with JNK inhibitor VIII. Moreover we 
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have shown that in these cells, CAT-2B which is potentially the predominant CAT 
transporter in these cells is inhibited by SP600125 at 3 μM. In RASMCs transport 
was inhibited by TAM-67 but not a-Fos suggesting selective regulation by c-Jun or at 
least a non Fos subunit. It is clear that while in RASMC SP600125 may not have an 
effect, JNK/AP-1 is still involved but like iNOS the effect is masked by compensation. 
JNK is also clearly involved in J774 macrophages. 
Data obtained in this chapter makes a vivid picture of how all the subunits of one 
transcription factor work alongside with all the compensatory and positive/negative 
effect on each other to determine the response of the cells to various stimulations. 
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5.1 Summary 
In conclusion our data indicates a series of different activation patterns in AP-1 
subunits whilst using LPS alone or with LPS/IFN- in J774 macrophages and 
RASMCs respectively. The data presented is to our knowledge the first to explore 
the complex regulation of all seven subunits of AP-1 in RASMCs and J774 
macrophages and has revealed some interesting but complex trends which may help 
explain the variation in responses of these two cell systems to pharmacological 
inhibition. Moreover, the data has contributed towards understanding the controversy 
that surrounds the role of JNK in the induction of iNOS. It would appear that JNK 
signalling is indeed critical for the latter process but may not always be evident in 
certain biological systems especially where the experimental approach has relied 
exclusively on a pharmacological intervention, or at least the use of SP600125. 
Furthermore, our findings have also revealed for the first time that L-arginine 
transport regulation in parallel with iNOS is partly dependent on JNK/AP-1 pathway. 
In RASMCs however this pattern is not observed using the pharmacological inhibitor 
which again confirms the compensatory mechanism of the other subunits which 
mask c-Jun up-regulation. 
Using the dominant negative constructs of AP-1 help to visualize better 
understanding of how the individual subunits are acting independently and 
dependent of each other. High level of c-Jun inhibition caused a down-regulation of 
iNOS-NO when TAM-67 was used and this inhibition was not enough in a-Fos 
transfected cell to inhibit iNOS-NO. In this regard, molecular approach shows more 
selective way to regulate this pattern. 
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General Discussion 
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Discussion 
The experiments described in this report were carried out to get a clear 
understanding of the mechanisms involved in the expression of the inducible L-
arginine-NO pathway in cultured vascular smooth muscle cells and J774 
macrophages focusing specifically on the JNK/AP-1 cascade.  
Although there has been a good deal of work carried out investigating the role of 
JNK/AP-1 in the induction of iNOS, the findings are inconclusive with contradictory 
reports which are poorly explained. Furthermore there is currently very little 
information in the literature as to whether the parallel up-regulation in L-arginine 
transport, widely reported under conditions of induced NO synthesis, also requires 
activation of the JNKs. The studies reported in this thesis were therefore carried out 
to determine unequivocally whether JNK/AP-1 signalling is indeed critical for the 
induction of iNOS and/or L-arginine transport in RASMCs and also in J774 
macrophages. These two cell systems were selected because they are two of the 
widely reported sites for iNOS expression in vivo and, perhaps more importantly, 
because of their critical role in the actions of pro-inflammatory mediators in disease 
states such as septic shock associated with overproduction of NO (Knowles et al., 
2004).  
For our studies, we exploited both pharmacological and molecular approaches to 
regulate JNK and/or AP-1 activity. This approach is essential if we are to understand 
the discrepancies in the literature and gain a better understanding of how over 
production of NO might be regulated in biological systems.  
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The first task in this study was to determine the responses of our cells to 
inflammatory condition and subsequently establish how JNK/AP-1 might affect the 
responses produced. Thus, LPS and IFN- were used to stimulate RASMCs and 
LPS alone was used in J774 macrophages at established concentrations identified in 
previous studies within the group (Baydoun et al., 1993). Both cells were consistently 
activated by the stimuli used and produced significant amount of iNOS and NO as 
well as increase their ability to transport L-arginine. What was interesting however 
was the fact that in RASMCs there was little response to JNK inhibition using the 
pharmacological inhibitors, while in J774 macrophages both inhibitors used caused 
significant suppression of these processes. 
It should be noted that in all the experiments conducted in this thesis different stimuli 
for two cell types were used. The high amount of LPS/IFN- for smooth muscle cells 
and low LPS for macrophages may affect interpretation of the results, because of the 
different signalling pathways consequently activated in each cell system. In RASMCs 
LPS alone cannot induce iNOS and requires co-incubation with the direct activator of 
adenylyl cyclise, forskolin. LPS will bind to a serum derived binding protein, CD14 
and activates TLR-4 receptors. But this mechanism for IFN- is different. Interferon-
regulatory factor-1 (IRF-1) is a protein transcription activator which is regulator of IFN 
system. Also two intracellular signalling pathways that have been implicated in the 
regulation of IRF-1 included JAK/STAT and NF-kB pathways (Liu et al., 2001). In 
smooth muscle cells both systems are required for the complete stimulation in the 
system. It has been shown that IFN- also can stabilise iNOS mRNA however in 
macrophages LPS alone in sufficient and there is no need for another factor for 
mRNA stabilisation (Wileman et al., 1995). 
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The findings in RASMCs are at odds with other reports in the same cell type which 
have suggested that inhibition of JNK/AP-1 can cause a reduction in NO production 
and iNOS expression (Hattori et al., 2003; Nakata et al., 2005) but consistent, at 
least in part, with others claiming that expression of iNOS in smooth muscle cells is 
indeed independent of JNK activation (Jiang et al., 2004). The situation in J774 
macrophages appear less complicated as activation of JNK/AP-1 has been 
confirmed for the induction of iNOS  (Chan et al., 1998; Cho et al., 2002) and it has 
been suggested that JNK may in fact be the dominant regulator of iNOS expression 
in these cells (Blanchette et al., 2008; Chen et al., 2008). It is worth noting, however, 
that JNK may only partially regulate the induction of iNOS and this process may in 
part require the ERKs in macrophage (Chan et al., 1998). Interestingly, there 
appears to be some differences between the changes in expression of iNOS and in 
the degree of inhibition of the JNKs that is seen.  It would appear that iNOS mRNA 
inhibition occurs even without complete blockade of JNK, suggesting that any 
inhibitory effect on iNOS transcription is only partially dependent on this MAPKs 
(Chan et al., 1998). Other studies have suggested that depending on the stimulus 
and cell type, MAPKs may play a positive (Bhat et al., 1998; Da Silva et al., 1997; 
Singh et al., 1996), negative (Guan et al., 1997), or neutral (Chan et al., 2001) 
regulatory role on iNOS expression. Thus, as with JNK, the critical requirement of 
other MAPKs like ERKs for the induction of iNOS may not be unambiguously 
universal.  
Other than the JNKs and ERKs there is also controversy about the role of other 
MAPKs such as the P38 MAPK which have been shown not to be essential for NO 
production and iNOS expression because LPS induced iNOS expression could not 
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be blocked by SB203580 (Caivano, 1998). By contrast, there it has been reported 
that activation of p38 and ERKs may be involved in LPS-induced iNOS expression in 
J774 macrophages (Kim et al., 2004) and in murine macrophages stimulation with 
LPS leads to increased phosphorylation and activation of ERK1/2, JNK, and p38 
kinase (Chen et al., 2008; Choi et al., 2007; Nakano et al., 1998). Baydoun et al., 
(1999) showed that SB203580 can potentiate NO production at lower concentration 
and inhibit it at the higher range in rat vascular smooth muscle cells therefore it can 
be speculated that these effect may be variable at diverse concentration of the 
inhibitor. 
With regards to JNK, it is perhaps worth pointing out again that the regulation of 
iNOS expression by these proteins and the interaction of JNK with its downstream 
targets AP-1 is complex. Such interactions may be determined by several factors, 
including the cell system being explored and the stimulus being applied. These do 
need careful consideration in experimental designs but even more important is 
ensuring that appropriate experiments are conducted that can unmask the full profile 
of drug actions at both the functional and molecular level. This point is emphasised 
in the findings of this thesis and discussed in further details below. 
As already described in earlier chapters, using a purely pharmacological approach 
failed to reveal a conclusive role for JNK in RASMCs while the molecular approach 
used, exploiting dominant negatives of AP-1 revealed effects which were not evident 
with a pharmacological inhibitor. In these studies, a-Fos, a dominant negative 
inhibitor of the Fos proteins, increased iNOS mRNA and protein as well as NO 
production while TAM-67, a dominant negative for c-Jun, caused down-regulation in 
iNOS mRNA, protein and NO synthesis.  
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To address the variations in the results we examined the expression profiles of the 
JNK isoforms and AP-1 subunits, which to our knowledge is the first time such 
detailed studies have been carried out. There is increasing evidence to suggest an 
important role for the different AP-1 subunits and their dimer formation in the control 
of cellular functions in diverse cell systems. These subunits may be regulated 
differentially by ERK, p38, and JNK, with each selectively regulating AP-1 
subcomponent and their DNA binding activity (Ding et al., 2008). This may depend 
on the cell type and stimulations used and may result in different biological 
outcomes. 
AP-1 may act either as an inducer or as a repressor of the iNOS gene promoter 
(Mendes et al., 2003) and these effects have been reported in cell types like J774 
macrophages (Chen et al., 1999; Lin et al., 2007) and RAW264.7 macrophages as 
inducer (Park et al., 2009), or repressor (Huh et al., 2007; Ichikawa et al., 2009), 
smooth muscle cells as inducer (Hattori et al., 2003; Knipp et al., 2004) or repressor 
(Chyu et al., 2004), gastric epithelial AGS cells (Cho et al., 2009), pancreatic beta-
cells (Gurzov et al., 2008) and  microglia (Chang et al., 2008) as inducer. However, 
there are other reports which suggest that AP-1 is not required for iNOS gene 
expression in cell types such as chondrocytes (Mendes et al., 2003) or smooth 
muscle cells (Matsumura et al., 2001). These differences are confusing however 
different experimental design or approach, different tissues or cell life cycle and lots 
of various conditions can lead to this inconsistency. 
It is becoming increasingly clear that the modulation and composition of AP-1 
complex formed can affect AP-1 transcriptional activity (Baskey et al., 2002). For 
example Fos-Jun hetro-dimers have been shown to be more stable than Jun-Jun 
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homo-dimers (Abate et al., 1991; Baskey et al., 2002) or c-Jun binding complex has 
a greater stability than those containing JunB or JunD (Ryseck et al., 1991). 
However, this is still controversial in terms of AP-1 composition and function and its 
role in iNOS induction. It is therefore important to determine the composition and the 
role of AP-1 under inflammatory conditions. 
It has been shown that iNOS gene promoter contains binding sites for AP-1 (Chu et 
al., 1998; Lowenstein et al., 1993) but in different cells the role of this transcription 
factor on iNOS gene expression has been shown to differ from induction (Giri et al., 
2002; Kristof et al., 2001) to repression (Kleinert et al., 1998; Pance et al., 2002) or 
even failing to show any effect as observed in bovine articular chondrocytes 
(Mendes et al., 2003). This controversy raises the question of the role of each 
subunit in the signalling events and suggests that different AP-1 dimers may have 
distinct roles (Shaulian et al., 2002) in the regulation of iNOS and/or CAT gene 
transcription. The hetro-dimer of c-Jun-c-Fos appear to be the most accepted dimer 
that regulate iNOS expression however recent studies have indicated that other AP-
1 dimers such as JunB or JunD can participate in the regulation of iNOS gene 
expression (Mendes et al., 2003). 
In our study the activation of the transcription factors was evident as early as 15 min 
and optimal at 2 hrs after activation. This rapid activation may reflect the fact that 
these are early response genes. However there was a study on RAW 264.7 
macrophages which showed that following the induction of iNOS with LPS there 
were either no or minor changes in AP-1 activation, but over a prolonged period of 
iNOS induction, nitric oxide itself caused the activation of AP-1 (von Knethen et al., 
2000). In our system, after activation with LPS/IFN- in RASMCs and LPS in J774 
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macrophages, there was sequential activation of various AP-1 subunits. In the first 
instance, there was an increase in c-Jun, JunD and Fra-1 in both cells and FosB only 
in J774 macrophages. In both cell types c-Jun was the first to be activated which 
shows an important role for this subunit and JunD enhancement which can be an 
indicator of its role in stabilization of c-Jun mRNA. 
The pattern of AP-1 activation was the same as for the activation of JNK which was 
phosphorylated within a few minutes (5-15 min) of activation. Moreover inhibition of 
JNK using SP600125 in both smooth muscle cells and J774 macrophages has the 
same effect on JNK phosphorylation; but then the activation profile of AP-1 subunits 
varied between smooth muscle cells and J774 macrophages. c-Jun, a proposed  
direct target for p-JNK had the same pattern of activation in both cells but the 
interaction between other subunits also determine the different response from cells; 
for instance as described in chapter 5, some subunits like JunB or even JunD and c-
Fos can substitute for c-Jun decline. 
Therefore our studies on the subunits provide strong evidence for c-Jun involvement 
in the signalling pathway that lead to iNOS expression in these cells especially in 
J774 macrophages as it showed an increase after LPS stimulation and decrease 
after using the JNK inhibitor SP600125. This followed the same pattern seen for 
iNOS/NO/L-arginine. This subunit may act as a homo-dimer of c-Jun-c-Jun or hetro-
dimer of c-Jun-Fra-1 following activation with LPS and/or IFN- as the time point of c-
Jun and Fra-1 activation had the same pattern. The suggestion of c-Jun-Fra-1 
combination has been shown previously (Singh et al., 2009). 
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In RASMCs c-Jun activity was reduced by SP600125 but that of JunB was elevated 
and this subunit may substitute for the decline in c-Jun as shown previously 
(Passegue et al., 2002). As a result iNOS gene transcription may still be initiated 
leading to iNOS expression and NO production even with SP600125 present. This 
potential compensation may explain why we could not see any blockade of iNOS 
when SP600125 was applied to the cells.  
The above suggestion is supported by the fact that TAM-67 suppressed c-Jun 
activation without altering JunB and, more importantly, reduced iNOS induction and 
NO production. This observation is taken to indicate that when c-Jun is suppressed 
without any compensatory up-regulation of Jun-B, we demonstrate inhibition of 
iNOS. In contrast, if Jun-B (or other subunits positively coupled to iNOS expression) 
is induced then the inhibition of iNOS that would be associated with the suppression 
of c-Jun may not be evident.  
It has been reported that in SK-N-SH neuroblastoma cell line, TAM-67 but not a-Fos 
decreased AP-1 transcriptional activation, which demonstrates the role of c-Jun as 
this subunit is the direct target of TAM-67; moreover c-Fos was not involved in the 
activated AP-1 complex and this study suggest a Jun homo-dimer format for AP-1 
complex (Herdman et al., 2006). 
These results suggest an essential requirement of the JNK/AP-1 pathway that may 
not always be evident in studies when using pharmacological inhibitors because of 
the induction of potential compensatory mechanisms that could mask their inhibitory 
action in certain cell systems. Thus, when identifying pathways that regulate 
expression of target proteins (eg iNOS) it is important to appreciate that there may 
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be compensatory mechanisms involving other targets beyond that being targeted by 
the pharmacological molecule used. This, as clearly demonstrated in this thesis, may 
skew the conclusions reached and could potentially account for some of the 
controversies in the literature. It is possible that AP-1 components interact together 
in a way that in smooth muscle cells, compensatory effect of subunits like JunB, 
JunD, c-Fos and Fra-1 overcome effect associated with, for instance, c-Jun 
reduction. When there is no compensation, the consequences of c-Jun inhibition 
becomes evident as seen with TAM-67 which selectively blocked c-Jun-DNA binding 
activity without altering other AP-1 subunits.  Also it seems that the level of inhibition 
and how much activity is inhibited is very important and determines how efficient the 
AP-1 complex may be at initiating gene transcription. This is perhaps evident with 
the data obtained for TAM-67 which showed greater inhibition of c-Jun than a-Fos 
and therefore showed its effect more strongly. As c-Jun is the positive regulator of 
iNOS expression and seems to have an important role in AP-1 complex we suggest 
that the c-Jun high level of inhibition and decline was the main reason for iNOS 
reduction level. 
In macrophages no compensatory effect from JunD and c-Fos was observed and 
therefore c-Jun reduction caused a down-regulation in iNOS expression. Because as 
it was shown before JunB, JunD and c-Fos can compensate c-Jun reduction (Nadori 
et al., 1997; Tkach et al., 2003). 
To summarise the interaction between subunits we can conclude that in 
macrophages c-Jun may be the main subunit. Its induction caused an increase in 
AP-1 positive transcriptional activity and its decline caused a down-regulation in AP-
1 activity and therefore in this cell type, c-Jun is a positive regulator which regulates 
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iNOS gene expression. In smooth muscle cells however, the mechanism is more 
complex. c-Jun is a positive regulator as its increase after activation with LPS 
resulted in iNOS induction, however other regulators such as c-Fos may also be 
involved as their activity did not changed when the cells were activated with 
LPS/IFN- but altered by the pharmacological JNK inhibitor SP600125 which could 
have caused a compensatory response to c-Jun inhibition, thus sustaining iNOS 
expression. This complex mechanism, summarised in Figure 6.1, needs a more 
detailed examination to enable us to have a full understanding of how iNOS 
induction may be regulated. 
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Figure 6.1 The proposed role of different AP-1 subunits in the induction of 
iNOS expression in RASMCs and J774 macrophages 
 
Classically activation of RASMCs or J774 macrophages (Ø) with inflammatory 
mediators may induce c-Jun activation which when complexed with another AP-1 
subunit initiates iNOS gene transcripotion and subsequent protein expression 
(Pannel A). This process may be blocked by SP600125 resulting in the inhibition of 
iNOS epxresion in J774 macrophages. In RASMCs this may be compensated for by 
the activation of other AP-1 subunits such as c-Fos which may complex with JunD 
and compensate for the loss of c-Jun activity (Pannel B). This may in turn sustain 
iNOS induction leading to no significant loss in NO production as reported in this 
thesis.   
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In parallel with studies on iNOS, the effect of JNK/AP-1 pathway on L-arginine 
transporter and its transporters was determined. Interestingly, the two dominant 
negatives regulated L-arginine transport differently with a-Fos showing no effect 
while TAM-67 partially blocked transport rates in RASMCs. These observations are 
the first to show that induction of transporter activity is dependent on the JNK/AP-1 
pathway and perhaps more interestingly that there may be differential regulation of 
CATs by different AP-1 subunits. In RASMCs CAT-1 mRNA declined when cells 
were exposed to LPS and IFN- and at the same time CAT-2B mRNA was enhanced 
with no effect on CAT-2A. Also, none of the transcripts for the transporters were 
affected by the JNK inhibitor SP600125 or a-Fos but CAT-2B was marginal reduced 
by TAM-67 and this is consistent with the reductions in transport rates seen under 
identical conditions.  In J774 macrophages, CAT-2A and CAT-2B mRNA increased 
following stimulation with LPS but CAT-1 didn’t show any changes. JNK inhibition 
with SP600125 reduced CAT-2B without affecting CAT-1 or CAT-2A mRNA levels 
which helped the conclusion that CAT-2B, one of the main transporters of L-arginine 
in these cells, is critically regulated at least in part by JNK activation. 
It should be noted that the experiments in this study were limited to pharmacological 
and molecular tools and further complementary experiments can be carry out to fully 
establish the role of the JNK/AP-1 pathway in inflammatory condition. These could 
include the use of knockout animals such as JNK-/- mice (Medeiros et al., 2007; 
Zingarelli et al., 2002). In these experiments JNK 1 and JNK 2 can separately be 
knock-out and the animals stimulated with LPS/ IFN- to reveal whether iNOS 
expression has been induced. These studies could be coupled with the 
determination of plasma nitrite levels and with changes in the expression profile of 
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iNOS protein in various tissues in comparison to the wild type animals. Furthermore, 
smooth muscle cells could be isolated and cultured in vitro to establish whether the 
cells will respond to stimulation by expressing iNOS.  In relation to these studies, 
Wang et al. (2009) has already used a MAPK phosphatise 1 (MKP-1) -/- mice model 
to determine the changes in inflammatory response to LPS. Their results reveal that 
in response to LPS, MKP-1 -/- mice produced much more inflammatory cytokines and 
nitric oxide and severe hypotension compared to wild type. These observations 
already begin to indicate a critical role of JNK as MKP-1 is an inhibitor of the 
upstream activator of JNK.  
Another approach could be the use of siRNA against AP-1 subunits to specifically 
knockout individual subunits component genes. The expression of each sub-unit 
gene could be blocked and the consequences on iNOS expression and NO 
production investigated. Alternatively, JNK and/or various AP-1 subunits could be 
overexpressed and the consequences on iNOS expresiona nd NO production again 
investigated through eth standard protocols described in this thesis. At the moment 
not much has been done on the effect of AP-1 subunits overexpression on iNOS 
induction and such studies would therefore be valuable. Studies by Wang et al. 
(2009) have used the co-transfection of c-Jun and c-Fos plasmids to inspect the 
effect of AP-1 overexpression on iNOS regulation and showed this resulted in a 
reduction of iNOS expression.  
To support the studies above, additional experiments could be carried out correlating 
changes in AP-1 subunits expression using western blotting with changes in iNOS 
expression and NO production after incubation with LPS and/or IFN-. This would 
confirm the trend observed in chapter 5 and give a clear indication of which subunits 
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may actually be critical for the induction of iNOS. Moreover all these experiments 
should be conduct in parallel with the experiments studying the L-arginine transport 
systems to verify how this system may be regulated by JNK.   
Another desirable experiment would be determining the possibility of any crosstalk 
between AP-1 and NF-B as Angel et al., 1991 revealed that TAM-67 may have 
regulatory effect on the p65 subunit of NF-B. Therefore western blotting can detect 
the expression of p65 in a TAM-67 transfected system. Additionally changes in NF-
B activity in response to TAM-67 treatment could be monitored by ELISA. Such 
studies would shed light on whether the effects of TAM-67 may, in part, relate to NF-
B signalling. 
 
 
 
 
 
 
 
 
 
 
316 
 
Summary  
It has been established that JNK/AP-1 pathway has a role in iNOS induction in both 
RASMCs and J774 macrophages. Although this effect is not clear in RASMCs, it 
seems that in these cells, JNK is phosphorylated by LPS/IFN- and after inhibition 
with SP600125, there is a down regulation in JNK which should potentially down-
regulate AP-1 leading to suppression of iNOS expression. This was however not 
apparent, potentially because of up-regulation of other AP-1 subunits, which may be 
positively coupled to iNOS gene promoter and thus able to sustain iNOS expression, 
regulating the induction of the enzyme. These findings reveal why pharmacological 
tools alone may not be sufficient for illustrating the complex signalling that may be 
essential for iNOS induction. Researchers should therefore consider appropriate 
experimental approaches to their studies and should exercise caution in interpreting 
data for which there is no additional studies in support that could account for the 
proposed underlying mechanism of action of drugs.  
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Future Work  
 
 As our experiments were limited in two cell types, it will be desirable to 
employ different cell types to get a clear picture and determine if the diversity 
of response is depend on the cell type or specious. Moreover it will be ideal to 
isolate macrophages from rat to compare the pathways in both macrophages 
but different species.  
 Investigate the signalling upstream of JNK to identify the diverse mechanisms 
that regulate iNOS and L-arginine transport. In this regard MKK4 and MKK7 
specific antibody can be employ to observe any differences in JNK1 and JNK 
2 from above. 
 Identify any cross-talk between AP-1 and NF-B pathways as TAM-67 may 
have regulatory effect on p65 subunit of NF-B. 
 Over-expression study needed for each subunit of AP-1 to observe their 
individual behaviour when over-expressed. Also a study with different AP-1 
dimer inhibition can be performing to clarify the role of various dimer 
combinations. 
 Investigation the role of JNK and it’s upstream MKK4/7 in CAT expression 
and determine which MAPK is involved in the regulation of these transporters. 
 Determine the role of each AP-1 subunits in CATs expression when there is 
over-expressed subunits system.  
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Appendix 1 
Griess reagent A (1000 ml): 2% Sulfanilamideamine in 10% Phosphoric acid (H3PO4) 
Greiss reagent B (1000 ml): 2% Napthylethylenediamine in dH2O 
On the day, mix them in equal volume 
 
Appendix 2 
Solutions for western blot  
1. Sample buffer: (50 ml): 
 
Ingredients Function 
1.51g Tris (250µM) and adjust the pH to 
6.8 
Maintains pH 
2g SDS (4%) Makes protein linear and provides 
negative charge 
5 ml glycerol (10%) Thickening agent 
1 ml -mercaptoethanol (2%) Breaks bonds to make proteins 
linear 
0.003g Bromophenol blue (0.006%) Colouring dye 
 
First dissolve Tris in about 25 ml of water and adjust the pH to 6.8 and then add 
other ingredients and make up the final volume to 50 ml with DDW (double distilled 
water). 
 
2. Ammonium Persulfate (APS) 10% 
 Dissolve 2g of APS (10%) in to 20 ml of DDW. 
Aliquot in 150µl each and store at -20oC. 
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Ammonium persulfate is used as starting agent to make polyacrylamide gel and it is 
quite unstable so, it should be stored at -20oC. 
 
3. Resolving Buffer: (1.5 M Tris-HCl) 
 Dissolve 91.05g of Tris in 500ml DDW and adjust the pH to 8.8. 
 
4. Stacking Buffer: (0.5 M Tris). 
 Dissolve 30.275g of Tris in 500ml of DDW and adjust the pH to 6.8. 
 
5. 10% SDS: 
 Dissolve 10g of SDS in 100ml of DDW. (keep it at room temperature) 
 
6. Transfer Buffer :( 10X) 
Ingredients Function 
29.3g glycine(39mM)  
58.2g Tris (48mM) Maintains pH 
3.75g SDS (0.0375%) Provides negative charge to proteins. 
 
First, dissolve all the ingredients and then adjust the pH to 8.3 and make it up to 1 
litre in DDW. On the day, take 100 ml of transfer buffer+200 ml methanol and make it 
up to 1 litre with DDW. Methanol prevents gel expansion and keeps protein absorbed 
on the membrane. 
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7. Washing Buffer: (10X) 
 
Ingredients Function 
12.1g Tris(10mM) Maintains pH 
58.4g NaCl(100mM) Removes weakly attached proteins from the 
membrane by electrically binding. 
 
Dissolve Tris and adjust the pH to 7.5 and then dissolve NaCl and make up to 1 litre 
in DDW. On the day, make it 1% and add 2 ml of Tween-20 for 2 litres of 1X washing 
buffer. 
 
8. Stripping Buffer: (1X) 
 Tris-7.578g/100ml (62.5 mM) 
 -mercaptoethanol- 700µl/100ml (0.7%v/v) 
 SDS-2g/100ml (0.2%w/v) 
Note: Add b-mercaptoethanol and SDS on the day in the stock solution made up 
with Tris. 
 
9. Staining solution: (1X) (Store at room temperature) 
 Coomassine brilliant blue R-250-1g 
 Methanol-450ml 
 DDW-450ml 
 Acetic acid-100ml 
 
10. Destaining solution: (1X) (Store at room temperature) 
 Methanol-500ml(20%) 
 Acetic acid-175ml(7%) 
 DDW-1825ml(73%) 
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11. Tank Buffer: (10X) (Store at room temperature) 
 Tris-30.27g/l 
 Glycine-144.14g/l 
 SDS-10g/l 
 
 
Resolving gel 10ml 
(2gels) 
20ml 
(4gels) 
30ml 
(6gels) 
50ml 
Ultra pure water from BDH 4.64ml 9.28ml 13.92ml 23.2ml 
30% Acrylamide bisacrylamide 
mixture 
2.66ml 5.32ml 7.98ml 12.5ml 
Resolving buffer 2.5ml 5ml 7.5ml 12.5ml 
10% SDS solution 100µl 200µl 300µl 500µl 
10% Ammonium persulphate 
(starting agent) 
100µl 200µl 300µl 500µl 
TEMED (catalytic agent) 6µl 12µl 18µl 30µl 
 
 
Stacking gel 4ml  
(2 gels) 
10ml  
(4 gels) 
20ml  
(6 gels) 
30ml 
Ultra pure water from BDH 2.44ml 6.1ml 12.2ml 18.3ml 
30% Acrylamide bisacrylamide 
mixture 
0.52ml 1.3ml 2.6ml 3.9ml 
Stacking buffer 1ml 2.5ml 5ml 7.5ml 
10% SDS solution 40µl 100µl 200µl 300µl 
10% Ammonium persulphate 20µl 50µl 100µl 150µl 
TEMED 4µl 10µl 20µl 30µl 
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Reagent for Blocking Buffer Quantity 
Washing buffer 10ml 
Tween 20 100µl 
5% fat free milk 5g 
DDW 90ml 
 
 
 
Appendix 3 
The JNK inhibitor structure 
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The Plasmid map  
a-Fos  
 
 
       
   
The pGFP-a-Fos plasmid map 
BamHI-HindIII fragment of pCMV a-Fos cloned into the BgIII-HindIII site of pEGFP-
C3 Kanamaycin resistance in E.Coli. 
    
 
 
 
383 
 
 The plasmid map 
TAM-67 
 
 
 
 
 
The pGFP-TAM-67 plasmid map 
TAM-67 was subcloned as described (Hennigan et al., 2001). The plasmid pGFP-
TAM-67 encodes Kanamycin resistance in E.Coli. 
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Materials 
 
Absolute ethanol                                                                  Fluka 
Acrylamide, ProtoGel                                                           National Diagnostics 
Agarose                                                                               Sigma 
Ammonium persulphate                                                       Acros Organics 
Anti-a monoclonal smooth muscle actin                              Sigma 
Anti-biotin, HRP-linked antibody, Detection Pack                Cell Signalling 
Anti-mouse IgG, FITC Conjugate developed in rabbit         Sigma 
Anti-iNOS monoclonal antibody                                          Transduction Laboratories 
Anti-β actin monoclonal antibody                                        Sigma 
Anti-mouse secondary antibody, Goat anti-mouse HRP     Transduction Labs 
BamHI                                                                                  Promega 
BCA Protein Assay Reagents                                              Pierce Perbio 
BSA (Bovine Albumin Serum) essentially fatty acid free      Sigma  
Calcium chloride 2-hydrate                                                   AnalaR    
Chloroform >99.8 %                                                             Sigma-Aldrich 
Coomassie brilliant blue                                                       Fluka 
Developer (GBX) Kodak Replenisher                                  Sigma 
D(+)Glucose                                                                        AnalaR 
DMEM, Dulbecco’s Modified Eagle’s Medium                    GIBCO 
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ECL Western Blotting Detection Reagents                       GE Healthcare / Amersham 
EDTA                                                                                  Sigma 
Ethanol                                                                                BDH 
Extra Thick Blot Paper                                                        BIO-RAD 
Fixer (GBX) Kodak Replenisher                                         Sigma 
Foetal Bovine Serum                                                          GIBCO Invitrogen 
Formaldehyde                                                                     Sigma 
Glycerol                                                                              Sigma 
Glycine                                                                               Fisher Scientific 
Goat anti-mouse HRP                                                        Transduction Labs 
JNK Inhibitor VIII                                                                Calbiochem 
HEPES                                                                               Fisher Scientific 
Hyperfilm (ECK & X-ray)                                                    Amersham 
Horseradish Peroxidase-linked Antibody                          Cell Signalling 
[H3]L-arginine (2 μ Ci/ml)                                                  Amersham Biosciences 
IMS, Industrial Methylated Spirit                                         BDH 
Isopropanol                                                                         BDH Biochemical AnalaR 
Interferon-gamma, Rat, Recombinant, E. Coli                    Calbiochem 
Kanamycin                                                                          Sigma 
KCl, potassium chloride                                                      BDH 
L-(+)-Arginin Hydrochloride                                                ALDRICH 
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Lipofectamine2000 Reagent                                                Invitrogen 
LPS (Lipopolysaccharide from E.Coli)                                  Fluka 
Liquiscint Scintillation Liquid                                                 National Diagnostics 
Magnesium chloride 6-hydrate                                            AnalaR 
2-Mercaptoethanol                                                               Sigma 
Methanol                                                                              Fisher Scientific                            
MTT (5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)   Sigma                                                            
NNN'N'-tetramethylethylenediamine (TEMED)                      Elecrtan 
Na3VO4, Sodium Orthovanadate                                           Sigma 
NaCl, Sodium Chloride                                                           BDH 
NaF, Sodium Fluoride                                                            Sigma 
NaH2PO4, Sodium Dihydrogen Orthophosphate 1-hydrate   BDH 
NaHCO3, Sodium Bicarbonate                                               BDH 
NaOH, Sodium hydroxide                                                      Sigma 
NaNO3, Sodium Nitrate                                                         Sigma 
Optimem 1                                                                           Invitrogen Corporation 
PBS, Phosphate Buffered Saline                                           GIBCO 
Penicillin-Streptomycin                                                         GIBCO Invitrogen 
Phosphate buffered saline tablet (PBS)                                Sigma 
Potassium chloride                                                               AnalaR 
PVDF membrane, Membrane Immobilon-P transfere            Millipore 
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Scintillation Liquid (Liquiscint)                                               National Diagnostics 
SDS, Sodium Dodecyl Sulphate                                           Sigma 
SP600125                                                                           Calbiochem 
TRIS Base                                                                           Fisher Scientific                                                        
Tween 20                                                                            Sigma 
Trypsin-EDTA                                                                        GIBCO 
XhoI (Restriction Enzyme)                                                   Promega 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
